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Abstract 
 
Synthetic biology is a rapidly growing field in which recent advances now allow the 
formation of minimal or artificial cells composed of a minimum number of components, 
capable of performing specific functions. New developments contributing to the 
complexity of artificial cells or making their design more cell-like increases the number 
of possible applications. To-date many processes and chemical reactions have been 
studied in these cells; many more remain to be explored. However, more sophisticated 
approaches to artificial cell design and preparation will be required to do this. The results 
presented here provide insights into how artificial cell development can contribute to our 
understanding of the self-assembly of biomolecules. 
The formation of lipid based vesicles is an inherent element of artificial cell development, 
which requires reliable techniques to prepare vesicles of cell size. The most widely 
applied methods have been evaluated here based on the size, quality and abundance of 
vesicles formed as well as the ease of encapsulating biological solutes. The effect of 
various lipid compositions, particularly cholesterol, has also been analysed. This 
comparison provides reliable information for tailoring the selection of experimental 
approach when building a model cell.  
Functionalisation of the artificial cell surface and its interior is required for many 
applications. For surface modification, there is growing interest in using glycolipids to 
fulfil a molecular recognition role. A synthetic glycolipid has been incorporated into the 
phospholipid membrane of giant unilamellar vesicles at biologically relevant 
concentrations. The synthetic glycolipid shows concentration-dependent phase behaviour 
in binary mixtures with DOPC and in ternary mixtures with DOPC and cholesterol. At 
low concentrations, the glycolipid is fully dispersed in the GUV membrane. At 
concentrations above 10%, the formation of lipid tubules was observed, consistent with 
the formation of a columnar lipid phase. Lipid tubules are observed in aqueous and oil 
solvents, suggesting that both hexagonal and inverted hexagonal lipid arrangements can 
be formed. 
The self- assembly of proteins in cells is required for normal biological function and 
unintended self-assembly also can occur following a change in environmental conditions, 
in some cases leading to disease. To understand these processes more fully, experiments 
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performed in controlled, but closer to physiological conditions are required. Artificial 
cells provide an idea platform to do this. Bovine Serum Albumin (BSA) was encapsulated 
in phospholipid based giant unilamellar vesicles of cell size. The formation of aggregates 
within the GUV was analysed using a fluorescent dye (Thioflavin T) and various modes 
of microscopy. While protein aggregation was observed inside the vesicles, harsh 
environmental conditions were required to induce this aggregation (e.g.heat, low pH).  
An approach to investigate protein condensation upon in-situ expression in 
physiologically relevant conditions was also explored. In this case, a protein that 
aggregates at physiological temperature and pH (the P23T mutant of human gamma D 
crystallin) was expressed in-situ inside a GUV using a cell-free expression system. The 
formation of P23T specific aggregates was observed after incubation for several hours at 
37°C. These aggregates have a fractal dimension lower than those normally observed for 
amorphous protein aggregate. Furthermore, we have demonstrated that the self-assembly 
of P23T can also be induced following transfection in mammalian cells, providing deeper 
insights into the mechanism by which the genetic cataract associated with this mutation 
occurs. 
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 Synthetic biology 
Synthetic biology emerged as a field of research over a decade ago.[1,2] It combines 
scientific and engineering approaches to study and manipulate cellular processes. The 
origin of synthetic biology can be traced back to 1961 and a study of the lac operon in 
E.coli, postulating the existence of a mechanism regulating the cell’s response to the 
environment.[3] Technological and scientific advancements, such as the discovery of 
transcriptional regulation, the PCR technique, automated DNA sequencing and modelling 
have significantly enhanced the ways in which biological systems can be manipulated.[2] 
Of great interest to synthetic biology is how to assemble cells from individual molecular 
components in a bottom up manner. There are three different paths to do just that; the 
protocell, the minimal cell and the artificial cell.[4] 
Protocell preparation involves the development of scenarios explaining the origin 
of life in prebiotic conditions. The cells are assembled from prebiotic molecules, 
containing either a small amount or none of the genetic information, in the form of 
peptides or RNA.[5–7] 
The minimal (or synthetic) cell method involves integrating DNA information and 
a simple metabolism into lipid compartments in order to prepare entities capable of self-
reproduction based on a minimal genome.[4,8,9] 
The artificial (or model) cell methodology, which is employed in this thesis, 
entails assembling cell-sized compartments equipped to perform biological functions by 
integrating natural and synthetic molecules to construct hybrid systems with new 
characteristics and functions.[10–12] These types of compartments are not only used to 
model biological processes but also as microreactors.[13] These synthetic cell assemblies 
may be prepared using either a top down approach, where synthetic DNA can be used to 
control viable bacterial cells[14] or a bottom up approach where synthetic or semi-synthetic 
components are used to reconstruct biological processes.[15–17] 
Another area of synthetic biology research is the creation of gene regulatory 
circuits, which carry out functions in a similar way to electrical circuits, to program cells 
to perform specific tasks.[18,19] Various cell processes and functions have been developed 
using gene circuits, such as togglling between two stable expression states in response to 
external signals,[20] ordered, periodic oscillation of repressor protein expression,[21] cell 
phenotype switches,[22] cell-cell communication[23] or the creation of permanent 
memory.[24,25] One of the successes of gene circuit research was the heterologous 
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production of precursors to artemisinin (an antimalarial drug),[26] which resulted in 2013 
in large scale production of the drug in yeast.[27] Another important development was the 
emergence of the clustered, regularly interspaced, short palindromic repeat (CRISPR) 
technology, which is a new approach for generating RNA-guided nucleases, such as Cas9, 
which can be targeted to almost any sequence.[2,28,29] Genome editing using CRISPR 
technology has been used to modify endogenous genes in a variety cell types and in 
organisms and to regulate endogenous gene expression or label specific genomic loci in 
living cells.[30–32] 
Other applications of the synthetic biology approach include information 
storage,[33] incorporation of unnatural nucleotides[34,35] and amino acids,[36–38] reduced 
amino acid libraries[39] or engineered proteins[40–42] and others.[43–45] 
 The artificial cell 
The artificial (or model) cell is a simplified system mimicking properties of 
biological cells, various components of cells or processes.[46,47] The simplest model cells 
are vesicles formed by lipid self-assembly into bilayers in aqueous solution. The lipid 
bilayer may be composed of natural lipids, identical to those present in cell membranes 
or may contain other components, such as polymers,[48] synthetic glycolipids,[49] 
transmembrane proteins[50] or pore forming proteins.[51] 
Vesicles composed of a variety of lipids have been used to study membrane 
related processes such as budding,[52,53] fusion,[54] fission[55] and various aspects of 
membrane dynamics,[56–58] membrane composition and phase behaviour.[59,60] 
While sometimes challenging, a variety of molecules have been encapsulated 
inside minimal cells, including small molecules,[61] nanoparticles,[62] biological 
molecules[63] and protein mixtures or cells.[64,65] 
Protein synthesis inside vesicles is an important aspect of artificial cell research. 
Initially cell extracts form E. coli[66] or wheat germ[67] were used. However, quick energy 
depletion and protein degradation by enzymes present in those extracts were a major 
disadvantage. Development of a purified cell-free system provided a new tool for 
synthetic biology and model cell research in particular.[68–70] The PURE system contains 
purified proteins, ribosomes, t-RNAs, recombinant T7 RNA polymerase and low 
molecular weight components necessary for the transcription and translation processes. 
Additionally, all of the components of the PURE system bear His-tag, which allows for 
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quick purification of the synthesized protein if necessary. The PURE system has several 
advantages over earlier expression systems, such as lower levels of proteases, nucleases 
and phosphatases, greater reproducibility and flexibility.[71] The PURE system can also 
be modified to mimic the macromolecular crowding of the cell.[72] It allows for the 
simultaneous expression of multiple polypeptides in a single reaction as shown for the 
heterotrimeric core of cytochrome c oxidase.[73] Recently published analysis of the gene 
expression dynamics provide valuable insights into the fine tuning of the expression 
process.[74] To date, various cell-free protein expression systems have been developed.[75–
79] Numerous proteins have been expressed inside lipid vesicles using cell-free expression 
systems, such as functional membrane proteins[80–84] and various water soluble 
proteins.[51,85–87] 
Due to advancements in methods for solution encapsulation and cell-free 
expression systems, various biological processes have been recreated in model cells, such 
as enzymatic reactions,[88,89] synthesis of nucleic acids[90,91] or lipids,[92] actin 
polymerization[93] or self-reproduction[94] and more recently self-proliferation.[95,96] 
Assembly processes, inevitable in biological cells may also be recreated in 
synthetic cells. Actin polymerization and the assembly of an actin cortex upon 
encapsulation of its building blocks within liposomes has been studied extensively 
providing insights into cell mechanics.[97,98] Xenopus egg extract have been used to 
recreate the process of assembly of cortical actin networks.[99,100] The understanding of 
the cell division processes and more specifically the formation of the mitotic spindle have 
been advanced by studying the embryos or the egg extracts of a variety of 
microorganisms.[101,102] One of the first self-assembly processes observed within lipid 
bilayers was the in-situ expression of α-hemolysin followed by the formation of a 
membrane pore via assembly of α-hemolysin heptamer following expression.[51] The 
possibility of pore formation also provided insights into extending the expression process 
of the cell-free system enclosed inside liposomes by means of providing a feeding 
solution on the exterior of the vesicle.  
In recent years there has been growing interest in using vesicles as microreactors 
for the analysis of biochemical reactions[103–105] or as a drug delivery vehicles.[106–110] 
Advances in synthetic biology and model cell research, some of which has been 
mention here, provides valuable insights into various biological processes such as 
ribosome synthesis,[111,112] cell adhesion,[106] mechanics,[65,113] reproduction[94] and 
proliferation.[95,96] 
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 Self-assembly of biological molecules 
Self-assembly is a spontaneous process tending towards equilibrium, in which 
individual components, that do not change their character upon integration, assemble in 
a specific way to form a well-defined structure uniquely determined by the size, number 
of components, geometry, and strength of interactions among the components.[114] Self-
assembly is driven by non-covalent interactions which are generally weaker than covalent 
bonds thus are reversible.[115] Self-assembly is an essential process in biological systems 
and virtually all biomolecules undergo self-assembly, which determines their structure 
and influences their function.[116–118] Various biological structures formed by a self- 
assembly process include the formation of the cell membrane, cytoskeleton, viral capsid 
or protein complexes involved in transcription and translation of genetic information.[119–
121] Self-assembly has also been explored in the context of non-biological applications 
such as nanotechnology and supramolecular or materials chemistry.[115,122,123] 
 Forces governing the assembly of biomolecules 
The self-assembly of biomolecules occurs as a result of non-covalent interactions 
between the assembling components. The stable and specific arrangement of components 
is a result of multiple non-covalent interactions. Non-covalent interactions are weaker 
than the covalent bonds (bond strengths on the order of 1-5 kcal/mol), therefore are 
reversible at physiological temperature and take place over longer distances, ca. 2 to 10 
Å.[124,125] Due to the nature of non-covalent interactions, the self-assembled structures 
usually remain in thermodynamic equilibrium and have the capability to rearrange.[115] 
Non-covalent interactions can be formed within a molecule (intra-) as in protein 
folding or between different molecules (inter-).[126] The main types of non-covalent 
interactions include: hydrogen bonds, van der Waals interactions, hydrophobic 
interactions and electrostatic interactions. 
 Hydrogen bonding 
The hydrogen bonding is an attractive interaction between a hydrogen atom 
covalently bonded to an electronegative donor atom of one molecule and an 
electronegative atom (acceptor) with at least one lone pair of electrons of the same or 
different molecule. The partial positive charge on the hydrogen atom, formed due to the 
polar character of the H-donor bond is the basis of its attraction to the lone pair of 
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electrons on the acceptor atom. In case of biological systems the electronegative atoms 
participating in hydrogen bonding are usually nitrogen and oxygen. The length of most 
hydrogen bonds is between 0.26 nm and 0.32 nm (0.27 nm in the water molecule) and 
has a strength of ~5 kcal/mol between water and 1 to 2 kcal/mol for biomolecules.[124] 
The strength of the hydrogen bond depends on the distance and the bond angle between 
donor and acceptor, with the strongest formed when the donor, the hydrogen, and the 
acceptor atom all lie in a straight line. Nonlinear hydrogen bonds are weaker but multiple 
nonlinear hydrogen bonds may act together. 
 Hydrogen bonding is particularly important in driving self-assembly due to its 
cooperative nature. The complex structure of biological molecules reveal the presence of 
multiple donor and acceptor sites within a single molecule. Hydrogen bonding, however 
weak in nature, is capable of stabilizing assembled structures.  
 Van der Waals interactions 
Van der Waals are non-specific attractive interactions resulting from the 
momentary random fluctuations in the distribution of the electrons of an atom, which 
results in a transient electric dipole. When two atoms are close enough the transient dipole 
in one atom generates a transient dipole in the second atom, and the two dipoles are 
weakly attracted by each other. This type of interaction occurs in all types of molecules. 
The strength of the van der Waals interaction is approximately 1 kcal/mol and depends 
on the distance between the two atoms; the larger the distance the weaker the 
interaction.[124] The distance over which the Van de Waals interactions occurs is generally 
twice the distance of the covalent bond between the same atoms, e.g. for a C-H interaction 
it is roughly 0.2 nm.[127] 
 The hydrophobic effect 
Hydrophobic interactions are relatively strong attractive interactions between 
non-polar groups, such as hydrocarbon chains of lipid molecules, separated by water. 
When non-polar groups are placed into water, their presence disrupts the hydrogen 
bonding network of the surrounding water molecules. This forces the rearrangement of 
water molecules around a hydrophobic surface, thus decreasing the number of possible 
orientations, which in turn decreases the entropy of the water. The assembly of 
hydrophobic groups occurs with the aim of decreasing the size of the hydrophobic surface 
in contact with water molecules (by excluding water from the hydrophobic region). The 
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increase in order of hydrocarbon groups is small compare to the increase in entropy 
related to the release of water molecules. The overall effect is the increase of entropy of 
the system.[117,128] Hydrophobic interactions are long range (up to 10 nm).[129] 
 Electrostatic interactions 
The electrostatic potential has either attractive or repulsive character depending 
on the relative sign and magnitude of the interacting charges.[129]  
A double layer is formed in the vicinity of the particle surface (e.g. biomolecules 
such as proteins) when exposed to a fluid (figure 1.1). The first layer, called the stern 
layer, consists of an increased concentration of strongly bound counter-ions. In the diffuse 
layer those counter-ions are less tightly bound. The slipping plane is located at the 
boundary between the diffuse layer and the bulk liquid, where the ions are uniformly 
distributed. The electrical potential at the slipping layer is referred to as zeta potential and 
it represents the magnitude of electrostatic interactions between the particles. 
 
 
Figure 1.1 Schematic representation of the electronic double layer and zeta potential. 
The interaction potential between two proteins can be described using DVLO 
theory (Derjaguin, Landau, Verwey and Overbeek). This theory combines the effects of 
the electrostatic repulsion and the van der Waals attraction. The electrostatic repulsion 
increases exponentially as the distance between particles decreases and the van der 
Waals’ attraction increases as an inverse power of separation. The net attraction between 
proteins can be characterised by negative interaction potential (figure 1.2a) and repulsive 
interactions by positive potential (figure 1.2b). 
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Figure 1.2 Schematic representation of an interaction potential between protein molecules.[130] 
 
 Lipid structure and self-assembly 
 Characteristics of lipids 
Lipid molecules are composed of hydrocarbon chains and a hydrophilic head 
group and in a similar way to other amphiphilic molecules, self-assemble in aqueous 
environments forming a variety of structures, such as micelles, vesicles or flat bilayers as 
shown in figure 1.3. 
 
Figure 1.3 Cross-section view of lipid organization in a micelle (left), vesicle (middle) and lipid 
bilayer (right), formed by lipids in aqueous solutions.[131]  
The assembly of lipid molecules in aqueous environments occurs due to the 
hydrophobic effect.[132] Hydrocarbon chains are water-insoluble and their assembly 
occurs in order to minimise the size of the hydrophobic surface in contact with water 
molecules. The overall effect is to increase the entropy of the system and it is the driving 
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force for the lipid assembly process.[117,128] Other non-covalent interactions playing a role 
in lipid self-assembly include hydrogen bonding, van der Waals and ionic 
interactions.[125] 
Lipid molecules assemble into a variety of structures, depending on the nature of 
both the head group and hydrocarbon chains.[133] The shape and size of structures formed 
upon assembly may be predicted based on the Israelachvili–Mitchell–Ninham packing 
parameter ρ, expressed by equation 3.1,[134,135]  
 𝜌 =
𝜈
𝑎0 𝑙𝑐
 1.1 
where ν is the volume of the hydrocarbon chain, ao is the optimal headgroup area and lc 
is the critical chain length. Cone-like shaped lipids (figure 1.4a), usually with one 
hydrocarbon chain and relatively large head group form mainly micelles. Lipid molecules 
with cylindrical shapes (figure 1.4b), with packing parameter between 0.5 and 1, assemble 
into bilayers, and inverted lipid structures (figure 1.4c) are usually formed by lipids with 
small head groups and bulky hydrocarbon chains.[136] 
 
 
Figure 1.4 Schematic representation of various shapes of lipid molecules; (a) cone, (b) 
cylindrical and (c) inverted cone, and main types of self-assembled lipid structures formed by 
those types of lipids. 
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 Lipid phases 
Geometric arrangements of lipid molecules include lamellar, hexagonal or cubic 
mesophases; with normal or inverse topography (figure 1.5) as well as nanotubes and 
toroidal structures.[117] The self-assembly process is driven by non-covalent interactions 
with the hydrophobic effect as the largest contribution. The type of self-assembled 
structure formed depends on variety of factors, including the nature of the lipid molecules, 
especially the head group, the interfacial curvature, temperature and the water content 
within the medium in which the assembly process occurs.[136,137] 
 
 
Figure 1.5 Schematic representation of self-assembled structures formed by amphiphilic 
molecules. 
A lamellar phase consists of two lipid layers with their hydrophilic head groups 
facing towards the water interface and the hydrophobic region facing each other, forming 
a lipid bilayer. This lipid arrangement is found in all biological and synthetic membranes. 
However, non-lamellar phases, including hexagonal and cubic phases are also observed 
within biological and synthetic systems.[137–139] Large numbers of non-lamellar lipids are 
present in biological membranes have been implicated in maintaining the structure and 
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therefore preserving the function of membrane proteins.[140] The transition between 
lamellar and non-lamellar phases may be induced by varying the composition or the 
temperature.[137] 
Biological and synthetic membranes are vastly dynamic assemblies. The types of 
lipid movements that can occur within the bilayer include lateral diffusion (exchange 
places with neighbouring lipid), transverse diffusion (or flip-flop, movement from one 
leaflet to the other), axial rotation and intra-chain motion (known as kink formation).[141] 
The rate at which a specific type of movement occurs depends on the nature and 
composition of the bilayer. Proteins within membranes can diffuse laterally, but not 
between the leaflets. 
Lipid bilayers of both natural and synthetic membranes exist in different physical 
states (figure 1.6), which are categorised by the lateral organisation and mobility within 
the membrane. The character of the bilayer may be altered by adjusting temperature, pH, 
ionic strength or modifying the lipid composition of the bilayer or the addition of 
cholesterol.[141] 
 
Figure 1.6 Schematic representation of physical states adopted by lipid bilayers in aqueous 
solution. 
The solid-ordered phase (also known as gel phase) is characterized by low 
mobility and a compact arrangement of lipid molecules due to a trans-configuration of 
the hydrocarbon chains, which may be tilted (Lᵦ’) or (Lᵦ) with regard to the bilayer surface 
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depending on water content (the lower the water content, the smaller the angle of the 
tilt).[142,143] Among the fluid phases, liquid-disordered (Ld) and liquid-ordered (Lo) phases 
may be distinguished.[141] The Ld phase is characterized by trans-gauche configuration 
resulting in shortening of the acyl chains and high degree of lateral and rotational 
movement of the lipid molecules. The transition between the So and Ld occurs at a 
temperature known as a phase transition (or melting) temperature (Tm), which depends 
on the length of the hydrocarbon chain, the structure of the headgroup and the degree of 
unsaturation and is specific for a given lipid type.[141] The lipid-ordered phase, also known 
as the liquid crystalline phase, is formed in the presence of cholesterol and is characterised 
by lateral and rotational diffusion that are similar to those of the Lo phase, but with a 
conformational order similar to the solid-ordered phase.[144–146] The ripple phase Pβ exists 
prior to the main chain melting and is characterized by periodic one-dimensional 
undulations on the surface of the lipid bilayer as a result of a periodic array of ordered 
and disordered domains.[147] 
The lipid phases, liquid-disordered, liquid-ordered and solid-ordered phase can 
coexist in the same bilayer. The coexistence of lipid phases has been observed in lipid 
bilayers composed of various lipid mixtures, usually containing cholesterol.[146,148–150] 
Various types of lipid molecules preferentially partition into either liquid-ordered or 
liquid-disordered phase, depending on their structure. 
Phospholipids favour the liquid-disordered lipid phase due to the structure of their 
hydrocarbon chains, the presence of cis double bonds which induces a kink and prevents 
very compact assemblies. Glyco- and sphingolipids on the other hand preferentially 
partition into the liquid-ordered phases within bilayers due to the characteristics of both 
the headgroup and the acyl chains.[151,152] Their ordered assembly is stabilized by the 
hydrogen bonding and van der Waals forces between these groups.[153] 
 Phase separation in biological membranes 
Various studies suggest that preferential partitioning of lipids and the formation 
of liquid-ordered phases enriched in cholesterol and sphingolipid occurs also in biological 
membranes.[154,155] However, the presence of these heterogeneous domains, also called 
lipid rafts, within biological membranes is still under debate.[156] Lipid rafts are usually 
small, 10-200 nm in diameter[157,158] but may form larger structures by stabilizing protein-
protein and protein-lipid interactions.[159,160] Lipid rafts play an important role in many 
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biological processes, such as the sorting and the transport of both membrane proteins and 
lipids during endocytosis and exocytosis, in cascade signalling as well as in other cellular 
processes such as apoptosis, membrane fusion, cell adhesion and migration.[155,157,161,162] 
It has been also suggested that lipid rafts are the target sites for cellular entry of various 
pathogens due to the high concentration of cellular receptors[163] and platforms for the 
assembly of the β-amyloid protein, associated with Alzheimer’s disease.[164] 
Biological membranes are extremely complex structures, therefore various 
mimetics have been developed, such as lipid monolayers, supported lipid bilayers or lipid 
vesicles, to facilitate studies of the behaviour and properties of membranes.[141] 
 Giant unilamellar vesicles (GUVs) 
Lipid vesicles, also called liposomes are cell-mimicking compartments consisting 
of lipid bilayers. Depending on the size, small (SUV, 20-200 nm), large (LUV, 200- 800 
nm) and giant unilamellar vesicles (vary from 1-300 µm) can be distinguished. In 
biological cells lipid membranes provide a 4 nm thick barrier between the interior and the 
exterior of a cell.[165] They were first described in the 1950s.[166] Bilayers of GUVs may 
be formed, depending on the purpose, from a variety of lipid categories, including 
phospholipids, sphingolipids, glycolipids or sterols. Structural differences between 
various lipid classes are manifested by differences in their behaviour within a lipid 
bilayer. Vesicles may also be prepared using block copolymers with amphiphilic 
properties.[119] 
 Preparation of GUVs 
The preparation of GUVs was first described in 1969 by a method now known as 
gentle hydration.[167] Since then a large number of methods are used to produce GUVs for 
many applications and these have been described in a several reviews.[165,168,169] 
Electroformation (or electro-swelling) is a widely used method for GUV 
preparation. Liposome formation induced by a static (DC) field was first described in 
1986[170] and then modified by application of an alternating (AC) electric field.[171] 
Electroformation may be performed by depositing a thin layer of lipid in organic solvent 
onto conductive indium tin oxide (ITO) coated glass, or a platinum wire and applying an 
external electric field. Spin-coating the lipid onto the slide creates lipid films with defined 
thickness which aids GUVs formation from lipid mixtures which do not easily form 
vesicles.[172] 
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GUVs may also be produced using hydration methods. There are several 
advantages of hydration methods over electroformation since large vesicle sizes are 
produced and the preparation conditions are mild.[173] Rapid hydration also produces cell-
sized vesicles and requires very short preparation times.[174] A recently developed method 
involving lipid hydration on an agarose film[175] facilitates the formation of a high yield 
of cell-size GUVs in solution at high ionic strength and from lipid mixtures usually found 
to be problematic (for example asolectin). It has also been used to encapsulate 
biomolecules, while retaining their biological activity.[65] 
An emulsion method (also termed inverted or w/o emulsion) was originally 
described by Pautot et al.[176] and involves the assembly of a bilayer on an aqueous droplet 
by lipid molecules dispersed in oil. The formation of cell-size vesicles, the possibility of 
forming asymmetric bilayers and high encapsulation efficiencies are among the many 
advantages of this method.[177,178] The emulsion transfer method has also been used to 
encapsulate a cell-free expression system. The continuous droplet interface crossing 
encapsulation (cDICE)[64] method was developed specifically for encapsulation and has 
been shown to lead to a high yield of cell-size vesicles. The cDICE method has been used 
to encapsulate a variety of solutions, including colloids, red blood cells, actin filaments[64] 
and parasites.[179] 
Other methods used to produce GUVs include fusion of small vesicles,[180,181] lipid 
stabilized w/o/w double emulsion,[182] lipid –coated ice droplets,[183,184] lipid dissolved in 
a water-miscible solvent[185] or micellar lipid solution methods,[186] among others. 
 Applications for GUVs 
Since their discovery, GUVs have been used to study biological processes such as 
budding,[52,53] fusion[54] and fission[55] or various aspects of membrane dynamics,[56,57] 
membrane composition and phase behaviour.[59,60] In recent years there has been growing 
interest in using vesicles as microcontainers for the analysis of biochemical reactions[105] 
and for the development of model cells.[16,187,188] 
 Lipid molecules used for liposomes preparation. 
 Phospholipids 
Depending on the alcohol group, phospholipids are commonly divided into 
glycerophospholipids and sphingomyelins. Glycerophospholipids are the lipids most 
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commonly used for the preparation of liposomes. They are the main components of the 
eukaryotic cell membrane, fulfilling a mainly structural role. They are composed of a 
glycerol backbone and symmetric hydrocarbon chains typically from 16 to 18 carbons 
long (figure 1.7).[189] The two main classes of glycerophospholipids used for GUV 
preparation include phosphatidylcholine (PC) and phosphatidylethanolamine (PE).[190] 
Two phosphatidylcholines used in this thesis are 1, 2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). 
DPPC is the main component of pulmonary surfactant, where it lowers the surface 
tension. Phosphatidylcholines are the most abundant lipids; they account for more than 
50% of lipid molecules in eukaryotic membranes. They are located mainly in the outer 
leaflet where they are part of the permeability barrier.[190] Phosphatidylcholines with 
unsaturated acyl hydrocarbon chains usually occur in liquid phase at room temperature. 
Due to a small head group they have nearly cylindrical shape and self-assemble into a 
planar bilayer and their inclusion into bilayers causes curvature stress.[191] 
 
 
Figure 1.7 Chemical structures of the phospholipids: DOPC (a), DPPC (b), brain 
sphingomyelin (c) and cholesterol (d). 
Sphingomyelins (SM) are abundant in cell membranes (2-15% of total lipid 
content), with higher concentrations found in nerve and red blood cells.[190] The chemical 
structure of brain sphingomyelin is shown in figure 1.7c. Sphingomyelins are composed 
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of a sphingosine backbone and asymmetric acyl chains in the tail. They exhibit more tight 
packing (gel phase) compared to PC due to a higher degree of saturation within the chains 
(on average 0.1-0.35 cis-double bonds in amide-linked acyl chains). The typical length of 
an acyl chain is usually more than 20 carbons. Sphingomyelins colocalize and strongly 
interact with cholesterol both in biological and synthetic membranes. 
 Cholesterol 
Cholesterol is a non-polar molecule and in biological membranes is responsible 
for maintaining structural integrity and fluidity (figure 1.7d). Most of the molecule is 
embedded within the hydrophobic portion of the bilayer while the –OH group interacts 
with head groups of other lipids.[190] Cholesterol has been shown to interact preferentially 
with sphingomyelin than with other non-saturated glycerophospholipids, which dictates 
the properties of SM/cholesterol bilayers (including low permeability). The strong 
interaction between sphingomyelin and cholesterol results from the van der Waals 
interactions between cholesterol and saturated lipid acyl chain of the sphingomyelin.[192] 
This interaction leads to the formation of a liquid-ordered phase within the lipid bilayers 
of both natural and synthetic membranes. In biological cells this favoured mixing of 
sphingomyelin and cholesterol has been implicated in the formation of lipid rafts, 
dynamic and ordered microdomains serving as an attachment for variety of protein 
molecules and implicated in membrane signalling and trafficking processes.[154,155,193] 
 Glycolipids 
Glycolipids are a class of lipids containing sugar-based headgroups. There are 
several classes of glycolipids, including glycoglycerolipids, glycophosphatidylinositols 
and glycosphingolipids.[194] Glycolipids, are major components of biological membranes, 
especially the outer leaflet. They are also abundant in intracellular membranes such as 
mitochondria, the Golgi apparatus, the nuclear membrane, lysosome, endosomes and the 
endoplasmic reticulum[195] or the apical side (facing inwards to the lumen) of polarized 
epithelial cells.[196] 
Glycolipids are composed of a carbohydrate-based head group which is 
continuously exposed at the surface of a bilayer, maximising the surface available for 
interactions and hydrocarbon chains buried within the hydrophobic portion of the lipid 
bilayer (figure 1.8). Glycolipids, like other lipids are amphiphilic, therefore upon self-
assembly (usually in mixtures with other lipids) can adopt a variety of structures, 
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including lamellar, hexagonal or cubic phases.[117] A variety of other structures, including 
helical ribbons have been observed in the presence of glycolipids.[197] The type of 
assemblies formed is dictated by the structure of both the head group and the hydrocarbon 
chain, expressed by a packing parameter.[136] Within the lipid bilayer of biological and 
synthetic membranes glycolipids can adopt both gel and fluid phases.[198] Transitions 
between these lamellar phases as for other lipids, is governed by the fluidity of the 
hydrocarbon chains (and strongly affected by temperature). For the majority of lipid 
types, the structure of the head group may shift the melt transition temperature in some 
cases, but generally it is as simple as determining the surface area per lipid molecule. 
 
 
Figure 1.8 Schematic representation of lipid bilayer composed of phospholipids, cholesterol, 
glycolipids and glycoproteins. 
However, this is not the case for glycolipid molecules where altering the structural 
features of the sugar-based head group such as the anomeric configuration of the glyosidic 
bond, isomeric configuration (D-galactose, D-galactose, D-mannose, etc.), charge or 
polarity also significantly alters the phase behaviour.[199–201] Hydration of the head group 
and the penetration of water into the interface have been shown to govern the type of non-
lamellar phases adopted by glycolipids.[202] Due to these interesting properties and the 
biological relevance of these membrane components, the phase behaviour and phase 
morphology of glycolipids have been extensively studied using both experimental and 
molecular dynamics simulation approaches.[203–207] 
Glycolipids contain a linkage area located between the head group and 
hydrocarbon chain capable of acting as both H-bond donor and acceptor. Hydrogen 
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bonding can also occur between the sugar head groups leading to the formation of clusters 
of molecules and therefore denser packing.[208] Interactions with other lipids, such as 
sphingolipids and cholesterol and a variety of membrane proteins leads to the formation 
of glycolipid-rich domains within phospholipid bilayers.[209] The types of microdomains 
containing glycolipids include glycosynapses (involved mainly in adhesion processes) or 
lipid rafts (with functions in signalling).[210–212] Glycolipids can also interact with 
complementary carbohydrates or proteins displayed on neighbouring cells which 
facilitates the specificity and direction of the interaction.[213] 
 Biological functions of glycolipids. 
Glycolipids are involved in a variety of biological functions. For many of those 
functions, recognition and signal transduction occurs within glycolipid-containing 
microdomains and through their interactions with other signal modulators such as kinases, 
G-coupled proteins, GPI-anchored proteins, immunoreceptors, tetraspanins and growth 
factor receptors.[196,210,214] 
The primary cellular functions involving carbohydrate-based signal processing 
includes cell adhesion, motility, differentiation,[215] growth,[216] proliferation and 
apoptosis.[217] Interactions between cell surface receptors and carbohydrates present on 
pathogens leads to recognition of infection and immune response. The most widely 
studied glycoconjugates are lipopolysaccharides (LPS), present on the surface of Gram-
negative bacteria. Their interaction with toll-like receptors (TLRs) and other members of 
the signalling complex leads to activation of the innate immune system and initiation of 
inflammation.[218] Interactions between pathogens and host surface glycolipids are often 
a way to mediate entry into host cells.[209,219,220] Glycolipids have been shown to play a 
role in the maintenance of membrane integrity,[221,222] photosynthesis[223] or certain 
aspects of energy transduction within biological systems.[224] 
 Fluorescent lipid analogues 
The properties, behaviour and various processes occurring within lipid 
membranes are often studied using different modes of fluorescent microscopy, such as 
wide field, confocal or superresolution microscopy.[225] In order to visualize these 
processes fluorescent lipid analogues are incorporated into lipid membranes. 
Commercially available fluorescent lipid analogues vary depending on the type of lipid 
used, the structure and therefore the spectral properties of the fluorescent label and its 
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location within the lipid molecule (head or chain). Their properties and cellular 
localization strongly depends on their structure. 
Apart from visualization by fluorescence microscopy, fluorescent lipids are also 
used as a phase-specific labels in phase behaviour studies, sensors of the cellular 
environment or trackers in cellular transport studies.[226] 
 Protein structure and assembly  
Proteins are polymeric chains composed of amino acids and are synthesized on 
ribosomes. They have a primary structure, which refers to the linear sequence of amino 
acids, determined by genetic information and these are held together by peptide bonds 
(figure 1.9). 
 
Figure 1.9 Levels of protein structure.[227] 
The polypeptide chains contain regions of localized organization with specific 
spatial arrangements, referred to as the secondary structure, stabilized by hydrogen 
bonding, such as in an α helix (right hand spiral conformation with 3.6 amino acids per 
turn), β sheet (fully extended alignments of short β strands) or a turn (U-shaped 4 residues 
long, with a H-bond between the end residues). Regions of polypeptide chains without 
stabilizing interactions assume a random-coil arrangement.[124]  
The protein tertiary structure refers to the three-dimensional protein structure 
driven by hydrophobic interactions between the nonpolar side chains, stabilized by 
hydrogen bonding, salt bridges and, in some proteins, by disulphide bonds. These 
stabilizing forces fold the α helices, β strands, turns, and random coils in a compact 
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internal scaffold. The quaternary structure of a protein describes the number and relative 
positions of the subunits in a multimeric protein and is stabilized by the same types of 
non-covalent interactions and disulphide bonds as the tertiary structure.[227] 
 Intramolecular self-assembly 
Folding a protein into its three-dimensional structure occurs by an intramolecular 
self-assembly process and is driven by the requirement to lower the free energy. Folding 
protein may assume various partially folded conformations before reaching the native 
folded state. Random sampling of possible conformations would require timescales 
beyond a biological lifetime.[228] The idea of a protein folding pathway was introduced to 
explain details of protein folding. Another way to present the protein folding is a statistical 
energy landscape representing possible partially folded states with a corresponding free 
energy.[229] For protein folding via a two-state transition mechanism in which only the 
denatured and native states are populated, the energy landscape is relatively smooth, 
lacking deep valleys and high barriers. However folding scenarios for most proteins 
involves rough, rugged landscapes representing multiple transient non-native species.  
Protein folding has been extensively studied providing insights into the structural 
diversity of non-native states, folding pathways or the folding efficiency.[230–234] However 
much remains unknown as the folding pathways of large proteins, membrane proteins or 
modified proteins have not yet been studied in great detail.[235–237] 
 Intermolecular self-assembly 
Proteins are often found to form oligomers composed of two or more subunits 
held together by various non-covalent interactions, such as hydrogen bonding, salt 
bridges or disulphide bonds. The quaternary protein structure is closely linked with its 
function and interactions with other proteins.[238,239] The four types of proteins based on 
their structure include fibrous, globular, integral membrane proteins, and disordered 
proteins. Regardless of the structure type, proteins can self-assemble into larger structures 
generally termed macromolecular assemblies.[124] 
Fibrous proteins assemble into rod or wire-like protein filaments usually via a 
coiled coil arrangement. Collagen is an example of a fibrous protein. It is a major protein 
of the extracellular matrix, forming 30-100 nm thick fibrils.[240] Collagen is a structural 
protein, providing strength to tissues. The collagen triple helix has a super-coiled, right-
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handed structure composed of three parallel α-chains, each with a polyproline II helical 
conformation.[241] 
Membrane proteins are either embedded into lipid bilayers (transmembrane 
protein) or are bound to their surface by electrostatic interactions with anionic lipids. 
Transmembrane proteins are usually composed of three domains: two water-soluble 
portions (cytosolic and exoplasmic) and one spanning the membrane, rich in hydrophobic 
amino acids.[124] Membrane proteins often self-assemble into multidomain complexes, 
such as ion channels, transporters or receptors.[242,243] One of the most commonly studied 
transmembrane complexes is the potassium channel. Its transmembrane domain is 
composed of four identical subunits forming an ion pore at the centre. The pore may be 
open or closed by conformational change within the channel in response to different 
signals requiring sensor domain transmitting information to the pore domain. Potassium 
channels contain a selectivity filter formed by a highly conserved sequence of five 
residues.[235,243] 
Globular proteins are spherical, water soluble molecules found in cytosol and 
body fluids. They form a variety of self-assembled complexes performing specific 
functions within the cellular environment. In the case of viruses, the capsid formed by 
protein assembly is a shell in which its genome is encapsulated.[244] Viruses, such as the 
tobacco mosaic virus or small plant viruses self-assemble spontaneously from a solution 
containing capsid proteins and single-stranded RNA.[245,246] Other self-assembled 
structures formed within the cellular environment include the nuclear pore complex, 
receptor/signalling complexes, proteasome, DNA polymerase III holoenzyme, RNA 
polymerase II holoenzyme or nucleosome.[247–253] 
 Non-native protein assembly 
Occasionally, proteins which normally do not form assemblies do so due to 
changes to solution conditions or conformational change within their structure. Structures 
formed as a result of non-native protein assembly, also referred to as aggregation, can 
adopt various conformations (folded up to fully unfolded) and different sizes (from small 
monomer up to hundreds of micrometres).[254,255] Aggregates can be associated by either 
covalent bond or non-covalent interactions. 
Understanding how and why proteins aggregate is extremely important in various 
branches of food and in the biopharmaceutical industry.[256] The effects of protein 
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aggregates present in biopharmaceutical formulations include decreased efficacy and 
stability or in some cases immunogenic response in patients.[257] Formation of protein 
aggregates has also been linked to several diseases such as Alzheimer’s or Parkinson’s 
disease and therefore better understanding of the aggregation process may lead to 
development of new strategies resulting in its prevention.[258,259] 
Protein solutions are a colloidal fluid (with radius of gyration ca. 1-2 nm) and 
therefore their stability can be considered in terms of both, the structural stability of the 
protein molecule and the solution stability.[260–262] The structural stability refers to the 
preservation of the native (folded) protein conformation. The solution stability discusses 
the ability of the protein molecules to exist as monomers in solution. Structural and 
colloidal stability are closely related since the aggregate formation often involves the 
presence of unfolded or partially folded protein species.[261] 
Techniques routinely employed in aggregation studies include chromatography, 
electrophoresis, mass spectrometry and UV-Vis spectroscopy, circular dichroism 
spectroscopy, various modes of microscopy and many more.[254,263]  
 Morphology of protein aggregates 
Based on morphology, aggregates can be divide into two types: amorphous or 
fibrillar.[263] Fibrillar aggregates have an average width of 10-20 nm, and are formed by 
the constituting proteins aligning perpendicular to the fibrillar axis,[264] resulting in a 
cross-β-sheet structure, identified by an X-ray diffraction signature known as the cross-β 
pattern.[265] They can be detected using various methods, most commonly by transmission 
electron microscopy (TEM), optical birefringence and increased fluorescence upon 
association of dyes such as Congo red and Thioflavin T(ThT).[266] Insoluble amyloid 
fibrils are formed from soluble proteins, usually by a nucleation driven mechanism.[264] It 
has been shown that lipid membranes play a role in fibril formation.[267] The mechanism 
of fibril formation has not yet been proven, however some studies suggests that the initial 
step involves binding of the protein to the lipid bilayer driven by the electrostatic 
attraction. Bound proteins are thought to undergo a structural transformation to the β-
sheet followed by the oligomerization of membrane bound proteins.[267] Lipid membranes 
and lipid rafts have also been shown to be the target for the toxic species.[164,267] Several 
studies have suggested that the oligomeric species formed in the earlier stage of amyloid 
aggregation are the main cytotoxic species.[268] 
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Amyloid fibrils have been linked to pathological changes observed in many 
neurodegenerative diseases. Parkinson’s disease is associated with the formation of 
intracellular fibrillar deposits of aggregated α-synuclein, known as Lewy bodies, in the 
dopaminergic neurons of the substantia nigra of the midbrain and other monoaminergic 
neurons in the brain stem.[269] Moreover, mutations associated with the early-onset forms 
of Parkinsonism give rise to neuronal degeneration in the absence of the accumulation of 
Lewy bodies.[270] Other neurodegenerative disorders associated with formation of protein 
fibrils include Alzheimer’s disease, Huntington’s disease and type II diabetes.[271–274] 
Protein fibrils are also involved in physiological processes. Examples of such protein 
include a Pmel17 which is a structural template for the formation of melanine polymers 
or the secretory granules of the endocrine system.[275] 
The term amorphous aggregate is used to describe a heterogeneous population of 
particulates formed in protein solutions, which do not exhibit a long range order. Studying 
amorphous aggregates has proven difficult due to their heterogeneity and light scattering 
properties, leading to notions that they lack distinguishable structure.[263] 
Certain amorphous aggregates associate with Congo red and ThT, dyes known to 
bind to the β-sheet structures found in fibrillar aggregates. This suggests that at least some 
amorphous aggregates undergo structural rearrangement increasing its β-sheet content as 
observed for insulin in the presence of sulfate anion.[276] However ThT was also shown 
to bind to hydrophobic pockets of globular proteins, such as human serum albumin[277] or 
acetylcholinesterase.[278] ThT binding in this case is mediated by the presence of aromatic 
residues and involves extensive π-stacking with Tyr and Trp residues. 
Formation of amorphous aggregates commonly occurs during protein 
processing,[279] in food (production of dairy products and wine) and in the 
biopharmaceutical industry.[256,280] The effects of protein aggregates present in 
biopharmaceutical formulations include decreased efficacy and stability or in some cases 
immunogenic response in patients.[257] Amorphous aggregates have also been linked to 
the formation of cataract, the opacity of the eye lens as a result of protein condensation. 
In congenital forms of cataract the formation of protein condensed phases such as 
crystals[281] or aggregates[282] is caused by a single amino acid substitution (due to single 
point mutation) in the sequence of the crystallin proteins. In age related types of cataract, 
a change in the solution behaviour of the crystallin proteins found in the eye lens occurs 
as a result of environmental changes, such as oxidative or osmotic stress.[283,284] 
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 Factors influencing the aggregation process 
Protein solutions are generally thermodynamically unstable and therefore 
predisposed to aggregation. However aggregation is also strongly influenced by various 
factors, depending on both the nature of the protein as well as the solution conditions.  
Single point mutations have been shown to be a cause aggregation of crystallin 
proteins without any significant changes within their structure.[282,285,286] The substitution 
of certain amino acids results in the formation of attractive patches on the surface of 
crystallin proteins (mainly gamma D crystallin), causing an increase in net protein-protein 
attractive interactions which in turn leads to the formation of aggregates and crystals of 
the crystallin proteins.[287,288] Aggregation can be induced by chemical modification of 
individual amino acids, such as deamidation and oxidation of methionine or cysteine.[255] 
One particular example of such a modification is the fluorescent labelling of proteins, 
routinely performed on studies involving fluorescence microscopy. It has been shown that 
the use of even small fractions of labelled protein may increase the net protein-protein 
attractive interactions.[289] 
Protein aggregation is also strongly influenced by the solution conditions. 
Altering the pH of the solution changes the overall charge of the protein and higher charge 
of the protein results in stronger electrostatic repulsion between molecules.[290] The 
addition of salts at high concentrations may cause screening of charges and therefore a 
reduction in the electrostatic repulsions. The presence of various co-solutes has been 
shown to stabilize the native protein conformation.[291,292] Aggregation of various proteins 
can also be influenced by the presence of lipid bilayers, mainly in case of fibrillar 
proteins.[293,294]  
 Mechanisms of protein aggregation 
The aggregation of proteins depends on the solution conditions as well as the 
thermodynamic stability of the folded protein. Aggregates may form via several 
pathways, often occurring simultaneously within a protein solution, resulting in a 
formation of aggregates with various characteristics.[295] There are five main mechanisms 
of protein aggregation. 
1. Reversible association of the native monomer 
This mechanism involves monomer assembly into small oligomers due to self-
complementarity of protein monomers in their native state.[295] This process may be 
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reversible if the aggregates are formed by non-covalent interaction, or irreversible if 
formation of covalent bonds (such as disulphide linkages) is involved. 
2. Aggregation of a conformationally - altered monomer 
This mechanism occurs when a protein undergoes a conformational change or partial 
unfolding (transition state) and is generally irreversible.[295] Studies suggests that it is the 
most dominant mechanism of aggregation, easily promoted by heat or shear stress and 
implicated in many diseases, involving aggregation of prions or alpha-synuclein.[296] 
3. Aggregates formed from a chemically-modified product 
This mechanism involves chemical degradation, such as oxidation, deamidation or 
proteolysis of the native monomer. The chemically modified monomers can induce the 
aggregation of native monomers by altering their structural properties. Aggregates 
formed via this mechanism can be composed of chemically modified monomers, but can 
also include native monomers.[295] 
4. Nucleation-controlled aggregation 
This mechanism involves two stages; nucleation and growth. Nucleation is the rate 
limiting step and involves the assembly of monomers to form a critical sized nucleus. 
Once formed nucleus acts as a seed for further growth of the aggregates.[263,295] 
5. Surface induced aggregation 
This mechanism involves an adsorption to surfaces during protein handling and storage. 
It is initiated by binding (usually reversible) of the native monomer to surfaces, which 
induces a conformational change in the monomer structure.[295] Aggregation propagates 
either on the surface or in the bulk, if the altered monomer is released into the solution. 
Surface induced aggregation is similar to nucleation-controlled aggregation, with the 
surface acting as a nucleus. 
 Characteristics of proteins used in this research 
 Green fluorescent protein (GFP) 
Green fluorescent protein was first isolated, together with aequorin, from the 
Aequorea victoria jellyfish (figure 1.10a) by Shimomura et al.[297] Soon after the 
excitation/emission spectrum of GFP was published,[298] followed by its crystal 
structure[299] and the identification of the structure of the chromophore.[300] However, it 
was not until the cloning[301] and expression of GFP in other organisms,[302,303] showing 
that all of information necessary for synthesis of functional protein was contained within 
                  
  
33 
 
its sequence, that the potential of fluorescent proteins has been realized.[304] GFP and other 
fluorescent proteins are used for a large number of applications including detection of 
gene expression, monitoring localization and fate of fusion proteins, fluorescent tag 
addition to various cell organelles or detection of various conditions such as Ca2+ level or 
membrane potential.[304] 
The structure of wild-type GFP is referred to as a β-can (figure 1.10b). It is 
composed of an 11-stranded β-barrel with an α-helix running inside the barrel along the 
axis of the cylinder and other short helical fragments at the ends of the cylinder.[305] The 
chromophore, p-hydroxybenzylideneimidazolinone is formed from residues Ser65-
Tyr66-Gly67 and is buried in the centre of the cylinder (figure 1.10 c). A large number 
of polar amino acids, including Gln69, Arg96, His148, Thr203, Ser205, and Glu222 and 
structured water molecules are buried adjacent to the chromophore.[304] 
 
 
Figure 1.10 Aequorea victoria jellyfish (a) from which the wild-type GFP was initially 
purified,[306] (b) crystal structure of wild-type GFP with the 11 β-sheets forming a β can 
structure (Protein Date Bank Id code 1WMA) and the structure of the chromophore of (c).[307] 
Wild-type GFP has a major excitation peak at 395 nm and a minor peak at 475 
nm. Excitation at 395 nm results in emission peaking at 508 nm, while excitation at 475 
nm gives an emission maximum at 503 nm.[308] The dependence of the emission spectrum 
on the wavelength of the exciting light is a result of the presence of two distinct species, 
both protonated and deprotonated which are not equilibrated within the lifetime of the 
                  
  
34 
 
excited state.[304] Folding of wild-type GFP is efficient at or below room temperature, but 
it is greatly reduced at higher temperatures.  
A large number of GFP variants have been developed by introducing various 
mutations, altering components of the chromophore or altering properties of the protein, 
such as improved folding at 37°C or reduced aggregation at high concentrations. GFP 
variants are usually classified based on the nature of the chromophore, into seven classes, 
which have a distinct set of excitation and emission wavelengths.[304] 
Emerald GFP belongs to a class 2 grouping variants with phenolate anions 
forming the chromophore. Replacement of serine at position 65 with threonine causes 
ionisation of the chromophore, resulting in increased maturation,[309] suppression of the 
395 nm excitation peak (natural phenol) and the enhancement and shift of the 470-475 
nm peak to 489-490 nm.[310] Other mutations, such as F64L, S72A, N149K, M153T and 
I167T (figure 1.11), improve folding at higher temperatures, resulting in greater 
brightness. 
 
Figure 1.11 GFP mutation map listing common mutations overlapped with a topological layout 
of the peptide structure (a). The β-sheets are represented as green cylinders (arrow pointing 
towards the C-terminus) and α-helices are shown as gray cylinders. Mutations are color-coded 
to represent the variants of fluorescent protein to which they apply (bottom left corner); folding, 
shared and monomerizing mutations are shown in gray. Emission/excitation spectrum of the 
emerald GFP protein (b), one of the green variants of GFP. 
EmGFP has quantum yield of 0.68, molar extinction coefficient of 57 mM-1cm-1 
and relative fluorescence of 100%, making it one of the brightest variants of GFP in its 
class.[311] Measuring photostability of this protein has been difficult due to an initial 
photobleaching component. Recent results of photostability measurements reported as 
time required to photobleach from 1,000 to 500 photons per second per molecule in live 
cells under widefield arc-lamp illumination, was found to be 101 s for EmGFP.[312] In 
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comparison, that value for the superfolded EmGFP was found to be 157 s. Other recent 
publications do not report photostability issues in a number of applications, including 
cell-free protein synthesis[313] or fluorescence imaging.[314] 
 Bovine serum albumin (BSA) 
Bovine serum albumin is also known as “Fraction V” which refers to the Cohn 
method of purification of blood plasma and its use as a treatment for severe blood lost.[315] 
Serum albumin is a globular protein produced in the liver and has a half-life of up to 19 
days. It is the most abundant protein in the blood and is responsible for maintaining the 
colloidal osmotic pressure in blood vessels.[316] Other functions of serum albumin include 
transport and the distribution of a variety of molecules including metabolites, hormones 
or drugs, buffering pH or preventing degradation of folic acid.[317] Albumins have several 
binding sites facilitating binding of various molecules. 
BSA has a structure similar to human serum albumin with 76% sequence 
homology.[318] The primary structure of BSA, containing 583 amino acids leads to the 
synthesis of a multi-domain monomer of BSA[319] with molecular weight of 66 kDa. The 
sequence of albumins has a unique arrangement of disulphide double loops. Nine such 
loops are found in the BSA structure, forming three homologus domains: I, II, and III, 
shown in figure1.12. These are further divided into subdomains; A consisting of six 
helices and B with four helices.[317] Some interesting characteristics of BSA’s amino acid 
sequence include a high percentage of cysteine and charged residues as well as lack of 
sites for enzymatic glycosylation. The secondary structure of BSA consists of α-helices 
(55%), β-sheets (16%) and disordered structure (29%) and its tertiary structure is 
stabilized by 17 disulphide bridges. 
Most structural investigations of albumin have been based on human serum 
albumin with more than 50 crystal structures of HAS available in the Protein Data Bank. 
Recent studies of the BSA structure reveal differences in the structure of serum albumin 
from various mammals.[316,319] 
BSA is widely used in research, mainly as a nutrient in cell culture, as a reagent 
in a variety of assays, such as ELISA, immunoblotting, immunohistochemistry or as a 
molecular weight standard.[319] BSA is also commonly used as a model protein 
drug.[320,321] 
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Figure 1.12 Structure of bovine serum albumin; domains and elements of secondary 
structure,[316] Protein Data Bank Id code 3V03. 
 
 Human γD-crystallin (HGD) and the Pro23 to Thr (P23T) single mutant 
The α-, β- and γ-crystallins are the most abundant proteins of fibre cells in the eye 
lens of vertebrates.[322] The concentration of crystallin proteins within the eye lens 
exceeds 400 mg/ml,[323] which results in a high refractive index, up to 1.418 in the centre 
of lens,[324] which is required for correct light focusing on the retina. Crystallins are 
mainly structural proteins, however α-crystallin also functions as a molecular chaperone 
preventing aberrant protein interactions.[325] 
The γ-crystallins are small, compact, globular proteins. They exhibit short range 
attractive interactions, unlike the α- and β-crystallins, which were shown to display 
mainly repulsive interactions in solution.[326] Due to this difference in behaviour γ-
crystallins are responsible for reducing the osmotic pressure in the fibre cells and 
maintaining the transparency of the eye lens.[322,327] The γ-crystallins are soluble at very 
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high concentrations but their attractive interactions result in increased susceptibility to 
phase separation. 
Human γD-crystallin (HGD) is one of the most abundantly expressed γ-crystallin 
in the lens.[328] It is composed of 174 residues with two polypeptide domains forming a 
monomer shown in figure 1.13.[329] Several single point mutants of γD-crystallin resulting 
in protein condensation (causing increased light scattering) have been implicated in 
congenital cataract.[281,282] Age-related cataract is the formation of aggregates as a result 
of environmental stress or post-translational protein modifications.[330] 
 
 
Figure 1.13 Crystal structure of human γD-crystallin, cartoon representation of the secondary 
structure (a), the space fill representation illustrating hydrohobicity (b) and the amino acid 
sequence (c). Protein Data Bank Id code 1hk0. 
One of the single point mutations of the human γD-crystallin is the Pro23 to Thr 
(P23T) substitution. This mutation results in significant decrease in solubility (2 mg/ml 
at room temperature) compared to wild-type HGD[282] without major conformational 
changes in the protein structure.[331] Additionally, the solubility of P23T decreases with 
increases in temperature.[282] It has been proposed that lower solubility of the P23T mutant 
is caused by increased hydrophobicity due to the presence of “sticky patches” on the 
protein surface and decreased flexibility of the backbone.[285,286,332] Other substitutions at 
the 23 position such as P23V and P23S were also shown to invert the temperature 
dependence of the solubility line but result in a less drastic decrease in solubility.[282,287] 
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 Thesis motivation 
The motivation for this work was to further our understanding of self-assembly of 
biomolecules and its role and applications in model cell development. To-date, the self-
assembly of lipids and glycolipids have been extensively studied, however many aspects 
of their phase behaviour remain unclear. In particular the phase behaviour of synthetic 
glycolipids is of interest since these types of molecules can be used as a mimics for 
molecular recognition studies. 
The self-assembly of proteins is not only a feature of natural biological function 
but can also be associated with a pathological state in protein condensation diseases (such 
as Parkinson’s disease, Alzheimer’s disease or cataract disease) or reduced quality of 
biopharmaceutical protein products. Protein aggregation has traditionally been studied in 
a bulk, but this approach is not always optimal since it is not the best representation of 
the cellular environment. Studies of assembly in model cells offers a cell-like 
environment, but without the complexity of biological cells. The model cell can therefore 
be designed to contain only the required components, making both observation of the 
assembly (potentially without the use of fluorescent labels) and the interpretation of data 
less problematic. Additionally, model cells are much more resistant to a range of 
environmental conditions, which are unsuitable for live cell imaging, such as broad pH 
range or increased temperature and as such they can be used as a microreactors, to study 
processes in cell-like volumes but beyond only physiological conditions.  
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 Buffer and regents preparation 
 Buffers 
For the preparation of buffers, analytical grade salts and Milli-Q water (ultra-pure) 
were used. The pH of the buffer solutions was adjusted using appropriate concentrated 
acid or base solutions. Buffer solutions were filtered through 0.45 μm, 47 mm nylon 
membranes (Merck Millipore, Ireland) and degassed using a vacuum pump (Merck 
Millipore, Ireland) if necessary. Buffers for preparation of protein solutions were 
supplemented with 0.02% of sodium azide (Fisher, UK). 
 Sodium phosphate 
Sodium phosphate buffers at pH 7.4 at various molarities were prepared by dissolving 
disodium phosphate (Na2HPO4, 268.07 g/mol; Fisher, UK) and monosodium phosphate 
(NaH2PO4, 156.01 g/mol; Fisher, UK) (quantities listed in table 2.1) in 1 L of Milli-Q 
water. If necessary pH was adjusted using appropriate concentrated acid or base solution. 
 
Table 2.1 Quantities of the components of sodium phosphate buffer with varying molarity. 
 5 mM 20 mM 50 mM 
Na2HPO4 1.037 g 4.149 g 10.37 g 
NaH2PO4 0.176 0.705 g 1.76 g 
 Tris-HCl 
0.5 M Tris-HCl at pH 6.8 was prepared by dissolving 6.06 g of Tris base (121.1 g/mol; 
Merc, Germany) in 100 ml of Milli-Q water and adjusting pH with concentrated HCl. 
1 M Tris-HCl at pH 8.8 was prepared by dissolving 30.3 g of Tris base (121.1 g/mol; 
Calbiochem, USA) in 250 ml of Milli-Q water and adjusting pH with concentrated HCl. 
 Glycine-HCl 
50 mM glycine-HCl at pH 3 was prepared by dissolving 3.752 g of glycine (75.07 g/mol, 
Calbiochem, USA) in 1 L of Milli-Q water) and adjusting pH with concentrated HCl. 
 Sodium acetate 
50 mM sodium acetate at pH 4 was prepared by dissolving 244.96 mg of sodium acetate 
(136 g/mol; Fisher, UK) in 200 ml of Milli-Q water and adjusting pH with acetic acid. 
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 Sodium borate  
50 mM sodium borate, pH 8.5 was prepared using 1.55 g of boric acid (61.8 g/mol; Sigma, 
USA) in 500 ml of Milli-Q water and adjusting pH with concentrated NaOH. 
 Loading buffer – 20 mM sodium phosphate 0.5 M sodium chloride 30 mM 
imidazole 0.02% sodium azide 
Loading buffer for protein purification, pH 7.4, was prepared using 4.149 g of disodium 
phosphate, 0.705 g of monosodium phosphate, 29.22 g of sodium chloride (58.44 g/mol; 
Fisher, UK), 2.042 g of imidazole (68.08 g/mol; Sigma, Ireland) and 0.2 g of sodium 
azide (65 g/mol) in 1 L of Milli-Q water. 
 Elution buffer – 20 mM sodium phosphate 0.5 M sodium chloride 1 M 
imidazole 0.02% sodium azide 
Elution buffer for protein purification, pH 7.4, was prepared by dissolving 4.149 g of 
disodium phosphate, 0.705 g of monosodium phosphate, 29.22 g of sodium chloride, 
68.08 g of imidazole and 0.2 g of sodium azide in 1 L of Milli-Q water. 
 Reagents 
 Sucrose 
A 2 M sucrose solution was prepared by dissolving 17.114 g of sucrose (342.29 g/mol; 
VWR, Belgium) in Milli-Q water and made up to 25 ml. 
 Thioflavin T (ThT) 
4 mM thioflavin T stock solution was prepared by dissolving 12.75 mg of ThT (318.86 
g/mol; Sigma, USA) in Milli-Q water and made up to 10 ml. The solution was filtered 
through 0.22 μm syringe driven filters (Millipore, Durapore) and stored at 4°C for up to 
a week. 
 Fluorescein isothiocyanate (FITC)  
A 5 mM FITC stock solution was prepared using 9.73 mg of FITC (389.38 g/mol; Fisher, 
USA) in 5 ml of Milli-Q water. FITC solutions were stored at -20°C for up to a month. A 
10mg/ml FITC for BSA labelling was prepared using 10 mg of FITC in 1 ml of DMF. 
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 Sodium chloride (NaCl) 
A 2 M sodium chloride solution was prepared by dissolving 11.68 g of sodium chloride 
in Milli-Q and made up to 100 ml. 
 Reagents for the E. coli culture 
Where indicated, reagents for the E.coli cell culture were autoclaved at 121°C and 0.212 
MPa pressure for 20 minutes in a SX-500E TOMY autoclave (Seiko, Japan). 
 Ampicillin stock solution 
A 50 mg/ml ampicillin solution was prepared using 1 g of ampicillin (Fisher, China) in 
20 ml of Milli-Q water. The solution was filtered through a 0.22 µm filter and stored at 
-20°C. 
 LB agar for agar plates 
37 g of LB agar (Fisher, Ireland) was dissolved in 1 L of Milli-Q water and autoclaved. 
Upon cooling (ca. 50°C) a stock solution of ampicillin was added to a final concentration 
of 100 µg/ml. The solution was poured into 10 cm petri dishes, allowed to set and stored 
at 4°C for up to a week. 
 LB broth 
25 g of LB broth (Fisher, Ireland) was dissolved in 1 L of Milli-Q water and autoclaved. 
Upon cooling (ca. 37°C) a stock solution of ampicillin was added to a final concentration 
of 100 µg/ml and the broth was inoculated from a single E. coli colony selected from an 
LB agar plate. 
 IPTG stock solution 
1 M IPTG solution was prepared using 4.76 g of Isopropyl β-D-1-thiogalactopyranoside 
(238 g/mol; Fisher, Ireland) in 20 ml of Milli-Q water. Aliquots were stored at -20°C. 
 Cell lysis buffer 
Lysis buffer was prepared by dissolving 0.0788 g (50 mM) of Tris-HCl, 0.01461 g (25 
mM) of NaCl and 0.0074 g (2 mM) of ethylenediaminetetraacetic acid (EDTA; Fisher, 
USA) in 10 ml of Milli-Q water. 
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 Reagents for the mammalian cell culture 
The solutions listed below were prepared using sterile reagents and solvents. All of the 
steps were performed in the laminar air flow cabinet using aseptic technique. Cell culture 
media were stored at 4°C and stock solutions at -20°C. 
 Complete cell culture media (cDMEM) 
450 ml of DMEM (4.5 g/l glucose, 4 mM L-glutamine, no sodium pyruvate; HyClone, 
USA) was supplemented with 50 ml of bovine calf serum (BCS) or fetal bovine serum 
(FBS) (heat inactivated at 54°C for 45 min; Sigma, USA) and 2.5 ml of penicillin (10000 
units/ml) - streptomycin (10 mg/ml) stock solution (Sigma, USA) and stored at 4°C. 
 Serum free cell culture media (sfDMEM) 
50 ml of DMEM was supplemented with 250 µl of Pen-Strep stock solution. 
 Poly-D-lysine stock solution 
A 100 mg/ml stock solution was prepared using 5 mg poly-D-lysine (70-150 kDa; Sigma, 
USA) in 50 ml of Milli-Q water. The solution was filter sterilized (0.22μm) and stored at 
4°C. 
 Phosphate-buffered saline (PBS buffer) 
To prepare 1X PBS, 10 ml of 10X (Sigma, USA) solution was added to 90 ml of Milli-Q 
water. Alternatively a PBS tablet (Oxoid, UK) was dissolved in 100 ml of Milli-Q water. 
The solution was filter sterilized (through 0.22 µm filters). Aliquots were stored at -20°C. 
 Blasticidin stock solution 
A 0.2 mg/ml blasticidin stock solution was prepared by dissolving 2 mg of Blasticidin S 
HCl (Fisher, Ireland) in 10 ml of Milli-Q water. The solution was filter sterilized (through 
0.22 µm syringe driven filters). Aliquots were stored at -20°C. 
 L-glutamine stock solution 
A 200 mM L-glutamine stock solution was prepared by dissolving 2.923 g of L-glutamine 
(146.15 g/ml; Fisher, Brazil) in 100 ml of Milli-Q water. The solution was filter sterilized 
(0.22 μm filters). Aliquots stored at -20°C. 
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 Trypsin-EDTA solution 
To prepare a 1X trypsin-EDTA solution, 300 µl of 10X trypsin-EDTA (Sigma, Ireland) 
was added to 2.7 ml of sterile PBS buffer. 
 Protein solutions 
 Bovine serum albumin (BSA) stock solution 
BSA (Sigma, USA, Lot SLBL2871V) was used without further purification. A fresh 
protein solution was prepared each time by dissolving BSA in 20 mM sodium phosphate 
buffer pH 7.4, incubated for 1 hour at room temperature and then washed of co-
precipitated salts by repeated ultrafiltration using Amicon Ultra 10 kDa (Millipore, 
Ireland) centrifugal devices at 3500 g. BSA concentrations were determined by UV/Vis 
absorbance using the extinction coefficient 0.66 ml mg−1 cm−1. 
 BSA labelling 
FITC is widely used to fluorescently tag a variety of proteins. The isothiocyanate group, 
which in the isomer I is located on the C-4 of the benzene ring reacts preferentially with 
surface exposed primary amines and the terminal amino group. Here BSA solution was 
fluorescently labelled with the isomer I of FITC (Pierce Biotechnology, USA). 
Procedure: FITC was dissolved in DMF at 10 mg/ml. The BSA was hydrated for 1 hour 
in the conjugation buffer (50 mM borate buffer at pH 8.5) at final concentration of 2-2.5 
mg/ml. The FITC solution was added at a 20-fold molar excess to the BSA and incubated 
at room temperature in the dark. The excess of unbound FITC was removed using 
fluorescent dye removal columns (Pierce Biotechnology, Rockford) followed by multiple 
washes using Amicon Ultra 10 kDa centrifugal filter units, until no FITC was detected 
within the filtrate. 
Calculations: The concentration of labelled BSA was calculated as follows: 
 factordilution
CFAA
Mconcprotein 



)(
)(. max280  2.1 
where: Amax is the absorbance of the dye solution at the wavelength maximum (λmax for 
FITC is 494 nm), CF is the correction factor adjusting for the amount of FITC absorbance 
at 280 nm (CF for FITC is 0.3) and ɛ is the molar extinction coefficient of BSA, 43,824 
M-1cm-1. To calculate the degree of labelling following equation was used: 
                  
  
45 
 
degree of labelling factordilution
MconcBSA
BSAlabelledofA



)(.,
 2.2 
where ɛ’ is the molar extinction coefficient of FITC, 68,000 M-1cm-1. 
 Emerald green fluorescent protein (EmGFP) stock solution 
EmGFP was expressed in E. coli and purified via affinity chromatography (see section 
2.7 and 2.9). Upon purification the elution buffer was exchanged with 20 mM sodium 
phosphate, pH 7.4 and the solution was stored in the dark (to prevent photobleaching) at 
4°C. Buffer exchange was performed using a stirred ultrafiltration unit and Ultracel 10 
kDa membranes (Millipore, Ireland). For small volumes and to increase concentration, 
Amicon Ultra 10 kDa were used, with centrifugation at 3500 g. EmGFP concentrations 
were determined by UV/Vis absorbance using the extinction coefficient 0.918 ml mg−1 
cm−1. 
 Microscopy 
 Introduction 
Microscopy is a technique which produces magnified images of objects or 
features not visible to the human eye. The first optical microscope, composed of a single 
lens, was invented by Robert Hook in the 1660s. Over the next few centuries the design 
of the microscope was altered by new approaches and discoveries, such as optimisation 
of the single lens design by Anton von Leeuwenhoek or the introduction of Kohler 
illumination.[333] Modern microscopes are equipped with interchangeable components 
incorporating multiple modes of microscopy in one instrument. Components of 
microscopes may be arranged as inverted or an upright designs. Inverted microscopes are 
becoming more popular, especially in biological sciences due to the possibility of direct 
observation of cells directly in culture flasks. 
There are three main branches of microscopy which include optical, electron and 
scanning probe microscopy. Optical microscopy uses light and multiple component 
optical systems. There are several optical microscopy techniques based on the type of 
sample illumination. Electron microscopy uses a beam of accelerated electrons as a source 
of sample illumination. Scanning probe microscopy (SPM) uses a physical probe to scan 
the specimen and offers resolution of the order of fraction of a nm.[334] 
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 Light microscopy techniques 
 Components of light microscope and bright field analysis 
Light is electromagnetic radiation with properties of both particles (energy 
defining wavelength and vibrational frequency) and waves (electric and magnetic field, 
oscillating as sinusoidal waves in perpendicular planes). These properties can be related 
using the following equation: 
 
𝐸 =
ℎ𝑐
𝜆
= ℎ𝑣 2.3 
where E is the energy (ergs), , h is Plank’s constant, c is the speed of light (3  108 m/s), 
λ is the wavelength (µm) and ν is the frequency (cycles/s). 
 The electromagnetic spectrum is shown in figure 2.1. The resolution limit of the 
human eye, electron and light microscopy is indicated above the scale. The visible light, 
used in light microscopy is a small portion of the spectrum. 
 
 
Figure 2.1 The electromagnetic spectrum with different classes of electromagnetic radiation in 
the range of wavelengths between picometer up to a meter. 
A typical microscope setup is illustrated in figure 2.2. Objectives are designed to 
image specimens either with air (refractive index, n=1) between the objective and the 
cover glass (n=1.5) or with other media, most commonly oil (n=1.51), water (n=1.33) or 
glycerol (n=1.47). Using an immersion medium reduces the difference in refractive index 
(the ratio of speed of light in vacuum and in the medium), therefore preventing the 
refraction of light at the lower surface of the lens and allowing higher working numerical 
apertures to be achieved.[335] 
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Figure 2.2 Image formation in modern light microscope. 
The resolution of a microscope is the shortest distance between two points of a 
specimen that can be viewed as separate entities. The limit of resolution of a microscope 
is restricted by the wavelength of light but also depends on the numerical aperture of the 
objectives, substage condenser and proper alignment of the optical components. A simple 
equation to calculate the limit of resolution when the NAcond ≥ NAobject is shown below 
 NA
R 61.0  2.4 
where, R is the resolution (µm), λ is the wavelength of light (µm) and NA is the numerical 
aperture of the objective. If the NAcond < NAobject then the resolution is expressed as: 
 
NAobjectiveNAcondenser
R


22.1
 2.5 
The resolving power of a microscope increases when light with shorter wavelengths is 
used. Therefore the best resolution is achieved when using near-ultraviolet, followed by 
blue, green and then red light. 
Final magnification of an image is a result of both the magnification of the 
objective and the eyepiece.[333,336] The optimal magnification required to resolve a details 
present within the image is set between 500 and 1000 times of the NA. Use of higher 
magnification will enlarge the object but will not add further detail resulting in blurred or 
indistinct images. 
Protocol: Bright field images were acquired using an Olympus BX61 microscope 
(Japan), equipped with various lenses (between 10x and 100x; Olympus, Japan). Images 
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were viewed and recorded using CellF software and processed using ImageJ.[337–339] 
Figures were prepared using FigureJ plugin for ImageJ.[340] 
 Phase contrast microscopy 
Phase contrast microscopy was developed in the 1930’s by Frits Zernike. His 
discovery revolutionised biology and medicine (Nobel Prize in 1953). This technique 
facilitates high-contrast imaging of transparent, unstained specimens, which do not 
absorb much light, such as living cells. Such objects, known as phase objects induce a 
phase shift of light passing through them due to diffraction and scattering, however either 
the human eye or a digital camera cannot detect differences in the phase of light. The 
optics of the phase contrast microscope transform the differences in phase of light to 
amplitude differences within the image.[333] 
In phase contrast microscopy the light passing through an object is divided into 
two components (direct and diffracted waves) shown in figure 2.3 by an annulus ring 
positioned at the front focal plane of the condenser.[336]  
 
 
Figure 2.3 Path of light and the location of optical components in phase contrast microscopy. 
The direct (or surrounding) bright light do not interact with the specimen. The 
scattered diffracted wave is relatively faint and retarded compared to the direct wave. 
Light passing through the specimen forms a ring of light at the rear focal plane of the 
objective. Light rays diffracted after interaction with the specimen are distributed over 
the objective’s focal plane. A phase difference of the two components (increasing the 
contrast) is achieved by placing a phase plate at the rear focal plane of the objective. The 
design of the phase plate is such that the surrounding light travels through the thinner part 
(so shorter distance) of the plate and therefore travels faster compared to the diffracted 
light. The plate is also coated with an absorbing film, reducing the amplitude of passing 
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light. Both of the waves are focused at the intermediate image plane, where the phase 
differs by λ/2 which results in a destructive interference pattern.[341] In the positive (or 
dark) phase contrast image dark specimen is observed on the light background. 
The main limitation of phase contrast microscopy is the presence of optical 
artefacts in the form of halos around outlines of specimens. The presence of halos affects 
the detection of boundaries within the specimen.[333] 
Protocol: Phase contrast images were acquired using an Olympus BX61 microscope 
(Japan), equipped with a phase rings and UPlanFLN lenses of various magnifications. 
Images were recorded using CellF software and processed using ImageJ. Figures were 
prepared using FigureJ plugin for ImageJ. 
 Polarized light microscopy 
Polarization microscopy is used to study several properties, such as molecular 
order, thickness and the refractive index of a variety of specimens. Diverse biological 
specimens studied using polarized light include lipid bilayers,[342,343] microtubules and 
actin filaments,[344] chloroplast,[345] collagen[346] and cell walls.[347] Polarization 
microscopy is also commonly used in geology, chemistry, optical crystallography and 
material sciences.[348] 
In a beam of linearly polarized light, electric field vectors of all waves vibrate in 
planes parallel to each other. The orientation of the plane in which vibrations occur is 
described by the angle of the tilt.[336] Polarized light can be obtained using a polarizer 
such as a Polaroid sheet, which is a film of parallel arrays of polyiodide crystals. Such a 
filter has a transmission axis, which allows light through, vibrating parallel to that axis 
and blocking other rays. Two polarizers (the second one is usually called the analyser) 
with their transmission axis parallel to each other will transmit polarized light (figure 2.4). 
As the relative orientation of the transmission axis changes from parallel to perpendicular, 
the amount of transmitted light decreases. In the case of crossed polarizers (arranged at 
90°) linear light from the polarizer is blocked by the analyzer resulting in final 
transmission of light close to 0.[336]  
Birefringent materials, such as quartz are optically anisotropic and cause splitting 
of a ray of light into two rays (linearly polarized and with electric field vectors vibrating 
in perpendicular planes) travelling through it by separate paths; the ordinary (following 
the laws of refraction) and extraordinary ray.[336] This is known as double refraction and 
is caused by the geometrical arrangement of the crystal and the differences of its refractive 
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index with the respect of the direction. Birefringent materials contain a unique optical 
axis (called uniaxial) and if the beam of light is perpendicular to that axis the resulting 
rays exit at the same location but are shifted in phase due to different path lengths.[348] 
The perpendicular orientation of the two vectors and the phase shift give rise to elliptically 
polarized light. This is how most biological samples are viewed using polarized light 
microscopy.[336] 
 
Figure 2.4 Polarization of light obtained with a polarizing filter (a). The light transmission 
through the analyzer and polarizer depends on the orientation of their transmission axis (b). 
The speed of light in a given medium is influenced by the interaction of light with 
electric fields present in that medium. This property is known as the dielectric constant 
(ε) and is related to the refractive index (n) of the medium (ɛ = n2). Polarized light 
microscopy of biological samples is possible due to the polarizability (distortion from the 
normal distribution of the electron cloud upon the interaction with light[130] of biological 
molecules. The more polarizable the molecule the more extensive its interaction with light 
resulting in lower velocity of passing light.[336] Biological polymers, such as cellophane, 
composed of cellulose are polarizable in the direction parallel to the polymeric chain. In 
this direction the refractive index is the highest, resulting in the slowest light transmission. 
Therefore the polarizability of larger structures, such as cellulose fibers strongly depends 
on their orientation and so the orientation of their optical axis in respect to the direction 
of polarized light. 
 Any compound microscope may be converted into a polarizing microscope by 
addition of the polarizer and analyzer into the light path. Birefringent specimens observed 
using both the polarizer and the analyzer produce images of light and dark contrast 
depending on the shape and molecular orientation of ordered structures. 
Protocol: Polarized light images were acquired using an Olympus BX61 microscope, 
equipped with polarizer (rotatable) and (stationary) analyser and various magnification 
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lenses. Images were recorded using CellF and processed using ImageJ. Figures were 
prepared using FigureJ plugin for ImageJ. 
 Fluorescence microscopy 
Fluorescence microscopy is a technique used to study properties of a variety of 
organic and inorganic molecules. Fluorescence is a property of atoms or molecules with 
the ability to absorb light of a specific wavelength followed by emission of light of a 
longer wavelength (therefore lower energy). Fluorescence microscopy is especially 
popular in material sciences and biology due to the difficulties in obtaining sufficient 
contrast when using other types of microscopy.[349]  
Absorption of a photon of light of specific wavelength by a fluorescent molecule 
happens on a timescale of femtoseconds and results in the excitation of the molecule from 
the ground state to its excited state as shown in figure 2.5. The excited states may be 
formed as a result of physical (absorption), mechanical or chemical processes.[350] 
  
 
Figure 2.5 Example of a Jabłoński diagram.[350] 
Excitation is followed by relaxation to the lowest excited state (S1) in a process 
referred to as internal conversion, most widely known as Franck-Condon principle. It 
results in a loss of energy due to a collisions of the excited fluorophore with solvent 
molecules.[351] Relaxation from the lowest excited state to the ground state is accompanied 
by emission of photons of lower energy and is referred to as fluorescence.[352] If the 
relaxation to the ground state involves intersystem crossing to a triplet state, the light 
emission occurs in a process known as phosphorescence.[353] Delayed fluorescence can 
also be observed as a result of transitions occurring from the excited triplet state through 
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the lowest excited (singlet state) and back to the ground state.[351] These transitions are 
graphically presented in the form of a Jabłoński diagram (figure 2.5). 
 Fluorescent molecules 
Molecules capable of producing fluorescence are known as fluorophores (or 
chromophores). They can be divided into two main groups.[354] Intrinsic fluorophores are 
naturally fluorescing molecules, such as aromatic amino acids (phenylalanine, tryptophan 
and tyrosine), enzyme cofactors (NADH), and fluorescent proteins (GFP). Extrinsic 
fluorophores (fluorescent dyes) are fluorescent molecules added to the sample (or 
chemically bonded to it) in order to provide the fluorescence or change the characteristics 
of an intrinsic fluorescence.[352,355] Fluorophores absorb and emit light over a 
characteristic spectrum of wavelengths, known as absorption/emission spectra (figure 
2.6). The shape of the peaks depends on solvent conditions, such as pH, O2 concentration, 
the nature of the solvent, etc. and whether the given fluorophore is free in solution or 
bound to another molecule.[336] The difference in wavelength between the absorption and 
emission maxima is known as the Stokes shift. Fluorescent molecules having a large 
Stokes shift are particularly useful in microscopy since it is easier to separate their 
emission and absorption using appropriate filters.[352] 
 
 
Figure 2.6 Absorption and emission spectrum of FITC (Fluorescence SpectraViewer, Fisher). 
The molar extinction coefficient of a fluorophore is a measure of its ability to 
absorb light under specific conditions. It is reported at specific wavelengths and is used 
to convert units of absorbance to the molar concentration.[350] The quantum yield (Q) 
represents the efficiency of a given fluorophore to emit fluorescence and is calculated as 
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a ratio of emitted photons relative to the number of absorbed photons.[354] Fluorescence 
is proportional to the absorbed light multiplied by the quantum yield: 
  xQcIF 0  2.6 
where I0 is the intensity of light illuminating the solution, ɛ is the molar extinction 
coefficient (at the absorption λmax), [c] is the concentration of the fluorophore and x is the 
pathlength of the beam of light passing through the solution.[351] If values of I0, ɛ, x and 
Q are known, the concentration c can be determined as a function of F. 
Another important characteristic of fluorescent molecules is the fluorescence 
lifetime which is a measure of time during which the fluorophore remains in excited state 
before the relaxation process take place.[354] In a uniform population of molecules excited 
with a brief pulse of light, the decay of fluorescence intensity as a function of time can be 
described by following exponential function: 
 
)/(
0)(
teItI   2.7 
where I(t) is the intensity measured at time t, I0 is the initial intensity and τ is the 
fluorescence lifetime, the time during which the fluorescence decays to 1/e of I0. 
As shown by Herman (1998)[351] the contribution of processes, such as quenching, 
phosphorescence and internal conversion, competing with the fluorescence (and therefore 
reducing its intensity) for access to the electrons in the excited state can be combined into 
a single variable named the non-radiative rate constant (knr). The quantum yield can be 
expressed as: 
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where kf is the rate constant for the fluorescence decay, τo is the intrinsic fluorescence (the 
lifetime of the excited state in the absence of non-radiative processes, it is an inverse of 
the rate constant of fluorescence decay) and τF is the measured lifetime which includes a 
contribution from the intrinsic lifetime and non-radiative processes.  
Fluorescence microscopes commonly use epi-illumination systems (figure 2.7) 
where the light from the source is reflected by a dichromatic beam splitting mirror onto 
the back aperture of the objective which acts as a condenser.[351] A beam splitter reflects 
light with shorter wavelengths and transmits light of longer wavelengths. Fluorescence 
emitted by the specimen is collected by the objective and passed onto the detector 
(photomultiplier tube or a camera). Since fluorescence emitted by specimens is usually 
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quite weak the objectives used need to have a high numerical aperture (and preferably oil 
immersion) in order to collect as much of the light emitted in all directions. 
 
 
Figure 2.7 Path of light and the location of optical components in fluorescence microscopy. 
The most commonly used light sources used in fluorescence microscopy include 
xenon arc and mercury vapour lamps. They emit light of various wavelengths, the 
wavelengths required for excitation of the specimen are selected using an excitation 
filters. Undesirable wavelengths which did pass through the filter (usually only a small 
percentage) are transmitted by the beam splitter. The emission filter also allows for 
selected wavelengths to be passed onto the detector, preventing the detection of scattered, 
not-filtered excitation light. The excitation and emission filters consist of glass disks 
coated with either a refractive or interference coating. Depending on the coating, various 
ranges (long and short or narrow pass filters) of wavelengths may be passed through while 
others are blocked. Combinations of short and long pass filters are used when very 
specific wavelengths are required. 
The epi-fluorescence set-up is one of many fluorescence techniques available. The 
choice of the type of fluorescence microscopy depends on the nature of the dyes and the 
specimen and the type of information to be obtained. A variety of advanced microscopic 
techniques utilising fluorescent emission have been developed, such as superresolution, 
fluorescence recovery after photobleaching (FRAP), total internal reflectance 
fluorescence microscopy (TIRF) and many more.[350,356] 
Protocol: Fluorescence microscopy images were acquired using an Olympus BX61 
microscope with either UPlanSApo or UPlanFLN PH3 lenses. Fluorophores were excited 
using a mercury vapour lamp and either FITC (excitation 470 nm – 495 nm, emission 510 
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nm – 550 nm) or CY5 (excitation 620 nm – 660 nm, emission, long pass from 665 nm) 
filters. Images were viewed and recorded using CellF software and processed using 
ImageJ. Figures were prepared using FigureJ plugin. 
  Confocal microscopy 
Confocal microscopes have several advantages over traditional fluorescence 
microscopy, such as control over depth of field, significant background reduction and 
removal of out of focus fluorescence (through spatial filtering), which is very useful when 
imaging thick specimens.[357] Most of the optical elements of the confocal and widefield 
fluorescence microscopy perform identical functions. The most commonly used light 
source is a laser system. For confocal microscopy, emitted light passes through a pinhole 
aperture located in a conjugated plane with a scanning point on the specimen.[358] A 
second pinhole aperture is located in front of the detector. Laser light is reflected by the 
dichromatic mirror onto the specimen in a defined focal plane. Fluorescence emitted by 
the specimen is focused as a confocal point at the pinhole aperture below the detector. 
Some of the differences between confocal and widefield microscopy include the 
detection system (confocal consists of a photomultiplier tube) or use of pinhole aperture 
acting as a spatial filter (not used in widefield microscopy).[357] Another significant 
difference is the specimen illumination, which in traditional fluorescence microscopy has 
a shape of wide cone which results in high background emission from object located 
beyond and above the focal plane. In confocal microscopy the specimen is illuminated by 
a point of illumination. This significantly reduces the photobleaching and the out-of-focus 
emission, resulting in high-contrast images. 
Protocol: Images were acquired using an Olympus FluoView1000 laser scanning 
confocal microscope (Tokyo, Japan), using 458 and 633 nm lasers as a source of 
excitation. Images were analysed using FluoView (Olympus) and ImageJ. Figures were 
prepared using FigureJ plugin for ImageJ 
 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is a microscopic technique where 
images are obtained using an electron beam. TEM is widely used to study the structure, 
morphology and chemical properties of variety of samples, including biological material, 
metals or minerals. Development of the first TEM designed by Knoll and Ruska in 1931 
was driven by the limit of resolution encountered by light microscopy. 
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The source of the electron beam in a TEM instrument is usually a tungsten 
filament, connected to voltage source, which releases electrons upon introduction of a 
sufficiently high current.[359] A gas pressure of around 10-4 Pa is used to prevent 
generation of an electrical arc and to reduce the collisions of electrons with gas atoms. A 
small electron beam (between 5 and 0.1 nm in diameter) is necessary to achieve a good 
image quality.[341,360] The wavelength of an electron depends on its velocity; the higher 
the velocity the smaller the resulting wavelength. The wavelength of an electron is also 
related to its energy and in TEM, λ may be as little as 0.004 nm for a 100 keV electron 
microscope.[361] Shifts in the beam of the electron path are introduced with the aid of an 
electrostatic field.[360] Magnification in TEM is achieved by varying the ratio of the 
distances between the specimen and the objective lens. Apertures are used to control the 
intensity of the electron beam and to remove scattered electrons.[362] 
Thin specimens for TEM analysis are usually deposited onto a copper grid, which 
then is placed onto the sample holder and introduced into the path of the beam of 
electrons.[363] The interaction of the electron beam with the specimen occurs 
simultaneously with its passage through it. If necessary, the specimen may be stained with 
a variety of reagents, such as uranyl acetate to aid imaging. TEM yields black and white 
images, where the darker areas represent more dense parts of the specimen. 
Protocol: TEM analysis was performed at the Royal College of Surgeons in Ireland. TEM 
images were acquired using Hitachi H-7650 Transmission Electron Microscope with a 
side mount 2k AMT camera. Specimen was mounted onto pioloform mesh copper grids, 
blotted and air dried for several minutes. TEM was operated at 100 kV. Images were 
taken at 7 k or 10 k magnifications. Figures were prepared using FigureJ plugin. 
 Preparation of giant unilamellar vesicles (GUVs) 
 Lipid stocks 
The synthetic glycolipid used in these experiments was obtained as a white 
powder, stored at -20°C and used without further purification. All of the lipids purchased 
from commercial sources were used without further purification. Stocks were prepared in 
chloroform or a 9:1 chloroform/methanol solution and the aliquots were stored under 
argon at -20°C or -80°C in case of fluorescent dyes. 
Lipids used for vesicle preparation are listed in the table 2.2. 
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Table 2.2 Lipids used for vesicles preparation. 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
Avanti Polar Lipids 
(Alabama, USA) 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
Avanti Polar Lipids 
(Alabama, USA) 
PEG-DOPE 
1,2-dioleoyl-sn-glycero-3-phospho-
ethanolamine-N-[methoxy (polyethylene 
glycol) - 2000] (ammonium salt) 
Avanti Polar Lipids 
(Alabama, USA) 
BSM 18:0 Brain sphingomyelin 
Avanti Polar Lipids 
(Alabama, USA) 
Cholesterol (3β)-cholest-5-en-3-ol 
Calbiochem 
(Germany) 
Egg-PC 1, 2-Diacyl-sn-glycero-3-phosphocholine Sigma (USA) 
Liss Rhod PE 
(18:1) 
1, 2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N -(lissamine rhodamine 
B sulfonyl) (ammonium salt) 
Avanti Polar Lipids 
(Alabama, USA) 
NBD-PC 
(14:0-12:0) 
1-Myristoyl-2-[12-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)aminododecanoyl]-sn-
Glycero-3-Phosphocholine 
Avanti Polar Lipids 
(Alabama, USA) 
Bodipy FL 
C5 ceramide 
N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-pentanoyl) sphingosine 
Invitrogen 
(California, USA) 
cholesteryl 
bodipy FL 
C12 
cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-
3a,4a-diaza-s-indacene-3-dodecanoate 
Invitrogen 
(California, USA) 
Bodipy TR 
ceramide 
N-((4-(4,4-difluoro-5- (2-thienyl)-4-bora-3a, 
4a-diaza-s-indacene-3-yl) phenoxy) acetyl 
sphingosine 
Invitrogen 
(California, USA) 
 
Lipid mixtures were prepared by addition of appropriate amounts of the stock 
solution of each component, based on weight or molar ratios. When necessary, solutions 
were diluted using chloroform or 9:1 chloroform: methanol mixtures. All of the lipid 
solutions were handled using a 100 µl Hamilton gas tight glass syringe and glass bottles. 
 Electroformation 
An electroformation cell was built in-house on a microscope slide using a protocol 
based on Okamura et. al.[364] Three sets of incisions, 2 mm apart, were made on the bottom 
of a perfusion chamber (Grace Bio-labs, USA) to accommodate two platinum wires 
(Fisher, Ireland) and a narrow glass capillary, 50-100 µm in diameter (figure 2.8). The 
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glass capillary was coated with a thin layer of a 0.1 M lipid solution in chloroform, and 
allowed to dry for several minutes. A perfusion chamber was placed onto the adhesive 
surface of an imaging spacer (Secure-Seal, Grace Bio-labs, USA) which was in turn 
placed onto a microscope slide and allowed to adhere for several minutes. The chamber 
then was filled with Milli-Q water ensuring no air bubbles were formed around the Pt 
wires or the glass capillary. The platinum wires were connected to a function generator 
(built in-house) operating at 10 Hz and 2 V using crocodile clips.  
 
Figure 2.8 Experimental setup for electroformation on a standard glass microscope slide. 
Electroformation was carried out typically for two hours. For visualization and 
measurement, the assembly was disconnected from the function generator and placed 
directly under the microscope. During electroformation evaporating Milli-Q water can be 
replace through the opening in the cover of the perfusion chamber if necessary. 
 Gentle hydration 
A previously described method was used.[173] 20 µl of lipid of the required 
composition, dissolved in chloroform (0.1 M) was placed in a pear-shaped flask. 180 µl 
of chloroform was added. Excess chloroform was removed by evaporation, forming a thin 
layer of lipid on the inner surface of the flask. The flask was then placed under vacuum 
for 24 hours to remove any remaining chloroform. Nitrogen gas was passed through 
MilliQ water at 50ºC and then onto the dried lipid film for 40 minutes. Enough sucrose 
solution (0.1 M) was added (gently to avoid disturbing the film) to the flask up to cover 
the lipid film. The flask was the sealed and placed in an oven at 50ºC for 24 hours. The 
contents of the flask were gently swirled once to ensure homogeneity but further 
movement was limited to minimise shearing of GUVs before observation. 
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 Rapid hydration 
A previously published protocol[174] was modified slightly as follows; 20 µl of 
lipid of the required composition, dissolved in chloroform (0.1 M) was placed in a pear-
shaped flask. A mixture of 150µl of ethanol and 900 µl of chloroform were added. Milli-
Q water (7 ml) was added to the flask along the inside wall and the organic phase was 
removed using a rotary evaporator at temperature ca. 40ºC. 
 Lipid film hydration on an agarose film  
A protocol published by Horger et al.[175] and modified by Tsai et al.[65] was used. 
Agarose was dissolved in Milli-Q water (1% w/w), and boiled for up to 2 minutes. 300µl 
of agarose was spin-coated onto a glass microscope slide at a speed of 1380-1500 rpm for 
30 sec (SCK-100 Spin Coater, Instras Scientific). The slide was then dried for 30 minutes 
at 37ºC. A lipid mixture containing DOPC and PEG-DOPE at the appropriate ratio was 
dissolved at a concentration of 3.75 mg/ml in 95:5 (v/v) chloroform/methanol and 
deposited onto the agarose film by spin-coating (150 µl for 5 minutes at 1380-1500 rpm). 
The slide was placed under vacuum for 1 hour. An imaging chamber was placed on top 
of the microscope slide. 200 µl of 50 mM sodium phosphate buffer or Milli-Q water was 
injected into the chamber and incubated for 1 hour. For encapsulation experiments, 30 µl 
of 0.25 mM FITC in 20 mM sodium phosphate or 25 µl of cell-free expression medium 
was placed on top of the lipid film and incubated for 1 h (at 4°C in case of cell-free 
solution). To aid visualisation vesicles were diluted by adding a further 300 µl of the 
sodium phosphate. 
 Inverted (or w/o) emulsion method 
A protocol based on the method originally described by Pautot et al.,[176] and 
modified by Noireaux and Libchaber[51] was used. A lipid mixture of the desired lipid 
composition was dissolved in mineral oil (Sigma, Ireland) at a concentration of 5 mg/ml. 
The mixture was then heated and sonicated at 50ºC for 1 hour and incubated overnight at 
room temperature. 200 µl of the clear supernatant and 1-1.5 µl of PBS buffer were 
vortexed for a few seconds to form a water-in-oil emulsion. After leaving the emulsion 
to rest for a few minutes, 50 µl of the emulsion was placed on top of PBS buffer (950 µl) 
and centrifuged at 2000 rpm for 1 hour to form GUVs. 
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A modified version of the above protocol was also used, mainly for the 
encapsulation experiments.[365] Egg-PC solution at 10 mg/ml in 9:1 chloroform: methanol 
was prepared. The solution was placed in a glass bottle and the solvent was evaporated 
under a stream of nitrogen. A bottle containing the lipid film was place under vacuum 
overnight to remove traces of solvent. Mineral oil was added to a final concentration of 
0.5 mM (ca. 0.38 mg/ml). The solution was incubated at room temperature for 1 hour and 
then sonicated for 1 hour at a temperature below 40°C. 
For the encapsulation experiments two solutions were prepared: 
1. the inner solution containing molecules to be encapsulated, such as FITC, BSA, 
EmGFP in 20 mM sodium phosphate, pH 7.4 or cell-free expression medium. 
2. the outer solution composed of sodium phosphate or small molecular weight 
component of the cell-free expression medium supplemented with sucrose at a 
concentration matching the osmolarity of the inner solution. 
30 µl of the inner solution was added to 300 µl of a lipid in oil solution and vortexed 
gently or pipetted up and down to form an emulsion, which was then equilibrated for a 
few minutes. 250 µl of the emulsion was placed on top of the outer solution and 
centrifuged at 18000 g, 4°C, for 30 minutes. The GUV suspension was removed from the 
bottom of the tube by gentle aspiration. 
 Continuous droplet interface crossing encapsulation (cDICE) 
A previously published cDICE method protocol was used.[64] A 0.5 mM egg-PC 
solution in mineral oil was prepared as described for the emulsion method. The formation 
chamber was made of two 35 mm petri dishes lids (one with an opening of 1 cm) glued 
together. The chamber was filled with 3 ml of the outer solution (sodium phosphate buffer 
supplemented with sucrose at concentration matching the osmolarity of the internal 
protein solution), 3.5 ml of lipid in oil solution and 1 ml of decane (Sigma, USA) as 
shown in figure 2.9. 
 
 
Figure 2.9 Side and top view of the set-up used for GUV preparation by the cDICE method. 
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The chamber was then fixed on a spin coater. A needle of gauge 30 to 34 
(Radionics, Ireland), connected to a syringe containing the internal solution, was 
introduced through the opening. Larger size needles were selected if concentrated protein 
solutions were used to avoid clogging of the needle tip. The chamber was rotated at 1400 
rpm separating the different liquid phases into layers. The internal solution was injected 
from the needle at 2-30 µl/min for 5 to 20 min. After the formation was completed the 
spin coater was gradually stopped and the aqueous layer containing vesicles was 
withdrawn through the opening of the chamber. 
 Size distribution analysis 
Images of vesicles prepared using various conditions were recorded using CellF 
software. The diameter of 200 randomly selected, spherical and free in solution vesicles 
was measured (unless stated otherwise). Multilamellar, oligovesicular or liposomes with 
visible membrane deformations were not included in the size distribution analysis. 
For each composition and for each method used, experiments were conducted in 
triplicate/quadruplicate (unless stated otherwise); meaning that for each size distribution, 
600-800 GUVs have been measured, unless indicated otherwise. The vesicle diameters 
were averaged across the 3-4 repeat experiments and the distribution was normalized. 
 Incorporation of glycolipid into a lipid bilayer 
The synthetic glycolipid used here was synthesised using L-aspartic acid building 
blocks.[366] The glycolipid was dissolved in chloroform or a chloroform: methanol 
mixture, depending on the method used for preparation. The glycolipid was incorporated 
into the bilayer with other lipids, DOPC, cholesterol, PEG-DOPE and fluorescent lipid 
dyes. Various mixtures of lipids in chloroform or chloroform/methanol at concentrations 
required by each method were prepared. The amount of each component was calculated 
as a weight or mole fraction. 
The GUVs and the lipid tubules were imaged using phase contrast, polarized light 
and fluorescent microscopy. The fluorescent dyes added to lipid mixtures included the 
bodipy FL C5 ceramide, bodipy TR ceramide, cholesteryl bodipy FL C12 and (14:0-12:0) 
NBD-PC. These dyes were used at concentrations between 0.1 to 1 mol percent of the 
total lipid composition. 
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 EmGFP expression in E. coli 
 Transformation and growth of DH5α Competent cells for plasmid 
propagation 
The pRSET-EmGFP Bacterial Expression Vector (Invitrogen, Ireland) was 
propagated in Library efficiency DH5α Competent cells (Invitrogen, Ireland). Cells were 
transformed using the protocol recommended by the manufacturer, consisting of a heat-
shock procedure. Cultures were grown in LB broth containing 100 µg/ml ampicillin, at 
37°C with vigorous shaking (300 rpm) in an Innova 42 incubator shaker (New Brunswick 
Scientific Co., INC). Plasmid DNA was isolated and purified with a Qiagen plasmid 
purification midi kit (Qiagen GmbH, Germany) using a method recommended by the 
manufacturer. The concentration of plasmid DNA was obtained using a SpectraMax M2e 
microplate reader (Molecular Devices, USA) by measuring UV absorbance at 260 nm, 
and using the relationship that A260 equal to 1 corresponds to 50 µg/ml of dsDNA. The 
purity of DNA was determined from the A260/A280 ratio of diluted DNA solution. The 
nucleotide sequence of the emerald GFP was confirmed by sequencing with the T7 
promoter primer using an automated capillary DNA sequencer (MRCPPU, University of 
Dundee, Scotland). 
 Transformation and growth in BL 21-Gold (DE3) Competent cells 
for protein overexpression 
EmGFP protein was expressed in BL 21-Gold (DE3) Competent cells (Stratagene, 
USA). Cells were transformed with the EmGFP plasmid using the protocol recommended 
by the manufacturer and were cultured in 1.2 L of LB broth containing 100 µg/ml 
ampicillin at 37°C and shaken at 225 rpm. Expression was induced after 3-4 hours of 
growth (OD600 between 0.8 and 1) by addition of isopropyl β-D-1-thio-galactopyranoside 
(IPTG) to a final concentration of 0.83 mM. The culture was grown for a further 5 hours. 
Cells were harvested by centrifugation at 6000 rpm for 8 minutes. Cell pellets were stored 
at -80°C before protein extraction. 
 Preparation of bacterial cell stock 
Bacterial cell stocks for long term storage were prepared by aliquoting 2 ml of the 
BL 21-Gold (DE3) Competent cells (in Log phase growth) into sterile cryogenic vials 
(Nalgene, Ireland). Stocks were stored at -80°C. 
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  Site directed mutagenesis and molecular cloning 
Site directed mutagenesis is a method for creating specific changes at a specific 
site in the DNA sequence. The mutation may be a substitution, deletion or insertion of 
one or more bases. This method requires synthesis of two short DNA oligomers (forward 
and reverse sequence), complementary to the DNA and containing the desired mutation. 
A PCR reaction using high fidelity DNA polymerase leads to production of copies 
containing the mutated sequence. The PCR product is transformed into E. coli. 
The Human γD crystallin (HGD) bacterial expression vector coding for the eye 
lens γD-crystallin was used to prepare HGD P23T plasmid DNA coding for its single 
mutant (proline to threonine substitution at the 23 position). Oligonucleotides with 
following sequence were used for the P23T mutation[282]; 
Forward primer: 5ʹ-GCA GCA GCG ACC ACA CCA ACC TGC AGC CC-3ʹ 
Reverse primer: 5ʹ-GGG CTG CAG GTT GGT GTG GTC GCT GCT GC-3ʹ. 
Oligonucleotides were synthesized by Life Technologies (Dublin, Ireland). Mutagenesis 
was performed with QuikChange II site-directed mutagenesis kit (Stratagene, USA) using 
procedure recommended by the manufacturer. The PCR reaction was assembled as 
follows: 
5 µl of 10X PCR reaction buffer 
1.01 µl (50 ng) of ds DNA template 
0.39 µl (125 ng) of forward primer 
0.37 µl (125 ng) of revers primer 
1 µl of dNTP mix 
1 µl of PfuUltraHF DNA polymerase 
Milli-Q to final volume of 50 µl 
 
The PCR reaction mixture was assembled in a thin-walled PCR tube, gently vortexed and 
briefly centrifuged before being subjected to the following heating cycles: 
 
Pre-heat led step 105°C 2 min 
1 cycle 95°C 30 sec 
16 cycles 95°C 30 sec 
65°C 1 min 
68°C 9 min 
 
Following the removal of methylated DNA, containing the unchanged sequence, 
plasmid was transformed into E.coli (section 2.7.1). The plasmid was amplified, purified 
and sequenced as described in section 2.9.1. 
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 Protein expression in cell-free medium. 
Cell-free protein synthesis was carried out using PURExpress (New England 
Biolabs, USA), the E. coli based, purified in-vitro transcription and translation system. 
As per manufacturer instruction the components of the kit (solutions A and B) 
were combined on ice using RNAse free pipette tips. The reaction mixture was 
supplemented with 20 units of RNase Inhibitor (New England Biolabs, USA) and 350 ng 
of plasmid DNA. The total volume was adjusted to 25 µl with Milli-Q water. Protein 
expression in solution was carried out at 37°C. The concentration of expressed protein 
was quantified using a SDS-PAGE protein quantification technique and ImageJ 
(described in section 2.9). 
 Protein expression in cell-free medium was also performed inside GUVs. In order 
to do so, 25 µl of the cell-free expression was encapsulated inside GUVs using the 
inverted emulsion method. The outer solution was composed of the low molecular 
components of the cell-free expression kit (solution A) supplemented with 50 mM 
sucrose. 
 Protein extraction, purification and characterization 
 Protein extraction 
Cell pellets containing E. coli overexpressing EmGFP were thawed at 30°C in a 
water bath. The pH of the cell suspension was adjusted to 7. The cell pellet was 
resuspended (by vortexing) in lysis buffer (10 ml) and complete protease inhibitor 
cocktail tablet (25 MU, Roche) was added. The cell suspension was incubated at room 
temperature for 2 hours before the addition of 160 µl of a 50 mg/ml lysozyme solution. 
The solution was vortexed and incubated at room temperature for a further 30 minutes. 
The cell suspension was subjected to four freeze (liquid nitrogen) – thaw (30°C water 
bath) cycles. After the last cycle, 2 ml of 1 mg/ml DNAse and 1 ml of 1 M MgSO4 
(premixed) was added and solution was incubated at room temperature for 30 minutes. 
The pH was adjusted to 7 and the solution was centrifuged at 10 000g overnight or until 
cell debris was fully removed. The supernatant was stored at 4°C for chromatographic 
purification and the cell pellet was analysed by SDS-PAGE and if necessary stored at -
80°C for further extraction. 
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  Immobilized metal ion affinity chromatography (IMAC) 
Affinity chromatography is an analytical purification method used for 
biochemical mixtures. It exploits a specific interaction between the stationary phase and 
the analyte.[367] In immobilized metal ion affinity chromatography (IMAC) the stationary 
phase contain metal ions (nickel, cobalt, iron or others) which have a high affinity for a 
specific tag (His-tag or sites of phosphorylation) introduced to the molecule structure via 
recombinant DNA technology.[368] Elution of the analyte is usually induced by change of 
pH or introduction of competing molecules (imidazole). 
IMAC set up: Immobilized metal ion affinity chromatography was carried out 
using AKTAprime plus (GE Healthcare BioSciences, Sweden) and the PrimeView 5.0 
software (GE Healthcare, Sweden) was used to control the instrument. Absorbance 
spectra at 280 nm were obtained using the optical unit. A glass column (XK 16) was 
packed with ca. 10 ml of Ni Sepharose™ High Performance (GE Healthcare, Sweden) 
using the protocol provided by the manufacturer. 
Purification procedure: IMAC was used for purification of EmGFP present in 
the E. coli cell lysate. Prior to each purification, the system was rinsed with 200 ml of 
Milli-Q water and 100 ml of the loading buffer. Once the column was connected the flow 
rate was set to 2 ml/min (or less) with a maximum pressure of 0.3 MPa (3 bar). The 
column was rinsed with 3 column volumes of Milli-Q (to remove ethanol used for 
storage) and 10 column volumes of the loading buffer. Before loading onto the column, 
the cell lysate containing the crude protein (after centrifugation step) was filtered through 
0.22 μm Millex-Gv Millipore low protein binding (PVDF) membrane filter units 
(Millipore, Ireland). The pH, sodium chloride and imidazole concentration in the cell 
lysate was matched to that of the loading buffer. The cell lysate was introduced onto the 
column via one of the solvent lines. In order to remove any unbound proteins the column 
was rinsed with 100 ml of the loading buffer. The EmGFP was removed from the column 
by gradient elution using imidazole at concentrations from 30 mM to 500 mM. After each 
purification the column was rinsed with 5 column volumes of Milli-Q water to remove 
the imidazole. For long term storage, the column was filled with a 20% ethanol solution. 
  High Performance Liquid Chromatography (HPLC) 
HPLC is an analytical technique used to separate or quantify components of a 
mixture based on their distribution in two immiscible phases. Size-exclusion HPLC 
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separates molecules based on their size. In this method, the liquid mobile phase moves, 
together with the analyte, through the pores of the stationary phase. Larger molecules are 
eluted first, smaller molecules interact more with the matrix of the packing material and 
therefore have a longer retention time.[369] HPLC analysis was performed in order to 
assess the purity of EmGFP after affinity chromatography separation. 
HPLC set up: Size exclusion HPLC was carried out using a Shimadzu SPD 
HPLC system. Shimadzu LC solution software was used to control the instrument. 
Absorbance spectra were obtained using a diode array detector (DAD) at 190 – 800 nm. 
A Superdex 200 10/300 column (GE Healthcare, Sweden) composed of crosslinked 
agarose and dextran, with a molecular weight range 10-600 kDa was used. 
Procedure: Prior to use the HPLC lines were purged and rinsed with the correct 
buffer to remove any air bubbles. The column was then rinsed until a stable baseline was 
attained. A sample analysis was performed using 100 mM sodium phosphate buffer (pH 
7) as the mobile phase and a flow rate of 0.5 ml/min. Samples were prepared in glass vial 
with rubber seal and introduced onto the column via autosampler set to a 20 µl injection 
volume. 
Sample preparation: An EmGFP solution (from liquid chromatography 
purification) at 2 mg/ml in 100 mM sodium phosphate buffer, pH 7 was prepared, filtered 
through the 0.22 µm syringe filter (Millipore, Ireland) and placed into a glass vial. 
Calibration of the column: A mixture of five proteins (listed in figure 2.10) with 
various molecular weights were dissolved at 2 mg/ml in 100 mM sodium phosphate buffer 
and filtered through 0.22 μm syringe driven filters into a glass vial. Proteins were run 
individually to assign a retention time and as a mixture to establish a column calibration 
curve. 
 
Figure 2.10 Calibration of Superdex 200 10/300 HPLC column. 
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  SDS-PAGE analysis 
SDS-PAGE is a type of electrophoresis in which the separation, detection or 
purification of molecules is based on their molecular weight.[370] In this method an anionic 
detergent (sodium dodecyl sulphate or SDS) binds to the protein giving it an overall 
negative charge (driving their migration in electric field towards the anode) and causing 
protein unfolding by breakage of hydrogen bonds. Whenever breakage of disulphide 
bonds is desired, a reducing agent, such as 2-mercaptoethanol may be used. 
SDS-PAGE analysis was performed in order to check if the desired protein is 
present in cell lysate or the pellet (after purification), to assess the purity of the protein 
solution or to quantify a specific protein in the mixture. 
Gel preparation: Gel plates were assembled in the mini-protean tetra cell (Bio-
Rad, Ireland) as per the manufacturer’s manual. The following solutions were prepared: 
Resolving gel (12.5%) solution: Stacking gel (4%) solution: 
3.15 ml of Milli-Q water  
2.5 ml of 1 M Tris-HCl pH 8.8 
100 µl of 10% w/v SDS 
4.2 ml of acrylamide/Bis (30% stock) 
3.05 ml of Milli-Q water 
0.65 ml of acrylamide bis 
1.25 ml of 0.5 M Tris-HCL pH 6.8 
50 µl of 10% w/v SDS 
 
The components of the resolving gel were mixed and degassed, followed by the addition 
of 50 µl of freshly prepared 10% (w/v) ammonium persulfate (Riedel-de-Haën, Germany) 
and 5 µl of tetramethylethylenediamine (TEMED) (Thermo Scientific, USA). Next, the 
solution was poured between the glass plates and allowed to set for 30 minutes. A thin 
layer of tert-amyl alcohol was placed on top of the gel to remove air bubbles and prevent 
drying. Once the gel was set, the tert-amyl alcohol was rinsed off, and the stacking gel 
(4%) was prepared by mixing its components and degassing the solution for 30 min. 25 
µl of 10% (w/v) ammonium persulfate and 5 µl of TEMED were added. The solution was 
poured on top of the resolving gel and allowed to set. Gels were stored (in cling film to 
prevent drying) at 4°C for up to a week before use. 
Sample preparation: Samples for SDS-PAGE analysis were mixed with the sample 
buffer, heated at ca. 95°C for 5 minutes and briefly centrifuged before loading onto the 
gel. For reducing SDS-PAGE sample buffer was supplemented with β-mercaptoethanol 
in a 1: 20 ratio. Molecular weight markers (Bio-Rad) (figure 2.11) were diluted in 
reducing sample buffer (1:20), and 10 µl aliquots were stored at -20○C. 
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Before use markers were thawed, heated at 95○C and briefly centrifuged. 
Sample buffer: 
4 ml of Milli-Q 
1 ml of 0.5 M TRIS-HCl pH 6.5 
0.8 ml of glycerol  
1.6 ml of 10% w/v SDS  
0.5 mg of bromethyl blue (Sigma Aldrich, Germany) 
Gels were run in a 4-gel electrophoresis tank (Bio-Rad) with the power source set to 200 
mV. Tris-glycine buffer was used as the running buffer. In order to visualise protein 
bands, gels were stained in Coomassie brilliant blue R-250 (Biorad, Ireland) for a 
minimum of 2 hours. Gels were de-stained in a 1:3:6 acetic acid: methanol: Milli-Q 
(v/v/v) solution. 
 
 
Figure 2.11 Low range (left) and broad range (right) molecular weight markers (MWM). 
 
 Protein quantification using SDS-PAGE 
The Concentration of P23T protein, expressed in the cell-free mix was quantified 
based on the intensity of the band from the SDS-PAGE gel analysis. A calibration curve 
was prepared for each gel and used for protein quantification with either BSA or HGD 
protein as standards. A range of concentrations of the standard were used. The cell-free 
expression samples and the calibration standards were mixed with the reducing sample 
buffer, heated at 95°C and briefly centrifuged before 15 µl of each was loaded onto a gel. 
The gel was run using the set-up and parameters described above and stained in 
Coomassie brilliant blue R-250 solution overnight. De-staining of the gel was performed 
in a 1:3:6 acetic acid: methanol: Milli-Q (v/v/v) solution. 
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Gel were scanned and digital images were saved in .tif or .png format. 
Densiometric analysis was performed using the ImageJ software. 
 Determination of protein concentration in GUVs 
The amount of light absorbed by the fluorophore can be related to its concentration  
 
0kcQIF   2.10 
where k is a constant, c is the concentration fluorophore, Q is the quantum yield and I0 is 
the intensity of light illuminating the solution.[351] This equation relates values of F and c 
at low concentration of the fluorophore. At higher fluorophore concentrations the 
fluorescence intensity is independent of its concentration: 
 0QIF   2.11 
When using the fluorescent intensity measurement to calculate the concentration 
of the fluorophore the value of I0 must be kept constant. The intensity of illuminating 
beam can be monitored using a fluorescent standard. 
 Monitoring mercury lamp intensity. 
Measurement of the fluorescence intensity may be affected by various factors, 
with the intensity of the illuminating beam being one of them. MultiSpeck Multispectral 
fluorescence microscopy standards (Molecular Probes, USA) were used to monitor the 
day to day performance of the mercury lamp, mainly the fluctuation in the intensity of 
illuminating light. 
MultiSpeck fluorescence standard is a suspension of microspheres, 4 µm in 
diameter emitting red, green and blue fluorescence when excited with the appropriate 
wavelength of light. 1 µl of the microsphere suspension was deposited onto a microscope 
slide and air dried. When fully dry, the mounting medium supplied with the kit was added 
and a coverslip was placed on top. Microspheres were imaged every time protein 
quantification or related calibration curve measurements were performed. 
Monitoring of the intensity of illuminating light allows for the detection of 
variation in the instrument performance. The fluorescence intensity measurements 
performed on the days when such variations arise may therefore be either repeated or 
corrected. 
                  
  
70 
 
 Calibration curve preparation for protein quantification 
A calibration curve for measuring the protein concentration in GUVs was 
obtained using glass capillaries (Hilgenberg, Germany) with internal diameters of 20, 30, 
40, 50, 70, 80 and 100 µm. Capillaries were filled with EmGFP solution in 20 mM 
phosphate buffer at pH 7.4. Filling of the capillaries was performed by capillary action 
(which lead to an uneven distribution of the protein solution across the length) and by 
connecting the capillaries with a syringe via silicon tubing then filling it by immersing 
the free tip of capillary in the GFP solution and slowly withdrawing the protein solution 
until a droplet of liquid was observed on the opposite tip of the capillary (the one 
connected to the syringe). The following concentrations of EmGFP were used: 0.21, 
0.348, 0.506, 0.84 and 1.08 mg/ml. 
Each capillary filled with the EmGFP solution was observed and two images were 
recorded using fluorescence microscopy (figure 2.12a) with 10x and 20x magnification. 
Images with various exposure times were also recorded, but a 20 ms exposure time was 
used for constructing the calibration curves presented here. The calibration curve was 
constructed by: (1) measuring the fluorescence intensity in the centre of the capillary 
(mid-point in relation to its width) or (2) recording the fluorescent intensity profiles across 
the width of the capillary (perpendicular to its length). Graphs representing the calibration 
plots were prepared using Origin V6.1 software. 
 
 
Figure 2.12 Schematic representation of the measurement of cross-sectional intensity of GFP-
filled capillary (a) or vesicle (c) and the resulting fluorescent intensity plot (b); used for either 
the preparation of calibration curve or direct measurement of protein concentration inside the 
vesicle. 
In both cases a total of six measurements (three for each image) were obtained for 
each capillary size and each protein concentration. A separate calibration curve was 
constructed for each capillary size by plotting the average fluorescence intensity, 
measured within the center of GUVs or obtained by measuring the area under the peak 
for each fluorescent intensity profile. 
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 Conversion between various objectives and exposure times.  
The calibration curve of protein (EmGFP) concentration as a function of the 
fluorescence intensity and diameter was recorded using 10x and 20x lenses. Since images 
of vesicles encapsulating EmGFP were recorded using either 60x or 100x, a scaling factor 
was determined using fluorescent microspheres as a standard. To do this, microspheres 
were imaged using objectives with magnification from 10x to 100x and their fluorescence 
intensity was measured as in section 2.7.2, table 2.3. The scaling factor was thereby 
determined as a difference of the fluorescence intensity within microspheres observed 
with 10x and any other objective. Fluorescence intensity of EmGFP encapsulated within 
a GUV may therefore be multiplied by the scaling factor corresponding to the objective 
used to record a given image. The obtained value corresponds to the EmGFP 
concentration which can be obtained from the calibration plot. 
 
Table 2.3 Conversion table listing fluorescence intensity measurements obtained using a 
fluorescent standard and a range of lenses. The scaling factor (for 10x calibration) allows 
conversion of intensity between higher magnification lenses used for imaging of GUVs and the 
10 X lens used to obtain measurements for the calibration curve. 
Lens 10x 20x 40x 60x* 60x** 60x** 60x** 100x 
Exposure time 10 ms 10 ms 10 ms 10 ms 10 ms 5 ms 2 ms 10 ms 
Fluorescence 
intensity (au) 
180.36 510.67 681.67 1225.3 1413.3 977.94 516.69 1315.6 
Scaling factor (10x) - 0.353 0.264 0.147 0.1276 0.184 0.349 0.137 
* UPlanFLN objective ** UPlanSapo objective 
 
 Quantification of protein concentration within GUVs 
Liposomes were prepared and protein solutions were encapsulated using one of 
the previously described methods. Upon formation, vesicles containing protein solutions 
were imaged using either 60x or 100x magnification. Fluorescence images were analysed 
using CellF and ImageJ software. 
For vesicles containing EmGFP solutions, fluorescence intensity was measured 
either in the centre of the vesicle (point measurement) or across the vesicle’s diameter 
and used to construct the intensity plot. The area under the curve and the scaling factor 
for a given lens were used to obtain the EmGFP concentration for a given GUV size. 
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 Quantification of BSA encapsulated inside vesicles was performed indirectly, by 
measuring the concentration of EmGFP present in the GUV. EmGFP was added to a BSA 
solution at 0.5% of the total protein concentration. The EmGFP concentration was 
obtained using the procedure above. The BSA concentration was then inferred by 
calculating the concentration of EmGFP and its contribution to the total protein 
concentration. 
Analysis of the effect of BSA on the fluorescence of EmGFP 
The fluorescence measurements were conducted using SpectraMax M2e multi-
platform reader. Solutions of EmGFP and EmGFP/BSA mixtures in 20 mM sodium 
phosphate buffer, pH 7.4 were prepared and placed in quartz cuvette. The sample was 
excited at 487 nm and emission spectra between 450 and 600 nm were recorded. 
 Aggregation of BSA in various solution conditions. 
 In bulk solution 
Experiments to monitor BSA solution behaviour were performed in 96-well, clear 
bottom plates. A BSA stock solution at a concentration of 100 mg/ml was prepared in 5 
mM sodium phosphate buffer, pH 7.4 and diluted to 10 mg/ml using an appropriate 50 
mM buffer: glycine-HCl (pH 2.2 and 3), sodium acetate (pH 4) and sodium phosphate 
(pH 7.4). ThT (if used) was added to a final concentration of 200 µM and NaCl was added 
from a 2 molar stock to achieve final concentrations ranging from 0 - 100 mM. The total 
volume in each well was fixed at 150 µl. Plates were incubated either at room temperature 
or at 65°C and cooled to room temperature before analysis. Fluorescence intensity 
measurements were performed immediately after preparation and at set time points (every 
12 hours for when incubated at room temperature and every 20 minutes when incubated 
at 65°C) using a SpectraMax M2e microplate reader. The excitation wavelength was set 
to 435 nm and the emission spectrum was recorded between 465 and 565 nm. 
Additionally absorbance at 450 nm and 600 nm was recorded and percentage 
transmittance (%T) was calculated using following equation: 
 )2(10% AT   2.12 
The measurements were performed in triplicate and the results reported as an average. 
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 Protein inside vesicles  
A 100 mg/ml BSA stock solution was prepared for the encapsulation experiments 
in 5 mM sodium phosphate buffer at pH 7.4. 
The inner solution (to be encapsulated in GUVs) was composed of: 
 a buffer at the correct pH: glycine-HCl (pH 2.2 and 3), sodium acetate (pH 4) or 
sodium phosphate (pH 7.4), 
 BSA at concentrations of 10, 20 or 40 mg/ml, 
 ThT at a concentration of 200 µM 
 50 mM NaCl was added to solutions where indicated. 
The inner solution was prepared immediately before the encapsulation. 
The outer solution (in which GUVs were suspended upon formation) was composed of: 
 a buffer at the correct pH, 
 sucrose at concentration (established experimentally) required to match the 
osmotic pressure of the BSA filled liposomes, 
 ThT at a concentration of 200 µM 
 50 mM NaCl was added to solutions where indicated. 
After formation the GUVs suspension was removed from under the oil layer, gently 
mixed and incubated at room temperature for approximately two hours. Next, the vesicle 
suspension was transferred into PCR tubes and incubated at either room temperature for 
up to 5 days or at 65°C for up to 100 minutes. 
 Mammalian cell culture 
 HEK 293T/17 cell line 
HEK 293T/17 was purchased from LGC (UK). HEK 293 is an epithelial cell line 
derived from human embryonic kidney cells transfected with mechanically sheared 
adenovirus 5 DNA, which then was integrated into chromosome 19.[371,372] The 293T cell 
line was created by inserting the temperature sensitive gene for the SV40 T-antigen. 
Clone 17 was selected due to its high transfectability. 
 Initiation of cell culture 
Vials containing frozen stocks of cells were defrosted at 37°C in a water bath for 
2 minutes. From this point all of the operations were carried out in a biological safety 
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cabinet (SafeFast Classic, Faster S.r.l.) under strict aseptic conditions. The contents of the 
vial were transferred into a falcon tube containing 9 ml of the complete DMEM and 
centrifuged at 125 g for 7 minutes. The supernatant was removed and cell pellet was 
resuspended in 6.5 ml of cDMEM and transferred into a T25 flask (Corning). Cells were 
grown in Memmert INCO 153 incubator (Germany) at 37°C, 90% humidity and 5% CO2. 
 Subculturing and maintenance of culture 
The cultures were maintained by refreshing the cDMEM every 2-3 days as 
indicated by confluence or change in colour of the cDMEM caused by change an in pH 
due to the presence of metabolites. When the culture reached 90% confluence, cells were 
subcultured using the following procedure (volumes are given for T25 flasks). The 
medium was removed and the cells were rinsed with 1X PBS, followed by the addition 
of 1 ml of trypsin-EDTA (500 mg/L porcine trypsin, 200 mg/L EDTA.4Na) in PBS 
solution. The flask was incubated at 37°C until the cells detached (but for no longer than 
10 minutes). 9 ml of cDMEM was added and the cells were harvested by gently aspirating 
the medium. The cell suspension was placed in a falcon tube and centrifuged at 125 x g 
for 10 minutes. The supernatant was discarded and the cells were resuspended in fresh 
medium. Cells were counted using a hemicytometer and seeded at an appropriate 
concentration, usually 2x105 cells/ml. 
 Cryopreservation of cell stocks 
Once confluent, cells were harvested using the protocol described above and 
resuspended in the cryopreservation medium composed of 95% of complete DMEM and 
5% diethyl sulfoxide (DMSO) at 3 x 106 cells/ml. The cell suspension was aliquoted into 
cryopreservation vials. The vials were first placed at 4°C for 5 minutes, next in a -20°C 
freezer for 1 hour followed by -80°C for 1 hour and finally into a liquid nitrogen storage 
container for long term storage. 
 Protein expression in mammalian cells 
 Transfection 
Transfection is a process by which a nucleic acids are introduced into a 
mammalian cell. There are several methods for transfection routinely used. Here, 
Lipofectamine 2000 (Invitrogen, USA) was used as the transfection reagent. It is a 
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cationic liposome formulation which forms complexes with DNA, via electrostatic 
interactions with the nucleic acid charge.[373] 
A mammalian expression vector containing the sequence of a fusion protein 
EmGFP-HGD was designed and the vector was synthesized by GeneArt (Thermofisher, 
GeneArt division, Germany). The mammalian vector pc-DNA6.2_C-EmGFP-DEST 
vector was used and the HGD gene was inserted at the C-terminus. The EmGFP-P23T 
vector was obtained by performing site directed mutagenesis of the mammalian 
expression vector. Mutagenesis was performed with QuikChange II site-directed 
mutagenesis kit using a primers and protocol described in section 2.9.3. The correct 
nucleotide sequence was confirmed by sequencing (MRCPPU, University of Dundee, 
Scotland) (see section 2.9.1 for details). 
The mammalian cells expressing EmGFP were obtained by transfection with the 
Vivid Colors™ pcDNA™ 6.2/EmGFP GW/TOPO mammalian expression vector 
(Invitrogene, USA). 
Transfection was performed once cells seeded in 6-well plate reached 90% 
confluency. Prior to transfection, the medium was exchanged to DMEM without serum 
(sfDMEM). The DNA plasmid was diluted in sfDMEM (2.5 µg in total of 100 µl per 
well). Lipofectamine was diluted in sfDMEM (5 µl into 95 µl of DMEM per well) and 
incubated at room temperature for 5 minutes. Diluted Lipofectamine was added to the 
diluted DNA, mixed and incubated at room temperature for 20 minutes. Next the DNA-
Lipofectamine complex solution was added to the cells and incubated at 37°C for 4 hours. 
Following that time the medium was exchanged for complete DMEM (containing serum). 
Transfected cells were visualized 4 days from the transfection date. 
 Generating stable cell lines 
The fusion plasmids used here contain the Blasticidin resistance gene to allow for 
selection of stable cell lines. In order to do that the minimum concentration of the 
antibiotic required to kill untransfected cells must be determined. 
Determining sensitivity of the HEK 293T/17 cells to Blasticidin: Cells were 
grown in 6-well plate. When confluency of around 25% was reached, the medium was 
replaced with fresh complete DMEM containing various Blasticidin concentrations 
ranging from 0 to 10 µg/ml. The growth of cells was monitored for 2 weeks. 
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A blasticidin concentration of 5 µg/ml was found to be the minimum 
concentration required to kill untransfected cells. Stable transfectants were selected using 
following protocol. The day after transfection (approximately 24 hours), cells were 
washed with PBS and fresh medium was added. On day 2, cells were split into fresh 
DMEM and seeded at 25% confluency. Cells were allowed to adhere for ~ 4 hours and 
the medium was replaced with the complete DMEM containing 5 µg/ml of blasticidin. 
The medium was replenished every 2-3 days for at least 2 weeks. 
 Microscopic imaging of live cells 
In order to facilitate cell growth on glass coverslips, surface treatment with poly-
D-lysine was performed. The coverslips were first cleaned and sterilised. Next, their 
surface was coated with 300 µl of 100 mg/ml poly-D-lysine (70-150 kDa) solution and 
incubated at 37°C. After 40 minutes, the coverslips were thoroughly rinsed with sterile 
Milli-Q water and allowed to dry for at least two hours. Coated glass slides were stored 
at 4°C. 
Coated glass cover slides were placed in the wells of 6- or 12- well plates. Cells 
were seeded at 2x105 cells/ml. Once the desired confluency was reached the medium was 
replaced with complete, phenol red-free DMEM and cells were incubated for 30 minutes. 
Prior to imaging the cover slide was placed on a glass slide and covered with second 
coverslip. An imaging spacer was placed between the two coverslips to prevent crushing 
the cells. The coverslip was sealed with melted agarose. Slides containing live cells, either 
with transient or stable transfectants, were imaged on a heated stage set to 37°C. Cells 
were observed using both phase contrast and fluorescence microscopy (section 2.3). 
Images were recorded using CellF software and processed using ImageJ. 
 
 Fractal dimension analysis 
A Fractal, also known as expanding symmetry is a natural or mathematical 
phenomenon characterized by repeating patterns exhibited at every scale (figure 2.13). 
The word ‘fractal’ originates from the Latin fractus, which means “to break” but also 
“irregular” and was coined by Benoit Mandelbrot[374] 
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Figure 2.13 Mathematical fractals (a): Gosper island and Koch snowflake and fractal patterns 
found in nature (b-e) (taken from mathworld.wolfram.com, fractalfoundation.org, 
sya.deviantart.com, cohabitaire.com and [375]). 
 
 Introduction: theory behind fractal analysis 
Fractals are self-similar, which means that the same pattern is observed regardless 
of scale or size. This can be realized using a lens to zoom in on the image, uncovering 
repeating shapes with no change or new detail.[374] Another characteristic of fractal 
structures is the fact that they follow non-linear scaling rules and their fractal dimension 
is greater than their topological dimension. For example if a 1-dimensional straight line 
is divided into three pieces each of them will be 1/3 of the original length resulting in 
fractal dimension of 1. This is not the case for a fractal object. For example if the Koch 
snowflake (also 1-dimensional) is divided into four pieces, each will have 1/3 of the 
original length (figure 2.14). Fractals cannot be measured using traditional approaches as 
the fractal curve is infinitely long.[376] It has been proposed that the boundary length of a 
fractal object can be expressed as a power law[377]: 
 𝐿(𝑟) = 𝑁 ∙ 𝑟𝐷𝐻 2.13 
where L(r) is the boundary length, r is the length of straight line fragments used to 
measure the boundary length, N is the number of such fragments and DB is the Hausdorff 
dimension, which after rearrangement becomes: 
 𝐷𝐻 = lim  𝑟→0
𝑙𝑜𝑔𝑁
log (
1
𝑟)
 2.14 
The Hausdorff dimension has a value between the topological dimension of the 
object and the topological dimension of the space which it occupies. A more complex 
boundary of a fractal object correlates to a higher value of the Hausdorff dimension. 
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Figure 2.14 Fractal dimension of the Koch curve.[376] 
 Fractal analysis is used to quantify and analyze similarities between patterns 
otherwise hard to describe. Approximate fractals can be found in nature (figure 2.13) and 
include snowflakes,[378] coastlines or earthquake locations[379] and river networks. Fractal 
dimensions have also been frequently used to analyse biological and biomedical images 
including retinal vasculature,[380] tumours,[381,382] cellular morphology,[383,384] bacterial 
growth patterns[385] or protein aggregates.[386,387] Fractal dimension analysis of biological 
samples is used to represent complexity of the shape of an object and to compare 
morphological features.[388] 
There are a large number of fractal dimensions, (some used only in pure 
mathematics) as well as several methods of measuring a fractal dimension. The methods 
most popular for analysing biological images include: box counting, perimeter-
stepping[389] or pixel dilation.[390] The fractals found in nature exhibit random fluctuations 
in their self-similar patterns, which results in statistical self-similarity expressed by a 
divider fractal dimension[391] or box-counting dimension.[377] Various types of software 
offering fractal dimension calculations are available such as Benoit,[392] BCF,[393] Fractal 
Analysis v02[394] and the FracLac plugin for ImageJ.[395] 
 Box-counting method 
ImageJ free software was used to prepare the digital images and the FracLac 
plugin for ImageJ, developed by A. Karperien was used for the fractal dimension 
calculation. The method outline was taken from the FracLac manual.[395] 
Image preparation  
In order to be analysed, digital microscopy images must be converted to binary 
images. This can be done using a threshold function, which divides pixels of an image 
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converting ones below a set value to black and above that set value to white, therefore 
assigning the background and foreground pixels. Binary images can further be converted 
to one-pixel wide outlines or skeletonized drawings (with lines of unchanging diameter). 
Box-counting method 
Box-counting is a method of data gathering for fractal dimension measurements. 
It involves a series of grids (boxes) of decreasing size laid over a digital image. Data 
collection involves counting how many boxes of each grid contains foreground pixels. 
Changing the grid calibre (the size of the box) results in changes in the number of pixels 
(or so called “mass”) in each box. The mean mass and the average number of foreground 
pixels per box at any given size may be used to calculate a mass dimension, lacunarity 
(inhomogeneity or texture) and multifractality. 
Fractal dimension is a measure of how a detail changes with resolution and is 
based on the concept of a dimension arising from N=RD where N is the number of counted 
parts of a pattern and R is the relative scale. FracLac uses a bounding box, which is the 
smallest rectangle oriented box enclosing all of the foreground pixels within an image, to 
determine the relative size of the largest box within the grid calibre and the scale for a 
given box counting scan. The degree of complexity is given by: 
 
D =  
𝑙𝑜𝑔𝑁𝜀
𝑙𝑜𝑔𝜀
 2.15 
where N is the number of new pieces and ɛ is the scale applied to an object and equal to 
box size/image size (so the size of boundary enclosing the foreground pixels). The fractal 
dimension is approximated as the slope of regression line from: 
 𝐷𝐵 = lim  
𝜀→0
𝑙𝑜𝑔𝑁𝜀
𝑙𝑜𝑔𝜀
 2.16 
The slope of the regression line is given by: 
 
𝑚 =
𝑛 ∑ 𝑆𝐶 − ∑ 𝑆 ∑ 𝐶
∑ 𝑆2 − (∑ 𝑆)
2  2.17 
where S is the log of the scale or size (ɛ), C is the log of the count, which is the number 
of sampling elements (boxes) containing foreground pixels, and n is the number of sizes. 
 FracLac allows the user to choose the number of grid positions, meaning the 
orientations of the grid with respect to an image. The first four orientations assume the 
grid positioning in the corners of the bounding box. If more than four grid positions were 
selected, the locations of remaining orientations are selected based on predetermined 
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random numbers generating the coordinates within the biggest box in the series of a given 
grid calibres and with respect to the four corner locations. 12 grid positions were selected 
for the fractal dimension calculations used here. The use of more than 12 positions was 
found to significantly increase the time required for measurement without any gain in the 
accuracy of the result. 
Since multiple grid locations were used, delivering multiple DB values, the mean 
fractal dimension was calculated using equation 2.18. 
 
?̅?𝐵 = ∑ 𝐷𝐵(𝐺)
𝐺𝑟𝑖𝑑𝑠
𝐺=1
× 𝐺𝑟𝑖𝑑𝑠−1 2.18 
FracLac also allows for custom selection of other options, such as the box size or 
shape. The box size was set to optimum values based on the image size. The smallest size 
of a grid was not predetermined, the largest grid was set to 45% of the image size. 
The results of fractal analysis, reported in table format were averaged over several 
digital images representing a set of experimental conditions. The standard deviation and 
the coefficient of variation were reported for each data set. 
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Preparation of giant unilamellar 
vesicles by a range of techniques 
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 Introduction 
Lipid vesicles can be prepared from a variety of lipids using numerous methods 
of preparation. Both the lipid composition and method of preparation affect various 
properties of the lipid bilayer within these vesicles. 
Since their discovery, lipid vesicles have been a work horse of cell membrane 
research, providing a better understanding of membrane properties and the processes 
occurring within. In recent years there has been growing interest in using vesicles as 
microcontainers for analysis of various biochemical reactions[105] or for development of 
model cells,[16,187,188] the latter being pursued in this work. 
The number of methods available for liposome preparation is large and still 
growing, due to recent technological advancements, such as improvements in 
microfluidic techniques. The choice of the right experimental approach however still 
remains unclear, as various methods produce different types of vesicles, with various 
yields, depending on the type of lipids used. Therefore the choice of method is strongly 
influenced by the intended application. Since comparison with published data is not 
always possible, a reliable and fast approach for the comparison of results of various 
methods of preparation is presented here. 
 GUVs are commonly used to study the phase behaviour of model 
membranes.[60,146,149,396–398] The presence of coexisting liquid phases (liquid-ordered and 
liquid-disordered) was previously shown for variety of lipid mixtures such as ternary lipid 
mixtures containing DOPC, cholesterol and DPPC or sphingomyelin (SM). In fact, only 
small differences were observed between phase diagrams for mixtures containing DPPC 
and/or the sphingomyelin.[145,399] Similar lipid mixtures were used to observe phase 
behaviour within lipid bilayers prepared by gentle hydration method. 
Giant unilamellar vesicles have been prepared by electroformation, lipid 
hydration methods (hydration on an agarose film, gentle and rapid hydration), water-in-
oil emulsion and continuous droplet interface crossing encapsulation (cDICE). For each 
method investigated GUVs were assessed qualitatively (by appearance, lamellarity, 
presence of surface defects, tendency to cluster) and also by constructing size distribution 
profiles. For electroformation and hydration methods lipid composition and the aqueous 
solution in which formation was performed were varied in order to assess the influence 
of a given parameter on the characteristics of vesicles formed. The base lipid composition 
used for most of the experiments was an 80:20 DOPC/DPPC mixture, since this 
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composition produced consistent GUVs by a number of different methods. Cholesterol 
and sphingomyelin were added to the membranes to assess how their presence altered 
both the quality and size distribution of the GUVs formed. Egg PC was mainly used in 
the cDICE and emulsion method, since it has previously been shown to form large and 
abundant GUVs. 
 While there are a number of methods available to prepare GUVs, it is often 
difficult to predict if the GUVs formed will be suitable for the experiment that a particular 
application requires, especially where the desired membrane composition differs from the 
one described in the literature. The diameter of vesicles is of particular interest since 
depending on the method of analysis a particular range of sizes may be required. While 
smaller vesicles (1-2 μm) may be sufficient for many applications, it is often easier to see 
features, such as lipid phase separation or details of liposome’s interior in substantially 
larger ones.[400] 
Several of the most widely used methods for GUV production were analysed, 
mainly those that do not require specialized or expensive equipment. Typical size 
distribution data and qualitative analysis of vesicles formed was provided for each method 
using a variety of lipid compositions.  
Additionally the applicability of the above methods for encapsulation of 
biomolecules was determined based. Above results provide information necessary for 
selecting the best method for specific application. 
 Results  
 Qualitative assessment of GUVs 
 Vesicles prepared by each of the methods listed above were observed by light 
microscopy. Their quality was assessed based on their appearance, the presence of surface 
defects, lamellarity and theformation of clusters or vesicles nests (number of small 
vesicles entrapped inside a larger one). Images of vesicles prepared by each of these 
methods are shown in figure 3.1. The quantities of each of the components are expressed 
in terms of molar ratios. 
Formation of vesicles consisting of a single bilayer is important for analysing 
membrane dynamics or lipid phase behaviour. Lamellarity also affects the encapsulation 
of molecules inside liposomes.[401] In order to assess the lamellarity, vesicles were 
observed using widefield fluorescent and confocal microscopy. These techniques allow 
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observation of multiple lipid layers within onion-like vesicles or oligovesicular vesicles 
(OVV). Due to the resolution limit light microscopy may not always be sufficient to 
distinguish between single and multiple lipid layers remaining in close contact with each 
other. This type of assessment requires bending elasticity measurements[402] or 
fluorescence quenching assay.[403] 
 
 
Figure 3.1 Phase contrast microscopy images of GUVs prepared by each of the methods 
described; a) 56:14:30 DOPC/DPPC/Cholesterol by electroformation; b) 80:20 DOPC/DPPC 
by electroformation; c) 64:16:20 DOPC/DPPC/Cholesterol by gentle hydration; d) 80:20 
DOPC/DPPC by rapid hydration; e) 95:5 DOPC/PEG-DOPE by lipid hydration on an agarose 
film; f) Egg-PC by cDICE method and g) Egg-PC by w/o emulsion method. Scale bar = 5 µm. 
 Examples of unilamellar vesicles prepared by lipid hydration on an agarose film 
and composed of 80:20 DOPC/DPPC with 0.05% of fluorescent the dye, bodipy TR 
ceramide, imaged by both confocal and widefield fluorescent microscopy are presented 
in figure 3.2. The fluorescent intensity plots are constructed by measuring fluorescent 
intensity across the diameter of the vesicle. The maximum intensity on the fluorescent 
intensity plots corresponds to the location of the bilayer. Differences in the images and 
the intensity plots arise from the characteristics of each of the techniques. Confocal 
microscopy uses spatial filtering to eliminate background fluorescent and out of focus 
light observed due to the thickness (diameter) of the vesicle exceeding the thickness of 
focal plane. Since spatial filtering is not available in widefield fluorescent microscopy, 
fluorescence of the dye incorporated into the membrane is observed also inside the 
vesicle. This effect can be slightly reduced by a decrease in the exposure time or reducing 
the amount of dye incorporated into the membrane. 
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Figure 3.2 Images and fluorescent intensity plots of unilamellar vesicles observed by widefield 
fluorescent (a) and confocal (b) microscopy. 
 Most methods of vesicle preparation yield, in addition to unilamellar vesicles a 
number of multilamellar GUVs and nests of vesicles. The term multilamellar vesicles 
(MLV) is used to describe multiple vesicles of nearly the same size and in close contact 
with each other, which cannot be distinguished by optical microscopy (figure 3.3c) as 
opposed to nest of vesicles which refers to a larger GUV containing a smaller one with a 
diameter less than 20% smaller (figure 3.3b).[404] Oligovesicular vesicles (OVV), which 
are simply small vesicles inside larger ones are also commonly observed (figure 3.3a).[133] 
These can be easily identified by both phase contrast and widefield fluorescent 
microscopy, as shown in figure 3.3 (for vesicles formed by lipid hydration on an agarose 
film, composed of 80:20 DOPC/DPPC with 0.05% of bodipy TR ceramide). The number 
of lipid bilayers may be estimated by analysis of the fluorescent intensity plots obtained 
from high resolution images. A small percentage of multilamellar vesicles were observed 
in every method analyzed. Nests of vesicles were observed mainly within samples 
prepared by the lipid hydration on an agarose film method and the emulsion method. 
 In the protocols for vesicle preparation by both the emulsion and cDICE methods, 
the inclusion of mineral oil dispersed with lipid molecules is required. For that reason 
traces of oil may also be present in the bulk of the aqueous solvent or within the bilayer. 
Oil droplets can usually be distinguished simply by observation with light microscopy. 
Since a monolayer of lipids may be present on the surface of the droplets, the detection 
of oil droplets using fluorescent lipid dyes may not be appropriate. To improve upon this, 
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we introduced a hydrophobic dye, Sudan Red, to the mineral oil used for GUV 
preparation (figure 3.4a). As a second way to distinguish oil droplets from GUVs 
unambiguously, we included FITC in the aqueous solvent. Aqueous compartments will 
encapsulate FITC, while oil droplets will exclude it (figure 3.4b and c), providing an easy 
classification method. 
 
Figure 3.3 Oligovesiclular vesicles (a), nest of unilamellar vesicles (b) and vesicle resembling 
onion-like structure (c) observed by phase contrast (left) and widefield fluorescent microscopy 
in the presence of 0.05% of bodipy TR ceramide dye (middle); fluorescent intensity plots (right). 
Scale bar = 5 µm. 
  
Figure 3.4 Identification of GUVs and mineral oil droplets. Mineral oil droplets exclude FITC 
aqueous solution (b) but the Sudan red, a dye only soluble in non-aqueous solvents was found to 
localize in the mineral oil droplets, with several Sudan Red crystals observed at the oil/water 
interface (a). GUVs formed by the inverted emulsion method can also be identified by 
encapsulation of FITC solution inside aqueous interior of the vesicle (c). Scale bar = 20 µm. 
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 Quantitative assessment of GUVs 
 Size distributions for each method have been constructed by measuring the 
diameters of GUV after imaging using light microscopy. By selecting 300-800 spherical 
and unilamellar vesicles the sizes of vesicles produced by each method were determined. 
Only isolated vesicles were counted, and GUVs were randomly sampled across the full 
sample volume. Lower numbers (100-200) were considered for methods with a low yield 
of vesicles fulfilling above criteria. The vesicle diameters were averaged across the 3-4 
repeat experiments and the size distribution plots were normalized. For all of the methods 
used here, large numbers of vesicles below 5 μm were observed and measured. However, 
for such small structures, determining the edges of the vesicles may produce some error. 
A summary of GUV sizes obtained by each of the different methods is shown in 
table 3.1. Whilst for all of the size distributions shown all data is included, for reporting 
vesicles sizes in table 1, the proportion of vesicles above both 5μm and 10μm respectively 
are used to compare each of the methods, since larger vesicles are most desired and this 
allows the usefulness of each method in terms of producing optimal vesicles sizes to be 
compared. 
 Electroformation 
Electroformation is a fast and highly reproducible method for the preparation of 
cell-sized GUVs. It is widely used, especially in membrane phase behaviour studies since 
it yields good quality unilamellar vesicles with bilayers free of organic solvents. An 
inexpensive setup, built on a microscope slide (developed previously in the lab) was used 
for these experiments (see experimental section). It facilitates GUVs formation from a 
dried lipid film deposited onto a glass surface by the application of an external electric 
field. The electroformation cell facilitates direct observation of the vesicles under an 
upright or inverted microscope. If desired, GUVs can be retrieved from the chamber 
through the opening at the top of the perfusion chamber. 
 Vesicles were produced for 80:20 DOPC/DPPC lipid mixtures and for 
DOPC/DPPC/cholesterol mixtures with increasing concentrations of cholesterol (from 10 
to 30 mole percent). Size distributions for each membrane composition prepared are 
shown in figure 3.5. 
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Table 3.1 Summary of GUVs sizes for different lipid compositions prepared by various methods. 
Method Composition Buffer 
% GUVs 
above 5μm 
% GUVs 
above 10μm 
Largest GUV 
observed (μm) 
Electroformation 
80:20 
DOPC/DPPC 
Milli-Q 
H2O 
42 8 24 
72:18:10 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
47 6 23 
64:16:20 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
38 6 23 
56:14:30 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
24 3 20 
80:20 
DOPC/BSM 
Milli-Q 
H2O 
56 7 22 
50:25:25 
DOPC/BSM/Cholesterol 
Milli-Q 
H2O 
37 6 17 
Gentle 
Hydration 
 
80:20 
DOPC/DPPC 
Milli-Q 
H2O 
36 4 17 
64:16:20 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
82 33 78 
33:33:33 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
39 12 14 
33:33:33 
DOPC/BSM/Cholesterol 
Milli-Q 
H2O 
23 3 15 
47:23:30 
DOPC/BSM/Cholesterol 
Milli-Q 
H2O 
26 4 16 
Rapid Hydration 
80:20 
DOPC/DPPC 
Milli-Q 
H2O 
56 13 33 
64:16:20 
DOPC/DPPC/Cholesterol 
Milli-Q 
H2O 
14 3 30 
Hydration on an 
agarose film 
98.5:1.5 
DOPC/PEG-DOPE 
Milli-Q 
H2O 
60 27 68 
95:5 
DOPC/PEG-DOPE 
Milli-Q 
H2O 
52 18 30 
98.5:1.5 
DOPC/PEG-DOPE 
50mM 
Na3PO4 
69 18 37 
95:5 
DOPC/PEG-DOPE 
50mM 
Na3PO4 
63 21 46 
Emulsion 
method 
Egg-PC 
20mM 
Na3PO4 
60 25 28 
cDICE Egg-PC 
20mM 
Na3PO4 
73 55 60 
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Figure 3.5 Size distributions for GUVs prepared by electroformation; in the absence of 
cholesterol a) 80:20 DOPC/DPPC and with increasing cholesterol concentration b) 72:18:10 
DOPC/DPPC/Cholesterol; c) 64:16:20 DOPC/DPPC/Cholesterol and d) 56:14:30 
DOPC/DPPC/Cholesterol. 
 GUVs obtained by this method were almost exclusively spherical, with rare 
membrane defects (figure 3.1b). Vesicle formation occurs by swelling of a thin lipid film 
deposited onto a glass capillary. Often GUVs remain attached to the surface of the glass 
capillary, which may be advantageous during microscopy observation.[405] This method 
rarely produces multilamellar vesicles (MLVs).[404] The absence of MLVs was confirmed 
by fluorescence microscopy. For the 20:80 DPPC/DOPC mixture, 42% of the GUVs 
formed were larger than 5 µm and a rather small percentage (8%) were larger than 10 µm 
(table 3.1). This was not altered significantly by the addition of 10% cholesterol. A 
cholesterol content above 20% decreases the average size of GUVs formed (figure 3.5c), 
narrows the size distribution and induces membrane irregularities (i.e. vesicles have 
various, also non-spherical shape and tend to stick to each other).[404,406] For lipid 
compositions containing 30% cholesterol, in addition to single GUVs, the formation of a 
network of connected GUVs was also observed (figure 3.1a), which is a feature consistent 
with lipid phase separation into lipid-ordered and lipid-disorder phases, corresponding to 
the formation of lipid rafts within biological membranes. Indeed studies of lipid phase 
behavior are often conducted with similar proportions of cholesterol.[145,146] At the highest 
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cholesterol content, only 24% of the GUVs are larger than 5 μm and a very small fraction 
(3%) are larger than 10 μm (table 3.1). Electroformation using the microscope slide setup 
up on the microscope slide yields vesicles with diameters ranging up to 24 µm for 
phospholipid only vesicles and up to 20 μm for vesicles containing 30% cholesterol. 
 GUVs were also formed by electroformation from lipid mixtures containing 
sphingomyelin (BSM) instead of DPPC. As mentioned before due to the shape of 
sphingomyelin, its molecules tend to pack more tightly and have previously been 
included, together with cholesterol, in lipid mixtures used for vesicles formation in order 
to observe lipid phase separation and lipid raft formation.[399] A high yield of spherical 
and unilamellar vesicles was observed. The size distributions for lipid mixtures composed 
of 80:20 DOPC/BSM and 50:25:25 DOPC/BSM/cholesterol are shown in figure 3.6. The 
size distributions are to some extent wider than for phospholipid-based liposomes. The 
addition of 25% of cholesterol to vesicles containing sphingomyelin has a similar, 
although a slightly smaller effect than for phospholipid vesicles, decreasing the number 
of vesicles above 5 µm from 56% to 37% for DOPC/BSM based GUVs (table 3.1). 
 
 
Figure 3.6 Size distributions for GUVs prepared by electroformation; a) 80:20 DOPC/BSM; b) 
50:25:25 DOPC/BSM/Cholesterol. 
 
 Methods employing lipid film hydration 
 Three methods based on the principle of lipid film hydration as a step leading to 
GUVs formation have been selected; lipid hydration on an agarose film, gentle and rapid 
hydration. These methods facilitate vesicle preparation across a wide range of aqueous 
solutions and at physiological salt concentrations. They also allow charged or PEG-
containing lipids to be efficiently incorporated into the membrane. Lipid hydration 
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methods facilitate entrapment of molecules inside liposomes, but the encapsulation 
efficiency differs significantly among those methods. 
 Gentle hydration 
 Vesicles prepared by the gentle hydration of a thin lipid film deposited onto a 
glass surface were mostly spherical with rare membrane defects (figure 3.1c). Isolated 
vesicles were used for the diameter measurements, but liposomes occurring in clusters 
were also observed. 36% of vesicles formed by this method at 80:20 DOPC/DPPC lipid 
composition were larger than 5 μm, with only 4% larger than 10 μm and sizes did not 
exceed 17 μm (figure 3.7a). Interestingly, the addition of cholesterol actually increased 
the mean diameter, the distribution of sizes and also the occurrence of larger GUVs. 
64:16:20 DOPC/DPPC/Cholesterol yielded the largest vesicles, with 82% of vesicles 
larger than 5 μm and 33% larger than 10 μm. The largest vesicles observed were 78 μm 
in diameter (figure 3.7b). 
 
 
Figure 3.7 Size distributions for GUVs prepared by gentle hydration; a) 80:20 DOPC/DPPC; 
b) 64:16:20 DOPC/DPPC/Cholesterol. 
 Giant unilamellar vesicles are frequently used as a model to study the phase 
behavior of a variety of lipids. Gentle hydration is one of the methods used for the 
preparation of vesicles for studying lipid phase behavior.[407,408] A lipid composition of 
1:1:1 DPPC/DOPC/cholesterol, previously shown to exhibit coexistence of liquid 
phases,[399] was used to form GUVs. 
Similar to previous results, phase separation manifested by the presence of dark 
regions within fluorescent bilayer. Clusters and nests of vesicles were also observed 
(figure 3.8a). Besides spherical and isolated GUVs, with sizes up to 14 µm (12% of 
vesicles with size above 10 µm) a large number of clusters and small vesicles inside 
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bigger ones were observed. Due to a generally low yield, 100 vesicles were used for the 
size distribution analysis (figure 3.9a). 
  
 
Figure 3.8 Lipid phase separation in vesicles prepared by gentle hydration method and 
composed of (a) 33:33:33 DPPC/DOPC/cholesterol, (b) 23:47:30 BSM/DOPC/cholesterol and 
(c) 33:33:33 BSM/DOPC/cholesterol. Scale bar = 5 µm. 
 Sphingomyelin is often used as a component of lipid mixtures for preparation of 
vesicles exhibiting lipid phase separation. Liposomes composed of 23:47:30, 33:33:33 
and 53:27:20 BSM/DOPC/cholesterol were prepared. As shown in figure 3.8 (b and c) 
phase separation was observed within bilayers composed of 23:47:30 and 33:33:33 
BSM/DOPC/cholesterol. Due to a high percentage of vesicle aggregates, GUVs within 
aggregates were also included in size measurements (where the edges of vesicles were 
clearly visible). Lipid bilayers containing 23 and 33% of sphingomyelin have narrow size 
distributions, similar to those with a high DPPC content (figure 3.9b), with the majority 
of vesicles below 5 µm (table 1.1). 
 
 
Figure 3.9 Size distributions for GUVs prepared by gentle hydration; a) 33:33:33 
DPPC/DOPC/cholesterol; b) 23:47:30, 33:33:33 (red) and 53:27:20 (black) 
BSM/DOPC/cholesterol. 
 A lipid composition containing 53 mole percent sphingomyelin resulted in a very 
low vesicle yield, which didn’t allow a size distribution analysis to be completed. Also 
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the majority of vesicles formed with high sphingomyelin content were multilamellar, star-
shaped and arranged in clusters. Phase separation in bilayers containing 53% 
sphingomyelin could not be explicitly confirmed. 
 Rapid hydration 
 The rapid hydration method generates mostly spherical vesicles with no 
membrane defects (figure 3.1d) and diameters below 33 µm (table 3.1). While 56% of the 
vesicles formed in the phospholipid mixture 80:20 DOPC/DPPC were greater than 5 μm 
in size, this reduced significantly with the addition of cholesterol (figure 3.10a). The lipid 
composition 64:16:20 DOPC/DPPC/cholesterol lead to the formation of vesicles with 
diameters up to 30 µm and the narrowest size distribution of all the methods and lipid 
compositions used (figure 3.10b). Only 14% of vesicles were 5 μm in diameter or larger. 
A significant number of smaller vesicles with sizes in the region of 1μm were also 
observed at this composition. 
 Due to relatively narrow size distribution and the use of organic solvent during 
preparation, rapid hydration was found not to be suitable for the observation of phase 
separation or encapsulation. 
 
 
Figure 3.10 Size distributions for GUVs prepared by rapid hydration; a) 80:20 DOPC/DPPC; 
b) 64:16:20 DOPC/DPPC/Cholesterol. 
 
 Lipid hydration on an agarose film 
 A method involving lipid hydration on an agarose film[65,175] lead to a high yield 
of cell-size GUVs across a range of solution conditions, even at high ionic strength. The 
lipid mixture used for lipid film preparation contained 5% PEG-DOPE, which reduces 
liposome aggregation commonly occurring in solutions at high ionic strength. Here, that 
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composition was reproduced but the size distributions obtained were smaller on average 
than those reported previously.[65,175] Also it was observed that a number of GUVs 
prepared by this method contained a number of smaller vesicles inside larger ones. There 
are several reasons why this may have been the case. Water or low ionic strength buffer 
was used to hydrate the GUVs, whereas Tsai et. al. encapsulated actin in physiological 
buffer. Additionally, a basic spin coating device was used to produce an agarose film, 
which may not have been as precise as in the earlier work. GUVs were also measured 
after being washed off the agarose film, so any larger vesicles which were attached to the 
agarose film would not have been observed. Formation of GUVs with lower proportions 
of PEG-DOPE (1.5 mole %) compared to 5 mole % used previously showed no significant 
difference in the sizes of GUVs prepared (figure 3.11). Both compositions had the 
majority of GUVs above 5μm, with 18-27% of GUVs formed above 10μm in size, 
depending on the composition and ionic strength of the aqueous medium used to hydrate 
the lipid film (table 3.1). 
 
Figure 3.11 Size distributions for GUVs prepared by lipid hydration on an agarose film; a) 
98.5:1.5 DOPC/PEG-DOPE hydrated with MilliQ water; B) 98.5:1.5 DOPC/PEG-DOPE 
hydrated with 50mM sodium phosphate buffer; c) 95:5 DOPC/PEG-DOPE hydrated with 
MilliQ; d) 95:5 DOPC/PEG-DOPE hydrated with 50mM sodium phosphate buffer. 
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 Methods employing lipid-in-oil dispersion 
 In addition to creating a lipid film by hydration, GUVs may also be prepared from 
lipids dispersed in mineral oil. The two methods employing this strategy are selected here. 
The inverted w/o emulsion and the continuous droplet interface crossing encapsulation 
(cDICE) method have been used and assessed. 
 Inverted emulsion method 
 The inverted emulsion method was first described by Pautot et. al.[176] It involves 
the preparation of a water-in-oil emulsion, where the droplets, which constitute the inner 
solution of vesicles, are surrounded (and stabilized) by lipid molecules. Forcing the lipid 
coated droplets through an oil-water interface, using centrifugal force, into another (outer) 
aqueous solution, results in the formation of second monolayer (outer leaflet). 
 A very high yield of vesicles were formed by the inverted emulsion method using 
egg-PC lipid, which were mainly spherical and free in solution (figure 3.1g). However, a 
high percentage of vesicles were either multilamellar, arranged in clusters or entrapped 
one inside another vesicle (figure 3.3). As mentioned previously these structures can be 
identified using a fluorescent lipid dyes. 
 An emulsification process leads to the presence of mineral oil droplets within the 
bulk of solution. The presence of oil within the bilayer limits their use to study membrane 
phase behaviour. However the high yield and large sizes of GUVs makes this method 
desirable for encapsulation experiments. The emulsion method forms mostly cell-sized 
vesicles (figure 3.12a), with 60% of total liposomes with size above 5 µm and 25% above 
10 µm (table 3.1). 
 
 
Figure 3.12 Size distributions for GUVs prepared by inverted emulsion (a) and cDICE method 
(b). 
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 Continuous droplet interface crossing encapsulation (cDICE) method. 
 The continuous droplet interface crossing encapsulation (cDICE) method[64] 
involves the formation of vesicles by forcing aqueous droplets through a lipid-rich oil-
water interface facilitated by centrifugal force. A good yield of spherical vesicles with no 
membrane defects was observed (figure 3.1f). A small percentage of small GUVs 
entrapped within bigger ones was also present. A wide size distribution (up to 60 µm) of 
vesicles prepared by the cDICE method was observed (figure 3.12b). 73% and 55% of 
the total number of GUVs formed had sizes above 5 and 10 µm respectively (table 3.1). 
A narrower size distribution and better control over the mean size could have been 
achieved using glass capillaries with a smaller diameter instead of 30 gauge needles with 
internal diameter of 80 µm. Similar to the inverted emulsion method, the presence of 
mineral oil droplets within vesicle suspensions was also observed.  
 Comparison of GUV preparation methods based on suitability for 
encapsulation. 
 All of the methods mentioned above can be used to encapsulate molecules inside 
vesicles, some more successfully than others. When selecting a suitable method of 
preparation, a number of factors, such as preparation time or use of organic solvents, must 
be taken into consideration. Vesicles prepared by electroformation or by gentle or rapid 
hydration are widely used in studies mimicking biological processes, such as membrane 
fusion or phase behaviour. These methods are less often selected for applications 
involving encapsulation due to lengthy preparation, use of electric fields or organic 
solvents. Also with these methods the composition of the interior and exterior solutions 
are identical during formation and additional steps (microdialysis or centrifugation) are 
required to change the outer solution. 
From the methods analysed here, three were selected for encapsulation 
experiments (in later chapters); the lipid hydration on an agarose film, the inverted 
emulsion and cDICE methods (figure 3.13). The lipid hydration on an agarose film has 
been previously used for encapsulation of cytoskeletal protein networks.[65] It offers a 
good yield of vesicles and relatively good encapsulation efficiency. However since the 
‘inner’ solution is simply placed on top of the lipid film, there is no control over how 
much of that solution is successfully encapsulated and how much of it is mixed with the 
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external solution. This leads to high background when encapsulating fluorescent 
molecules. 
The continuous droplet interface crossing encapsulation method has been 
designed with encapsulation in mind.[64] It is fast and produces the largest vesicles among 
the methods analysed. The range of sizes produced by this method can be tuned by 
varying the experimental parameters (e.g. needle diameter and the centrifugal force). A 
large volume of the external and internal solution or requirements for few specific tools 
(e.g. needles or rotating motor) are the main disadvantages of this method. 
The w/o emulsion method has been successfully used to encapsulate a variety of 
molecules, including proteins,[113] enzymes[177] or components of E.coli extract.[51] Small 
volumes of the inner and outer solution, high yields of cell-sized vesicles and a high 
encapsulation efficiency are among the most important advantages of this method. 
However, the possibility of oil residues within the bilayer may be undesirable.[113] 
 
 
Figure 3.13 EmGFP solution in 20 mM sodium phosphate buffer encapsulated inside 
phospholipid vesicles, prepared by hydration on an agarose (a), cDICE (b) and inverted 
emulsion (c) methods. Scale bar 5 µm. 
 
 Conclusions 
 Giant unilamellar vesicles may be prepared by several different methods 
(electroformation, lipid film hydration or methods involving lipid dispersion). The 
methods described here are relatively easy, rarely require specialized equipment and 
exhibit a high degree of reproducibility. Each of the methods examined here produce 
unilamellar vesicles of biological cell size (or larger) which facilitates their observation 
by phase contrast microscopy and with addition of fluorescent dye, also by fluorescence 
microscopy. The proportion of vesicles of larger sizes formed depends on both the method 
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used to prepare them and as well as the lipid mixture used. For a fixed composition, 
substantially larger vesicles can be prepared by selecting an alternative method. Here, 
size distributions have been measured for a set of membrane compositions using several 
of the methods described. Comparison of the overall size distributions and the proportions 
of larger vesicles formed for each lipid composition and method may simplify the process 
of selecting a method optimal for a given application. 
 During the course of the project some undesirable forms of vesicles (or artifacts) 
have been observed. Approaches for their identification have been proposed, and include 
addition of fluorescent lipid dye for identification of MLVs and vesicle nests and oil-
soluble dye for detection of oil droplets. 
 All of the methods described above may be used for encapsulation (of 
biomacromolecules, for example); however the success will depend strongly on the 
method chosen. Electroformation along with gentle and rapid hydration are generally not 
selected for encapsulation for several reasons,[165] mainly due to low efficiency. The 
applicability of a given method for encapsulation was determined based on the use and 
time required for preparation, reproducibility of the results and finally the level of 
encapsulation efficiency. Here, lipid hydration on an agarose film or the inverted 
emulsion and cDICE method were selected and used for this purpose, which will be 
discussed in following chapters. 
 The above results provide comparison of several methods of vesicle preparation 
based on the size and quality of vesicles, as well as the ability to efficiently encapsulate 
variety of molecules. This type of assessment provides information necessary for 
application tailored selection of method. 
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 Introduction 
Glycolipids are a highly diverse class of lipids. In addition to naturally occurring 
molecules, a range of synthetic glycolipids have been developed.[203,204,409–411] This 
structural and functional variety is widely used in a range of academic and industrial 
applications.[412–415] Glycolipid biosurfactants have potential antimicrobial applications 
due to their ability to damage cell membranes or to prevent the formation of biofilms.[416] 
A variety of biological processes such as cellular uptake, molecular trafficking and certain 
aspects of immune response have been studied within natural and model membranes 
using fluorescent, photoactive, biotinylated and radio-labelled glycolipid-based probes 
discussed extensively in a recent review.[417] 
Glycolipids (both natural and synthetic) may be incorporated into the lipid 
bilayers of giant unilamellar vesicles. These types of vesicles are used to study glycolipid 
phase behaviour and the properties of glycolipid-rich domains.[418–420] Studies involving 
the phase behaviour, shape transformation or fission of GUVs containing 
lipopolysaccharides (LPS) are of special interest since LPS are strongly involved in the 
inflammation process.[421,422] Glycolipid containing vesicles, due to the specificity of 
carbohydrate interactions are investigated as vehicles for targeted drug delivery.[423,424] 
The defined structure of the carbohydrate head group facilitates delivery onto selected 
organs or tissues, by specific interaction with an appropriate receptor (for the 
carbohydrate used). For example vesicles containing sialyated Lewis antigens, which 
bind to selectin receptors present on the surface of various cell types, such as endothelial 
cells, platelets and leukocytes can mimic biological antigens and therefore alter the 
immune response of targeted cells.[425–427] A variety of drugs may be encapsulated within 
glycolipid vesicles providing a way to induce an immune response,[428] alternative 
therapies for immunodeficiency,[429] inflammation[430] or cancer[431] to name just a few. 
Recently, liposomes incorporating glycolipids have also been used for targeted delivery 
of gene-based therapeutics.[432] Growing interest in the role of glycolipids in bacterial and 
viral infections and studies involving the interaction of pathogenic antigens with 
glycolipid vesicles may lead to new glycolipid-based therapeutic strategies or novel 
approaches to drug delivery and molecular recognition.[433,434] 
 The preparation of a model cell mimicking cell adhesion or signalling requires the 
presence of molecules involved in this processes within the lipid bilayer. The aim of this 
study was to incorporate a protected synthetic glycolipid, with a galactose-based 
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headgroup and two asymmetrical hydrocarbon tails, into phospholipid and phospholipid-
cholesterol based liposomes at biologically relevant concentrations. The stability and the 
appearance of the glycolipid-containing vesicles were observed by phase contrast and 
fluorescence microscopy. The phase behaviour of the synthetic glycolipid was analysed 
using various modes of microscopy (phase contrast, polarized light and fluorescence) 
with the aid of various fluorescent dyes depending on its concentration in the lipid 
mixture. 
The use of synthetic structures as glycolipid mimetics also removes the necessity 
of difficult and often time consuming purification of naturally occurring forms. The 
synthetic design of the glycolipid used here provides the opportunity for further 
modification of the functionality of the carbohydrate head group, greatly extending the 
number of ways in which the specificity of the interaction may be altered. 
 Results and discussion 
 Incorporation of glycolipid within bilayer. 
Giant unilamellar vesicles were prepared using variety of methods, including 
electroformation, gentle and rapid hydration, the water-in-oil emulsion method and the 
hydration on an agarose film method, as described in section 2.4. Lipid mixtures used 
were composed of DOPC, cholesterol, a range of fluorescent lipid-based dyes and the 
synthetic glycolipid which structure is shown in figure 4.1. The synthesis of the glycolipid 
has been described previously.[366] Its structure consists of an acetylated (-OAc instead of 
-OH) galactose-based head group, flexible ethylene linker and two asymmetric 
hydrocarbon tails. 
The aim of the initial experiments was to confirm the presence of the protected 
synthetic glycolipid within the lipid bilayer formed. A lipid film consisting of only the 
synthetic glycolipid (100%) does not swell after hydration and therefore does not produce 
vesicles. Vesicles were produced when glycolipid concentrations between 1-5 mol 
percent were added to binary lipid mixtures with DOPC or ternary lipid mixtures with 
DOPC and cholesterol. At concentration greater than 5 mol % of glycolipid, in addition 
to vesicles, tubular structures, discussed in section 4.3.3, were also observed. 
Successful formation of vesicles in the presence of glycolipid was achieved using 
all of the methods attempted, such as the electroformation, lipid film hydration methods 
or the inverted emulsion method. 
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Figure 4.1 Chemical structure of the synthetic glycolipid. 
 
 Fluorescent dyes used in microscopic analysis of structures formed in the 
presence of the synthetic glycolipid 
Direct observation of the glycolipid within bilayer was not possible, since there is 
no label attached directly to it. Lipid bilayer containing the synthetic glycolipid was 
observed by widefield fluorescent microscopy in the presence of fluorescent dyes, such 
as bodipy FL C5 ceramide, bodipy TR ceramide or cholesteryl bodipy FL C12 (figure 4.2). 
The amount of dye used depends on its photo-stability, lifetime and the quantum yield. 
Additionally it was shown that for majority of fluorescent dyes the addition of dye below 
2 mol % of total lipid content have negligible effect on mechanical properties of 
membrane.[435] Nonetheless, the presence of the fluorescent dye within the bilayer was 
not a conformation of the incorporation of the glycolipid. Instead to confirm the presence 
of the synthetic glycolipid within the lipid membrane the properties of vesicles formed in 
the presence of the glycolipid was compared to those formed in its absence. 
 Evidence of glycolipid incorporation into GUVs 
During the preparation of the vesicles, care was taken to ensure that the synthetic 
glycolipid was fully dispersed within the solvent (chloroform or mineral oil) and within 
the resulting lipid film. Low total lipid concentrations (10 mM) and spin-coating instead 
of droplet deposition (where applicable) were used to ensure the formation of a thin and 
uniform lipid film which in turn promotes its full hydration and complete swelling. 
Following the completion of vesicle formation, no evidence of the presence of a lipid film 
still present on the surfaces was observed, which indicated that the glycolipid did swell 
at the same time as the other lipids present in the film. Also, no artefacts or free-floating 
material of any sort was present within the vesicle suspension. This strongly suggests that 
all of the glycolipid present within the lipid film was fully incorporated into the lipid 
bilayer. 
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Figure 4.2 Chemical structures of the bodipy FL C5 ceramide (a) and bodipy TR ceramide (b), 
cholesteryl bodipy FL C12 (c) and (14:0-12:0) NBD-PC (d). 
 
 Characteristics of glycolipid vesicles 
A very high yield of spherical vesicles prepared in the presence of 1-5 mol % 
glycolipid was observed. Liposomes containing the synthetic glycolipid exhibit 
characteristics not observed in phospholipid-based GUVs. The differences include a 
strong tendency to form chains and clusters (figure 4.3), which was not observed in the 
absence of the glycolipid, with the exception of GUVs formed in the presence of 30% 
cholesterol (see chapter 3, figure 3.1a). The presence of the synthetic glycolipid also leads 
to formation of higher numbers of multilamellar and elongated vesicles. 
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Figure 4.3 Clusters of GUVs containing the synthetic glycolipid, formed by gentle hydration 
method, composed of 1:9 glycolipid–phospholipid mixtures and 0.1% of bodipy FL ceramide. 
Scale bar = 10 µm. 
A size distribution analysis of liposomes prepared by the gentle hydration method 
composed of 1:9 glycolipid/phospholipid (DOPC) was performed using the method 
described in section 3.3.2. In comparison with vesicles composed of 1:9 DPPC/DOPC 
prepared in the same way, the glycolipid-GUVs were significantly smaller and had 
narrower size distributions (figure 4.4). 
The vesicles containing the synthetic glycolipid were rather stable. No changes in 
the shape or stability of the vesicles stored at room temperature were observed for up to 
12 days, which is longer than for phospholipid-based vesicles. Hydrogen bonding 
interactions altering the polarity of the lipid head group are believed to be the reason of 
the improved stability.[436] 
 
 
Figure 4.4 Size distribution of GUVs prepared by gentle hydration method from lipid film 
containing only phospholipids (red) or 1:9 glycolipid/phospholipid mixtures (green). 
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 Glycolipid phase behavior – lamellar phase formation  
Model membranes composed of variety of lipid mixtures are commonly used to 
study lipid phase behavior.[60,437] The coexistence of various lamellar phases (mainly the 
liquid ordered Lo and liquid-disordered Ld) was previously shown for variety of lipid 
mixtures, such as ternary mixtures containing DOPC, cholesterol and DPPC or 
sphingomyelin (SM) and in fact substitution of DPPC for SM results in only small 
differences in the phase diagrams.[145,149,399] The 1:1:1 DPPC/DOPC/cholesterol, 1:1:1 
BSM/DOPC/ cholesterol and 23:47:30 BSM/DOPC/cholesterol lipid mixtures were 
previously used to form vesicles exhibiting phase separation (chapter 3 figure 3.8). The 
synthetic glycolipid used here and the sphingomyelin share some structural similarities. 
GUVs containing the synthetic glycolipid were therefore formed in the presence of 
fluorescent dyes and analyzed using fluorescent microscopy to investigate whether the 
synthetic glycolipid causes phase behavior similar to that observed for membranes in the 
presence of sphingomyelin. 
 The effect of glycolipid concentration on lipids phase behavior 
Giant unilamellar vesicles were prepared using the gentle hydration method from 
DOPC in mixtures with increasing concentrations of the synthetic glycolipid (figure 4.5). 
Fluorescent dyes, bodipy FL C5 ceramide and bodipy TR ceramide were added to the 
lipid mixture in order to facilitate observation of phase separation by widefield 
fluorescence microscopy. The glycolipid appears to be uniformly and fully incorporated 
within the bilayer as no lipid phase separation or residual material remaining after 
hydration was observed. The presence of the synthetic glycolipid leads to formation of 
higher numbers of multilamellar and elongated vesicles. Also the size and yield of 
vesicles decreased with an increase of glycolipid content within the bilayer, with the most 
drastic effect observed at 20 mol % of glycolipid. This effect is very similar to behaviour 
observed for vesicles formed with high cholesterol content within DOPC/DPPC lipid 
mixtures discussed in section 3.3.3 (see figure 3.5).  
Vesicles containing identical lipid compositions as shown in figure 4.5 were also 
prepared using a rapid hydration method (data not shown). The size and the appearance 
of GUVs prepared by the gentle and rapid hydration methods were almost identical. The 
glycolipid was uniformly distributed within the bilayer and no phase separation was 
detected. This suggests that the observations with regard to the appearance and size 
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decrease accompanying the increase in glycolipid concentration were due to the presence 
of glycolipid (and not related to the method of preparation). 
 
Figure 4.5 Fluorescence microscopy images of GUVs prepared by gentle hydration from 
mixtures of synthetic glycolipid, DOPC (lipid composition at the top of the image) and 0.1% of 
bodipy FL C5 ceramide. Scale bar = 10 µm. 
 
 The effect of cholesterol concentration on lipid phase behavior 
The effect of cholesterol on glycolipid containing membranes was evaluated. 
Cholesterol is known to induce phase separation in membranes of various 
compositions.[145,150,397,438] Moreover its presence was implicated in the formation of 
sphingomyelin/cholesterol rich domains within biological membranes.[155,193] The phase 
behaviour of glycolipid in the ternary lipid mixtures was analysed in vesicles composed 
of DOPC, 5 mol % glycolipid, 0.05 mol % cholesteryl bodipy FL C12 and various 
concentrations of cholesterol and DOPC, prepared using gentle hydration method (figure 
4.6). The cholesteryl bodipy dye was previously used to study lipid phase behaviour.[439] 
It was shown to preferentially partition into the cholesterol-rich liquid-ordered phase due 
to its structural similarity to cholesterol (figure 4.2c). 
 
 
Figure 4.6 Fluorescence microscopy images of GUVs prepared by gentle hydration method 
from lipid mixtures containing 0.05% cholesteryl bodipy FL C12 and a) 85:10:5 DOPC/ 
cholesterol/glycolipid; b) 80:15:5 DOPC/cholesterol/glycolipid; c) 75:20:5 DOPC/cholesterol/ 
glycolipid; d) 70:25:5 DOPC/cholesterol/glycolipid; e) 65:30:5 DOPC/cholesterol/glycolipid. 
Scale bar = 5 µm. 
Within lipid bilayers containing both the glycolipid and various concentrations of 
cholesterol, the fluorescent cholesteryl bodipy dye was uniformly distributed and no 
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evidence of lipid-ordered and lipid-disordered phase coexistence was observed. However, 
increasing concentrations of cholesterol present within the bilayer lead to a decrease in 
the number of vesicles formed. Also, significantly smaller average diameters of the 
liposomes were related to high cholesterol content within the membrane. 
 Analysis of lipid phase behavior using fluorescent dye pairs  
 Vesicles were also prepared using equimolar concentrations of the synthetic 
glycolipid, DOPC and cholesterol. The coexistence of the lipid phase separation for 
similar lipid mixtures, but with either DPPC or sphingomyelin instead of the glycolipid 
was shown in figure 3.8 (see section 3.3.4). The 33% content is above glycolipid’s 
solubility within the lipid bilayer and guarantee its oversaturation in the membrane. Lipid 
vesicles with equimolar mixtures of the glycolipid, DOPC and cholesterol were formed 
in the presence of both of the ceramide-based dyes; bodipy FL C5 (green) and bodipy TR 
ceramide (red) which, based on their structural features were expected to partition into 
the glycolipid-rich phase (figure 4.2 a and b). This was done in order to determine whether 
the small difference in the structure of the fluorescent tag, may alter their behavior within 
the coexisting lamellar phases. Phase separation was not observed and both dyes seemed 
to be co-localized and uniformly distributed within the membrane. To test if either of the 
two fluorescent ceramide dyes was capable of detecting phase separation within the 
bilayer, they were used in pairs with other well-known dyes, the cholesteryl bodipy FL 
C12 and the NBD-PC (figure 4.7). The cholesteryl bodipy FL C12 (figure 4.2c) is a 
cholesterol analogue, that partitions into cholesterol-rich domains, also known as lipid 
rafts or lipid-disordered lamellar phases. NBD-PC (figure 4.2d) is known to partition into 
phospholipid-rich domains.[225,440,441] In fact, the cholesteryl bodipy FL C12 dye was 
previously used to observe phase separation within lipid bilayers formed from 
DPPC/DOPC/cholesterol and BSM/DOPC/cholesterol mixtures (chapter 3, figure 3.8). 
The use of glycolipid/DOPC lipid mixtures with the above pairs of fluorescent 
dyes was to examine whether the phase separation of the glycolipid from either the 
phospholipid-rich or cholesterol-rich domains was occurring. Since both pair of dyes 
were homogenously dispersed within the lipid bilayer of liposomes and separation of the 
fluorescent dyes was not observed (figure 4.7) it was concluded that the synthetic 
glycolipid was also uniformly distributed in the lipid bilayer of vesicles with all of the 
lipid mixtures studied. 
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Figure 4.7 Fluorescent microscopy images of GUVs (33:33:33 DOPC/glycolipid/cholesterol) 
prepared by gentle hydration. Lipid bilayer was labelled with: (a-c) 0.05% cholesteryl bodipy 
FL C12 and 0.05% bodipy TR ceramide; (d-f) 0.05% bodipy TR ceramide 1% NBD-PC; (c & f) 
overlay of the two images. 
It is important to note that the preference of a given fluorescent lipid to partition 
into either the liquid-ordered or liquid-disordered phase is strongly influenced by its 
structure, mainly the size, chemical character and location of the tag within the lipid 
molecule. The dye’s preference towards one of the lipid phases also strongly depends on 
the characteristics of the other lipids present in the mixture. For that reason the choice of 
the dye should be carefully considered and partitioning preferences of a given dye should 
be tested individually for every lipid mixture. 
 Lipid phase behavior in GUVs formed by inverted emulsion method 
Vesicles containing the synthetic glycolipid were also prepared using the inverted 
emulsion method. GUVs were observed within the bulk of the aqueous solution as well 
as on the surface of mineral oil droplets. As discussed in section 3.3.1 formation of 
mineral oil droplets is a common artifact of this method. Fluorescent dye was included in 
the lipid mixture to analyze the lipid distribution on the surface of the droplets. Similarly 
to results described above (gentle and rapid hydration methods), glycolipid incorporation 
lead to its uniform distribution within the lipid bilayer, for liposomes present in the bulk 
and attached onto the surface of the oil droplet. 
In order to analyze the behavior of the synthetic glycolipid on the surface attached 
vesicles two fluorescent dyes; bodipy TR ceramide and NBD-PC were also incorporated 
into the bilayer (figure 4.8 a and b). Both of these dyes were uniformly distributed as 
shown in the overlay of the images (figure 4.8c) and the fluorescent intensity profile 
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(figure 4.8d) and therefore no phase separation was observed on the surface of mineral 
oil droplets. However it was presumed that the vesicles present on the surface of the oil 
droplets are very likely the source of material for the formation of the lipid tubules 
(described later).  
 
 
Figure 4.8 Fluorescent microscopy images of GUVs attached to the surface of the mineral oil 
droplet; (a-c) composed of 80:20 DOPC/glycolipid with 0.1% bodipy FL C5 ceramide and1% 
NBD-PC); (d) fluorescent intensity profile (cross-section intensity). 
 
 Glycolipid phase behavior – non-lamellar phases 
Lipid mixtures containing up to 5 mol % of the synthetic glycolipid form GUVs 
with a uniform distribution of the bilayer components. Incorporation of larger quantities 
of the glycolipids (10 mol % and above), results in the simultaneous formation of both, 
lipid vesicles and tubular structures as illustrated in figure 4.9. Imaging of both of these 
at the same time was challenging, mainly due to the difference in their size and 
localization within the focal plane. 
Lipid tubules were initially observed in the sample from electroformation, where 
the lipid film was swelled in aqueous solvent with an aid of an AC field (figure 4.10). 
They were usually observed in form of bundles of tubules resembling overall spherical 
structures and were present mainly in the vicinity of the glass capillary, onto which the 
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lipid film was deposited, however the majority seemed to be floating freely in solution as 
opposed to being attached to the lipid film deposited on the surface of glass capillary. The 
number of tubular structures increased with higher concentration of the synthetic 
glycolipid included in the initial lipid mixture. 
 
 
Figure 4.9 Simultaneous formation of vesicles and tubular structures from lipid mixtures 
containing above 5% of the synthetic glycolipid (here 10:90 glycolipid/DOPC) by gentle 
hydration method. Scale bar = 10 µm. 
 
 
Figure 4.10 Phase contrast images of tubules formed by the electroformation method in 
aqueous solvent from a lipid composition 20:80 glycolipid/DOPC. Scale bar = 10 µm. 
 Both vesicles and tubules were also observed in lipid preparations containing 
more than 5% glycolipid prepared by the gentle (figure 4.9) and rapid hydration (figure 
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4.11) methods (indicating again that the structure are not an artifact of a particular 
preparation method). In fact the same type of self-assembled structures are formed by all 
of these methods, as long as the glycolipid content is kept identical. This clearly suggested 
that presence of the lipid tubules (at glycolipid concentration above 5 mol %) can be fully 
attributed to the behavior of the protected glycolipid within the phospholipid membrane. 
Tubules were formed both in the presence (figure 4.11) and absence (figure 4.10) of 
fluorescent dyes, which eliminates the possibility of dye-induced phase separation. 
However the presence of the fluorescent ceramide dyes in the tubules is a conformation 
that these types of dyes can be used to observe glycolipid behavior within the membrane. 
Since the fluorescence images show the ceramide dyes to be uniformly distributed, it 
suggest that the lipid composition in the tubules is also homogenous. 
 Lipid tubules formed from binary mixtures (glycolipid and DOPC) were also 
analyzed using polarized light microscopy (figure 4.11 middle panel). In this method the 
polarized light interacts with the birefringent sample and generates a bright image with a 
black background (see section 2.3.2). As the lipid tubules formed here can be visualized 
using polarized light microscopy, it is clear that they are not an amorphous material but 
possess some degree of structural order. Similar properties were observed for ternary lipid 
mixtures containing the synthetic glycolipid, DOPC and cholesterol, however, in those 
lipid mixtures the presence of crystalline material was shown to be due to the presence of 
cholesterol and were most likely cholesterol crystals. 
 
 
Figure 4.11 Optical microscopy images of tubular structures observed in binary mixtures of 
DOPC/glycolipid with 0.1% of bodipy FL C5 ceramide; left panel; phase contrast, middle 
panel; polarization; right panel, fluorescence due to presence of the dye. Scale bar = 5 µm. 
 Different behavior was observed while using the inverted emulsion method. A 
Relatively small number of vesicles (compared to the hydration methods) were present 
within the aqueous solvent and on the surface of mineral oil droplets, as shown in the 
figure 4.8. Rather, the tubular structures which in the case of hydration methods were 
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found in the aqueous solvent, here were formed within the interior of the mineral oil 
droplets (figure 4.12 d-e). Moreover, with increasing size of the droplet, which in turn 
means a higher concentration of the lipid molecules, the size of the tubule bundles 
increases. The overall size of the bundles of tubular structures was similar in both solvents 
(water and oil) as shown in figure 4.12. Given that the synthetic glycolipid was fully 
dispersed in both the chloroform and the mineral oil, the formation of the tubular 
structures cannot be attributed to its insolubility in either of the solvents but rather is an 
outcome of oversaturation within the lipid bilayer. 
 
 
Figure 4.12 Fluorescence microscopy images of tubules formed in aqueous solvent (a-c) and in 
mineral oil (d-e). Scale bar = 20 µm. 
The above observations suggest the formation of a columnar lipid phase, where 
in aqueous solvent the tubules consists of lipid molecules arranged hexagonally and in 
mineral oil they exhibit inverted hexagonal packing. It was estimated, based on the size 
of the tubular structures, that they were formed by several layers of lipid with a hexagonal 
arrangement. Extensive studies of phospholipid phase behavior indicate that pure DOPC 
or DOPC/cholesterol mixtures do not exhibit a lamellar to hexagonal phase transition. 
This type of behavior was observed after the inclusion of non-membrane forming lipids, 
usually PE.[139,408] This strongly suggests that the glycolipid must be present within the 
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tubular structures in order to drive this behavior as similar structures are not observed in 
its absence. 
Taken together, these observations support the initial assumption that the 
glycolipid is incorporated in both the lipid vesicles and the tubular structures. However 
whether the glycolipid is present in these structures at concentrations identical to those 
used in the lipid film preparation cannot be confirmed unambiguously, although there is 
no evidence to suggest otherwise. 
Formation of the hexagonal and inverted hexagonal phases has been observed for 
a variety of lipids, including various glycolipids.[204,442,443] The transition between 
lamellar and hexagonal or inverted hexagonal arrangements have been shown to occur in 
biological membranes due to the presence of high concentrations of lipids with a tendency 
to form non-lamellar structures.[137] These types of lipid phases are associated with a 
variety of biological processes, including the formation of tight junctions or as 
intermediates in membrane fusion.[444] Factors affecting lipid phase behavior have 
previously been reviewed[137] and include the properties of the headgroup (mainly its 
hydrophilicity), type of chain linkage, structure of hydrocarbon chain or the nature of the 
solute. 
At glycolipid concentrations below 5 mol %, only the lamellar phase was 
observed. Above that concentration, which also is considered to be the solubility of the 
glycolipid within bilayer, coexistence of lamellar and columnar (arrangement depends on 
the solvent system) lipid phases was observed. The transition between lamellar and 
hexagonal lipid phases is driven by the curvature stress exerted,[445] which in the lipid 
mixtures studied here, occurs via a high concentration of the synthetic glycolipid present 
within the lipid membrane. 
This behavior may be considered in terms of the packing parameter ρ = ν / a l, 
which depends on the nature and area of the head group, a and the length l and volume, ν 
of the hydrocarbon chains. The packing parameter is commonly used to predict the type 
of self-assembled structure formed by a given lipid.[134] 
Lamellar phase formation is preferred in the case of lipid mixtures with an overall 
packing parameter of ρ < 1, which, based on the experimental results presented above is 
the case for lipid mixtures with a synthetic glycolipid content below 5 mol %. The 
structure of the protected glycolipid used here, consists of bulky sugar-based head group 
and two asymmetrical, fully saturated hydrocarbon tail groups, which results in a larger 
head group area, a, and smaller value for the volume hydrocarbon chain, v when 
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compared with the phospholipid components. Therefore in lipid mixtures containing 10 
mol % or more of the glycolipid, the packing parameter will have a value below 1, 
resulting in the occurrence of the normal hexagonal phase (HI), where the sugar based 
head groups are facing the toward the aqueous solvent (figure 4.13). The presence of 
flexible linker in the structure of the synthetic glycolipid allows the reorientation of head-
group, possibly resulting in larger (ρ >1) value of the packing parameter and making the 
formation of inverted hexagonal phase (HII) possible. 
The transition between lipid phases can be triggered by changing the 
environmental conditions, e.g. temperature or hydration.[139] In the system studied here 
the hexagonal phase was observed within the aqueous solvent. In the presence of the 
hydrophobic solvent the formation of an inverted hexagonal phase with the hydrocarbon 
chains facing the solvent, is expected to be more energetically favorable. The possibility 
of the formation of the inverted hexagonal phase within the aqueous solvent due to 
slightly hydrophobic character of the protected groups present on the sugar moiety was 
also considered. However due to the presence of l4 and 8-carbon long chains the HI phase 
was presumed to be entropically more favorable. 
 
 
Figure 4.13 Schematic representation of the arrangement of lipids in columnar phases; (a) 
normal hexagonal phase (HII) with glycolipid headgroups oriented towards the aqueous solvent 
and inverted hexagonal phase (HI), where the glycolipid tail groups are oriented towards the 
mineral oil solvent. 
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 Conclusions 
A protected synthetic glycolipid has been incorporated into GUV membranes by 
a variety of methods at biologically relevant concentrations in binary mixtures with 
DOPC and in ternary mixtures with DOPC and cholesterol. In both cases, the glycolipid 
was fully dispersed in the solvent prior to the preparation and homogenously distributed 
within the lipid bilayer. At glycolipid concentrations below 5 mol % only the lamellar 
lipid phase was observed, giving rise to large numbers of vesicles. Coexistence of the 
lipid-disordered and lipid-ordered lamellar phases was not observed in the range of 
concentrations where the glycolipid was soluble in the vesicle membrane. Liposomes 
were prepared in the presence of various glycolipid and cholesterol concentrations, and 
increasing their concentration was shown to decrease the size of vesicles formed. The 
preparation of liposomes containing the synthetic glycolipids was not affected by the 
method of preparation or the presence of fluorescent dyes within the membrane. 
Synthetic glycolipid concentrations above 10% lead to the formation of lipid 
tubules, which are composed of columnar lipid phases. The arrangement of lipid 
molecules in either the hexagonal or inverted hexagonal phases was dependent on the 
chemical nature of the solvent system used. The glycolipid was shown to be 
homogenously distributed within the tubular structures. Since the tubules were optically 
birefringent, it was presumed that they exhibit some degree of structural order as opposed 
to resembling aggregated material. Their formation was shown both in aqueous solvent 
and in mineral oil droplets, therefore suggesting the hexagonal and inverted hexagonal 
lipid arrangement respectively. The formation of the bundles of tubular structures was 
found to arise from cooperative action of both the glycolipid and DOPC since none of 
these components form similar structures separately. 
There is a growing interest in the use of a variety of glycolipids incorporated into 
GUVs for variety of applications, including studies of molecular recognition or targeted 
drug delivery. Phase behaviour of both naturally occurring and synthetic glycolipids, and 
factors affecting their behaviour and their potential applications have not been fully 
explored. This work contributes to the understanding of concentration-dependent phase 
behaviour of synthetic glycolipid.[49] 
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Encapsulation and aggregation of 
BSA in Giant Unilamellar vesicles 
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 Introduction 
An important feature of building a model cell is the requirement to encapsulate 
biomolecules, such as nucleic acids, peptides or proteins, within the interior of the 
phospholipid vesicles. There are a large number of methods available to do this and the 
choice of a suitable method needs to be carefully considered as it may affect the activity 
of the biomolecules. Upon encapsulation various processes can be observed within the 
interior of the vesicle, such as nucleic acid amplification or protein synthesis. One of the 
advantages of using liposomes as reaction vessels is the small volume, therefore small 
amounts of reagents are required. In order to evaluate the reactions or processes occurring 
within vesicles, the encapsulation efficiency and the concentration of molecules within a 
specific vesicles need to be quantified.[188] There are several methods for the estimation 
of encapsulation efficiency, reporting the efficiency as either the average amount of solute 
per vesicle in suspension[446] or as a quantity obtained for a single vesicle,[61,447] protein 
subunit[448] or for a biological cell.[449] The suitability of the method of quantification 
strongly depends on the application. Drug or gene delivery studies are more concerned in 
analysing the average encapsulation efficiency, however if chemical or biochemical 
reactions are studied within a model cell consisting of a single liposome, then the 
concentration of individual reagents may be crucial. 
Assembly processes are at the centre of minimal cell research. Formation of the 
lipid bilayer, folding of protein or formation of signalling complexes are just a few 
examples of assembled structures inherent to biological cells and are often recreated in 
model cells. One of the assembly processes commonly occurring in cells is protein 
aggregation; which may be defined as a non-native assembly process leading to formation 
of species with a molecular weight higher than a monomer.[450] Virtually all proteins are 
susceptible to aggregation depending on the solution conditions, such as pH, ionic 
strength, temperature, presence of denaturants or the characteristics of the surface (charge 
distribution and presence of hydrophobic patches) of a protein molecule.[254] These 
various solution conditions and the protein properties will allow aggregates to form by 
different aggregation mechanisms[254,451] and result in the formation of various types of 
protein particles, from fibril-type structures to amorphous aggregates.[452] Aggregation 
processes may be reversible or can result in the formation of insoluble particulates.[254] 
Protein aggregation, its mechanisms and the conditions under which it occurs has 
been extensively studied.[291,292,295,450,453] These studies provide valuable insights into 
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protein structure, stability and the folding process. Understanding how and why proteins 
aggregate is extremely important in various branches of food and in the 
biopharmaceutical industry.[256] The effects of protein aggregates present in 
biopharmaceutical formulations include decreased efficacy and stability or in some cases 
immunogenic response in patients.[257] Formation of protein aggregates has also been 
linked to several diseases such as Alzheimer’s or Parkinson’s disease and therefore better 
understanding of the aggregation process may lead to development of new strategies 
resulting in its prevention.[258,259] 
Protein aggregation studies have traditionally been performed in bulk. This 
approach offers the possibility of performing analysis across a range of conditions, using 
a variety of instrumentation, and provides specific details about the mechanisms leading 
to aggregation. However care must be taken when interpreting results of such studies as 
the conditions in which they are performed lack the complexity of the cellular 
environment, such as molecular crowding or protein-membrane interactions. The 
conditions under which in vivo studies may be carried out are however significantly 
limited due to the sensitivity of cell culture. Additionally the interior of a cell is filled 
with a variety of biomolecules and therefore identifying the key factors that play a role in 
the aggregation process is extremely difficult. Furthermore several studies have 
emphasized the role of lipid bilayers in the aggregation process and this type of interaction 
cannot be reproduced unless supported lipid bilayers or giant unilamellar vesicles are 
used.[293,454,455] 
 Firstly a method to quantify the amount of protein encapsulated in a GUV is 
presented. Aggregation of BSA was then analysed in solution to select a set of conditions 
where aggregation occurs. Formation of aggregates in solution was monitored by 
Thioflavin T (ThT) fluorescence and solution turbidity. ThT becomes fluorescent upon 
binding to either protein aggregates or amyloid fibrils. Finally, BSA was encapsulated 
into GUVs and its aggregation in-situ was monitored using phase contrast and 
fluorescence microscopy. Fractal analysis of the aggregates formed in solution and in 
liposomes is used to compare the aggregates formed in each case. 
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 Results and discussion 
 Production and characterisation of emerald variant green 
fluorescent protein (EmGFP) 
Emerald variant of green fluorescent protein (EmGFP) was expressed in E.coli as 
described in the experimental section 2.7. Transformed E.coli cells were inspected using 
fluorescence microscopy (figure 5.1). Bacterial cells expressing EmGFP emit green 
fluorescence (emission maximum at 509 nm), which can was observed under 
fluorescence microscope upon excitation with blue light (excitation maximum at 487 nm). 
 
 
Figure 5.1 Fluorescence microscopy image of bacterial cells (E.coli) expressing EmGFP; 
image was acquired using the FITC filter set. 
Following cell lysis, the lysate, containing GFP was purified on a Ni-NTA column 
(figure 5.2). The protein fractions corresponding to the second peak were selected based 
on visual inspection of the solution (green colour is indicative of the presence of EmGFP). 
Selected fractions were analysed by reducing SDS-PAGE (figure 5.3). The presence of a 
single band corresponding to EmGFP monomer confirms the purity of the solution. 
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Figure 5.2 Affinity chromatography purification of EmGFP protein. The fractions 
corresponding to the second peak contain the purified EmGFP. 
 
 
Figure 5.3 SDS-PAGE gel of the cell lysate and purified EmGFP. MWM, is the molecular 
weight marker. Two concentrations of the purified EmGFP were run to determine if any low 
concentration contaminants were present. 
Purified EmGFP was also analyzed with size exclusion HPLC (SE-HPLC). The 
presence of a single peak at 19.11 min confirmed the purity of the EmGFP (figure 5.4). 
From the calibration of the Superdex 75 10/300 GL SE-HPLC column (for details see 
section 2.9), a peak at 19.11 min indicates a molecular weight in the region of 30.5 kDa, 
which is consistent with the molecular weight of a EmGFP monomer. 
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Figure 5.4 SE-HPLC profile of purified EmGFP in 100 mM sodium phosphate buffer pH 7.4. 
Purified EmGFP solution was stored in the dark at 4°C and was stable for several weeks. 
 Quantification of protein concentration in GUVs 
As discussed in the chapter 2 (section 2.3), the amount of light absorbed by a 
fluorescent molecule and emitted in the form of fluorescence can be related to its 
concentration by the following equation; 
 kcQIF   5.1 
where k is a constant, c is the concentration of the fluorophore, Q is the quantum yield 
and I0 is the intensity of light illuminating the solution.
[351] The above equation relates 
values of F and c at low concentrations of the fluorophore. Since kc∝ A the fluorescence 
intensity is also directly proportional to the absorbance but only at low concentrations of 
fluorescent molecules. Therefore the relationship between the fluorescence and the 
concentration of a fluorophore must also be analysed. Here a concentration range between 
0.2 and 1.2 mg/ml was analysed. As will be shown in this chapter, the relationship 
between fluorescence intensity and protein concentration is linear for the selected range 
of EmGFP concentrations. 
The concentration of protein was estimated based on the measurement of 
fluorescence emitted by the emerald variant of GFP. Fluorescent protein was chosen over 
other light emitting molecules, such as luciferase or small organic molecules, due to its 
compatibility and inert nature in respect to other biological molecules and the possibility 
that it can be synthesized in situ inside a model or biological cell.[456] 
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 Calibration curve 
In order to obtain a calibration plot allowing for the quantification of protein 
concentration within GUVs, glass capillaries filled with a solution of EmGFP were used. 
A similar approach was previously used by Leonhardt et al.,[449] where rectangular PDMS 
microchannels were used for the quantification of expression levels of GFP in mammalian 
cells. The choice was dictated by the similarity of the cross-sectional geometry and the 
focal depth of both the capillaries and the vesicles. In both cases the objective was focused 
at the center of the capillary (in the z-direction), (for experimental details see section 
2.10). Empty glass capillaries were also observed under identical conditions to ensure no 
background fluorescence was contributing to calibration measurement. 
 Image analysis 
Images used for fluorescence intensity measurements were recorded with the 
FITC excitation-emission filter engaged and using CellF software with a manually set 
exposure time. The intensity of the illuminating beam of light, monitored using the 
MultiSpeck multispectral fluorescence microscopy standard, showed no significant 
fluctuations for up to 280 hours of usage of the mercury burner. After that time the burner 
was replaced. Imaging of EmGFP was performed in a manner that ensured the 
preservation of the EmGFP fluorescence; the focusing and centering (placing an object 
of interest in the center of the field of view) steps were performed promptly, usually with 
the use of neutral density filters reducing the intensity of illuminating light, up to 50%. 
Background subtraction and flat-field correction were performed when necessary.[457–459] 
Image processing and fluorescence intensity measurements were performed using CellF 
and ImageJ software. 
The first method used to prepare the calibration curve involved the measurement 
of fluorescence intensity at a point in the middle of the glass capillary filled with GFP 
solution (figure 5.5). The glass capillary was first filled with the protein solution using a 
syringe and a silicon connector. Capillaries were placed onto a glass slide and imaged 
using a 10X objective. All of the above steps were performed in the dark to prevent 
bleaching of the EmGFP solution. Measurements for the calibration plot were performed 
with five different EmGFP concentrations and capillaries of various diameters. 
Another calibration curve was obtained by measuring fluorescence intensity 
across the width of the capillary and plotting the area under the intensity curve for each 
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EmGFP concentration and various capillary diameters (figure 5.6). This approach offers 
more consistent results, especially in cases where the solutions exhibits uneven mixing of 
the fluorophore or is adsorbing onto the glass surface.[460] In the case of EmGFP none of 
these characteristics were observed. 
 
Figure 5.5 Calibration plot for protein quantification based on point measurement of 
fluorescence intensity within a range of different size capillaries. 
 
 
Figure 5.6 Calibration plot for protein quantification based on the cross-sectional 
measurement of fluorescence intensity within a range of different size capillaries. 
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The calibration plot of EmGFP concentration as a function of the fluorescence 
intensity and capillary diameter was recorded using a 10x objective. Since images of 
vesicles encapsulating EmGFP were recorded using either 60 or 100x objectives, a 
scaling factor was determined for each objective pair (table 5.1). A scaling factor allows 
one to convert the fluorescence intensity recorded by the higher magnification objectives 
to a value for a 10x lens, which then can be used to obtain the concentration of EmGFP 
from the calibration plot. 
 
Table 5.1 Conversion table listing fluorescence intensity measurements obtained using a 
fluorescent standard and a range of objectives. The scaling factor allows conversion of intensity 
between higher magnification lenses used for imaging of GUVs and the 10x lens used to obtain 
measurements for the calibration curve. 
Lens 10x 20x 40x 60x* 60x** 60x** 60x** 100x 
Exposure time 10 ms 10 ms 10 ms 10 ms 10 ms 5 ms 2 ms 10 ms 
Scaling factor (for 
10x calibration) 
- 0.353 0.264 0.147 0.1276 0.184 0.349 0.137 
* UPlanFLN objective ** UPlanSapo objective 
 
The calibration plots shown in figure 5.5 and 5.6 allow one to obtain the 
concentration of protein encapsulated within vesicles of sizes similar to the sizes of 
capillaries. These results are also represented in the form of a surface plot (figure 5.7).  
 
Figure 5.7 Surface plot of calibration for protein concentration determination based on the 
cross-sectional measurement of fluorescence intensity. 
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  This method can be used to quantify concentrations of fluorescent proteins upon 
encapsulation inside giant unilamellar vesicles. Fluorescence measurements are sensitive 
to solution conditions; therefore the calibration and the encapsulation should be 
performed using identical buffer conditions. If changes are introduced, the impact on the 
fluorescence intensity should be examined. 
Due to the sensitivity of fluorescence measurements to buffer conditions, the 
multiple steps involved in the vesicle preparation process, and variation in the 
performance of the equipment (such as short time changes in the intensity of illuminating 
light), the concentration of protein encapsulated may only be estimated to the nearest 0.1 
mg/ml.[304] 
 Encapsulation of molecules inside GUVs 
 EmGFP encapsulation inside giant unilamellar vesicles (GUVs) 
Encapsulation of EmGFP inside GUVs was performed using either the inverted 
emulsion or cDICE method as described in section 2.4. The osmotic pressure was 
balanced by the addition of sucrose to the external solution. The concentration of sucrose 
required was assessed experimentally for every protein concentration used. Once the 
vesicles were formed, images were recorded. Next, the background fluorescence and the 
fluorescence intensity across the diameter of the vesicle was measured. Background 
subtraction was performed either using rolling ball toll in ImageJ or by manual subtraction 
of the fluorescence intensity measured in the area of the image surrounding the vesicle. 
The second method was used more often as it allows for more control of the intensity 
subtraction and it represents a more accurate approach in the case of an uneven 
background due to the presence of out of focus vesicles. The value for the intensity 
obtained (usually as an area under the fluorescence intensity curve) was then multiplied 
by the scaling factor appropriate for a given set of objectives. The concentration of 
EmGFP was obtained using the calibration plots shown in figures 5.6 and 5.7. EmGFP in 
the concentration range of 0.1 to 1 mg/ml was successfully encapsulated within lipid 
vesicles. Encapsulation efficiencies were calculated as ratios of EmGFP concentration in 
individual vesicles to its concentration in the solution used for encapsulation. Examples 
of vesicles encapsulating EmGFP and corresponding encapsulation efficiencies are 
shown in figure 5.8. The observed difference in intensity between the two images 
corresponds to the difference in the EmGFP concentration. 
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Figure 5.8 EmGFP encapsulated into GUVs; the concentration of protein and the efficiency of 
the encapsulation are indicated above. Scale bar = 20 µm. 
Encapsulation of EmGFP was also be performed in vesicles composed of mixtures 
of phospholipids and the galactose-based synthetic glycolipid described in chapter 4 and 
can be seen in figure 5.9. No difference in the vesicle yield or the encapsulation efficiency 
was found when compared to the phospholipid-based GUVs. 
 
 
Figure 5.9 EmGFP at a concentration of 0.34 mg/ml encapsulated in GUVs containing a 95:5 
phospholipid (DOPC)-glycolipid mixture and 0.05% bodipy TR ceramide. Vesicles were imaged 
with the CY5 (left) and FITC (right) fluorescence filters. Scale bar = 10 µm. 
 
 EmGFP/BSA mixtures encapsulation inside GUVs 
Bovine serum albumin (BSA) was also encapsulated in GUVs at concentrations 
ranging from 10 to 100 mg/ml. Just as for EmGFP encapsulation, rupture of vesicles due 
to the osmotic pressure differences between the interior and exterior of the vesicle was 
prevented by the addition of sucrose to the external solution. BSA is not fluorescent in 
the visible region of the spectrum and therefore direct measurement of its concentration 
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inside vesicles using the method described in section 5.2.2 is not possible. In order to 
provide the means for quantification based on fluorescence measurements, up to 0.5% of 
EmGFP was added to BSA solutions before encapsulation. Examples of vesicles 
encapsulating mixtures of BSA with EmGFP are shown in figure 5.10.  
 
 
Figure 5.10 EmGFP and BSA mixtures encapsulated in GUVs. The total protein concentration 
and the efficiency of encapsulation are shown above. Scale bar = 10 µm. 
The concentration of EmGFP inside the GUVs was obtained using the method 
described in section 5.2.2. It was previously shown that fluorescence intensity 
measurements are sensitive to solution conditions such as buffer type, pH and ionic 
strength.[304] The effect of BSA on the fluorescence intensity of EmGFP was analyzed by 
comparing emission spectra of EmGFP at a known concentration with and without BSA 
in the solution (figure 5.11). It was found that the addition of BSA results in an increase 
in the fluorescence intensity of the EmGFP solution by 5.4%. Due to this, the fluorescence 
intensity used to obtain the concentration of EmGFP was corrected for this effect. One 
thing to note is that this method to determine the BSA concentration assumes that there 
is complete mixing of the two proteins and that the solution encapsulated is representative 
of the stock solution. No phase separation of the BSA and GFP solutions were observed. 
Once the concentration of EmGFP (corrected for the effect of BSA present in the 
solution) was obtained from the calibration plot and its content in the mixture with BSA 
was known (up to 0.5% of total protein concentration), the concentration of BSA in the 
individual vesicles could be calculated. Examples of protein concentrations in vesicles 
and encapsulation efficiencies are shown in figure 5.10.  
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Figure 5.11 Comparison of the emission spectra (left) and the fluorescence intensity at 512 nm 
of an EmGFP solution and EmGFP/BSA mixtures with identical EmGFP content. 
Vesicles containing protein solutions were stable for several days at room 
temperature. They were also stable after incubation at 65°C for up to 2 hours. The number 
of vesicles gradually decreased over time but no significant decrease in protein 
concentration within the remaining vesicles was observed, suggesting that no leakage of 
content took place. 
The values representing encapsulation efficiencies shown in figures 5.8 to 5.10 
are only examples of the efficiencies obtained under specified conditions. In fact various 
encapsulation efficiencies ranging from approximately 25-110% of the stock protein 
solution were observed within any given experiment. The distributions of various 
efficiencies were not analyzed. This variation in encapsulation efficiency, however not 
its extent, was previously published.[188,461,462] The solute occupancy distribution inside 
vesicles was shown to be determined by a power law, resulting in a range of solute 
concentrations observed for a given vesicle size. The presence of “super-filled” vesicles, 
containing concentrations of protein significantly exceeding (up to 50 times) the 
concentration within the bulk solution has previously been reported[462] for small vesicles 
(up to 1μm in size) , and it is not clear if the enhancement of entrapment occur in giant 
vesicles to the same extent as this issue is still being investigated.[462] 
The observation of vesicles showing either very low or very high encapsulation 
efficiency have been attributed to the mechanism of droplet formation and the 
redistribution of solutes from larger droplets between two smaller ones during the 
fragmentation step.[462] The heterogeneity of solute concentration within w/o droplets was 
suggested to be the source in the variability of encapsulation efficiencies observed. 
Additionally, the range of protein concentrations observed here may be in fact be limited, 
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since the vesicles would become unstable due to the osmotic pressure differences between 
the interior and the exterior of the vesicle. 
 Screening conditions promoting BSA aggregation in solution 
The process of protein aggregation and the conditions leading to it have been 
studied extensively.[291,292,295,450,453] Bovine serum albumin (BSA) is often selected for 
such studies as a model globular protein. The range of solution conditions under which 
BSA forms aggregates were measured first. Relatively short incubation times were used 
since identical experimental conditions were later replicated in phospholipid vesicles. 
Previously published results suggests that the aggregation of BSA can be induced in 
acidic buffer conditions.[321,463,464] Additionally these studies showed that the presence of 
high salt concentrations enhances the aggregation process. The effect of a range of acidic 
pHs on the aggregation of BSA was measured. 
Solutions of BSA at 10 mg/ml in buffers of various pH (2.2, 3, and 4) and with 
various concentrations of NaCl (0 to 100 mM) were prepared in a 96 well plate. For 
comparison, BSA at physiological pH was also prepared. Thioflavin T (200 µM) was 
added to the solution and fluorescence intensity of the dye was monitored at 485 nm 
(following excitation at 435 nm). Increases in the fluorescence intensity of ThT is most 
often used to confirm the formation of amyloid-like fibrils, particularly the cross-β-sheet 
structure commonly found in amyloid proteins,[465,466] although an increase in 
fluorescence intensity is also observed for amorphous protein aggregates.[277,278] The 
absorbance at 600 nm was also recorded in order to monitor the formation of amorphous 
protein aggregates and the corresponding decrease in % transmission due to the formation 
of large particles. 
 Monitoring BSA behaviour upon incubation at room temperature 
Upon incubation at room temperature the highest ThT fluorescence intensity was 
observed for BSA at 10 mg/ml in a glycine-HCl buffer at pH 3 with 100 mM NaCl (figure 
5.12 left), indicating the formation of some type of BSA aggregate. No significant 
increase in absorbance at 600 nm was observed (figure 5.12 right panel), which suggests 
that aggregates formed are too small to be detected using this technique. 
For glycine-HCl at pH 2.2 and sodium acetate at pH 4 (data not shown), no 
significant increase in fluorescence intensity over the three day observation period was 
seen. Additionally no change in % transmission and no visible aggregates were observed 
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using phase contrast microscopy for BSA solutions at 10 mg/ml incubated in any of the 
buffers analysed. 
 
 
Figure 5.12 Observation of BSA behavior in solutions at 10 mg/ml under various buffer 
conditions during incubation at room temperature. 
 
 Monitoring BSA behavior after heating 
Protein aggregation is often induced by an exposure to increased temperature 
which aids protein unfolding.[467] BSA buffer solutions at various pH and NaCl 
concentrations were incubated at 65°C. This temperature has been shown to cause partial 
unfolding of BSA at pH 3.[468] It has also been shown that amyloid-like fibrils are formed 
in BSA in glycine-HCl at pH 3 upon incubation at 65°C.[464] 
As shown in figure 5.13 an increase in ThT fluorescence was observed at pH 3 
and pH 7.4 indicating the formation of aggregates. However due to the lack of a lag phase, 
characteristic of the growth profiles for fibrils,[453] it is most likely that these aggregates 
are amorphous. Detection of amyloid-like fibril formation needs to be confirmed using 
other methods (such as TEM), since ThT is capable of non-specific binding under various 
conditions.[466] A reduction in % transmission was also observed, most prominent in the 
case of BSA solutions at pH 3 in the presence of 50 mM NaCl. No significant increase in 
the ThT fluorescence was observed for BSA in buffer at pH 2.2 (data not shown). 
Aggregates formed under conditions tested above were imaged using various modes of 
light microscopy (figure 5.14). 
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Figure 5.13 Aggregation of BSA in different solution conditions during incubation at 65°C. 
 
 
Figure 5.14 BSA aggregates formed after incubation at 65°C at pH 2.2 (a-c), pH 3 (d-g), pH 3 
with 50 mM NaCl (h-k) and at pH 7.4 (l-o). Images were recorded using polarized light 
microscopy (f, j, l), fluorescence microscopy with a FITC emission/excitation filter (c, h, n) and 
with a phase contrast. Brightness and contrast adjusted to aid visualization. Scale bar = 10 µm. 
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Upon visual inspection of BSA solutions at pH 2.2 in the presence of 50 mM 
NaCl, the formation of a weak, clear protein gel was observed. This is in agreement with 
previous studies.[321] Large portions of the gel were observed with smaller particulates 
present at the edge of the gel, which were imaged (figure 5.14a). The presence of a green 
fluorescent signal co-localized with the gel material suggests binding of ThT in these 
regions. However the polarized microscopy did not confirm the presence of any ordered 
structures, suggesting that no amyloids are present and it is therefore more likely that the 
gel is formed from a network of amorphous aggregates. 
Aggregates formed at pH 3 appear to be amorphous by phase contrast microscopy 
(figure 5.15d, f, h and j). However observation under polarized light revealed that the 
structures formed are optically birefringent which indicates that these structures are 
ordered (figure 5.15 g and k) and may suggest the presence of amyloid material in these 
aggregates. Very small aggregates were formed at pH 7.4 in the presence of NaCl. No 
aggregates were observed in BSA solutions at pH 2.2 and pH 7.4 in the absence of salt. 
 Encapsulation and aggregation of BSA in GUVs 
BSA at 10, 20 and 40 mg/ml in glycine-HCl (pH 2.2 and 3), sodium acetate (pH 
4) and sodium phosphate (pH 7.4) buffers with increasing concentrations of NaCl (0-100 
mM) was encapsulated in phospholipid-based liposomes using the inverted emulsion 
method (see section 2.4.6 and 2.11.2). Initially, when encapsulation was performed in the 
presence of 100 mM NaCl, a very low yield of vesicles was achieved. Therefore, NaCl 
concentrations of 50mM were used thereafter. Thioflavin T was added to the solutions at 
200 µM. Solutions of BSA containing 0.5% of protein labelled with a FITC dye were also 
encapsulated in GUVs (but never simultaneously with ThT as both emit green 
fluorescence). Images of vesicles were recorded both immediately after formation and 
after the specified incubation period. In the case of incubation at 65°C, the vesicle 
suspension was cooled to room temperature for at least 60 minutes before imaging. 
Concentrations of BSA in excess of 10mg/ml were required to observe 
aggregation inside GUVs, since aggregates larger than 1μm in size are necessary to 
observe the aggregates by optical microscopy. The absence of aggregates at 10 mg/ml 
can be linked to the encapsulation efficiency discussed in section 5.2.3. Quantification of 
protein concentration in individual vesicles was not possible as the acidic pH leads to 
quenching of GFP fluorescence.[304] 
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 Observation of vesicles encapsulated with BSA  
Vesicles encapsulating various concentrations of BSA at pH 2.2, 3 and 7.4 at 0 
mM and 50 mM NaCl were incubated at room temperature. Fluorescence and phase 
contrast images were recorded after vesicle formation and every 24 hours thereafter. 
Previous observations of protein-filled vesicles suggest that vesicles formed at neutral pH 
are stable for several days (see section 5.2.3). However phospholipid-based liposomes 
formed at acidic pH were found to remain stable for roughly four days of incubation at 
room temperature. After that time the number of vesicles observed started to decrease. 
Additionally, the average size of GUVs observed appears to decrease overtime, 
suggesting that larger vesicles are significantly less stable under these conditions. 
Incubation at room temperature did lead to a minor increase in the ThT 
fluorescence of the protein encapsulated in the vesicles (compared to the background) for 
liposomes formed at pH 3 in the presence of 50 mM NaCl. No other solution condition 
produced any aggregation that could be imaged by light microscopy at room temperature.  
 Observation of BSA aggregates formation in vesicles at pH 2.2 after 
incubation at 65°C 
At pH 2.2 and after incubation at 65°C there were indications of BSA aggregates 
either on the membrane (figure 5.15a) or within the interior of the vesicle (figure 5.15c).  
 
 
Figure 5.15 Phase contrast and fluorescence microscopy images of GUVs containing BSA 
solutions at pH 2.2 without NaCl (a-d) and in the presence of 50 mM NaCl (e-h) after 
incubation at 65°C for 90 minutes (and returned to room temperature for imaging). Brightness 
and contrast adjusted to aid visualization. Scale bar = 5 µm. 
                  
  
134 
 
Regions in which increased ThT fluorescence was observed are co-localized with 
the aggregates observed by phase contrast. In bulk, BSA solutions in glycine-HCl buffer 
at pH 2.2 with 50 mM NaCl after incubation at 65°C form a weak protein gel. BSA 
solutions after encapsulation in vesicles and incubation under the same conditions formed 
aggregates similar to those formed in the absence of salt. However they appear to be 
somewhat larger and present in slightly greater number (figure 5.15e). Additionally, 
structures which appear to be formed on the surface of the lipid bilayer were observed by 
phase contrast (figure 5.15g). The increase in the fluorescence intensity of ThT appears 
to be highly inhomogeneous and restricted to the interior of vesicles (figure 5.15h). 
 Observation of BSA aggregates in vesicles at pH 3 after incubation at 65°C 
The interior of vesicles encapsulating BSA at pH 3 both in the presence of 50 mM 
NaCl and in its absence, appear darker under phase contrast observation compared to 
those formed at neutral pH. Phase contrast microscopy produces images that can be 
roughly interpreted as density maps.[469] The amplitude and intensity observed in phase 
contrast images are related to refractive index and optical path length, therefore image 
density can be utilized as a scale for approximating relationships between various 
structures. Essentially, a structure having increasing density are visualized as darker 
objects relative to the background. In case of BSA containing vesicles at neutral pH the 
density inside vesicles is comparable to that of the bulk solution. However at pH 3 the 
density inside vesicles is significantly higher. 
 
 
Figure 5.16 Phase contrast and fluorescence microscopy images of GUVs containing BSA 
solutions at pH 3 without NaCl (a-d) and in the presence of 50 mM NaCl (e-h) after incubation 
at 65°C for 90 minutes (and returned to room temperature for imaging). Brightness and 
contrast were adjusted to aid visualization. Scale bar = 5 µm. 
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As shown in figure 5.16, the presence of micrometer-sized aggregates were 
observed in several GUVs. The aggregates occurred throughout the vesicle and were 
polydisperse in size. Significant increases in ThT fluorescence were observed in the 
majority of vesicles, even in vesicles were phase contrast microscopy did not indicate the 
presence of aggregates (most probably due to the formation of aggregates smaller than 
1μm. Smaller areas of more intense green fluorescence were co-localized with the 
aggregates observed with light microscopy as shown in figure 5.16 a, b, e and f. 
 Observation of BSA aggregates in vesicles at pH 7.4 after incubation at 65°C 
BSA aggregates were also observed, albeit significantly less frequently in vesicles 
formed at pH 7.4, but only after the concentration of encapsulated protein was increased 
to 40 mg/ml. The increase in fluorescence intensity of ThT was significantly lower than 
at pH 3. Any ThT fluorescence observed was quite uniform, with increases in the intensity 
co-localized with aggregates large enough to be observed by phase contrast microscopy.  
 
 
Figure 5.17 Phase contrast and fluorescence microscopy images of GUVs containing a BSA 
solution at pH 7.4 without NaCl (a-d) and in the presence of 50 mM NaCl (e-h) after incubation 
at 65°C for 90 minutes (imaged at room temperature). Brightness and contrast were adjusted to 
aid visualization. Scale bar = 5 µm. 
 
 Observation of BSA aggregates formed in the presence of FITC-labelled BSA 
Vesicles encapsulating a mixture of BSA and 0.5% of FITC-labelled BSA at a 
total protein concentration of 40 mg/ml, in buffer at pH 3 and pH 7.4 with 50 mM NaCl 
were found to contain aggregates similar to those observed in the unlabelled BSA (figure 
5.18). 
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FITC is commonly used to label proteins for fluorescent microscopy 
applications.[470] A previous study showed that the labeled protein preferentially partitions 
into the more concentrated phase after liquid-liquid phase separation and that labelling 
the protein is the equivalent of adding an attractive component to the protein-protein 
interaction potential, making the labeled protein more prone to aggregation than the 
unlabelled protein.[289] The FITC-labelled BSA was added in order to investigate whether 
similar behavior will be observed in case of BSA, and if so, can it be used to obtain images 
with better quality than those in the presence of ThT dye. This was not possible as the 
fluorescence images show uniform distribution of the labelled protein (figure 5.18). The 
preferential partitioning of the FITC-labelled BSA was however not observed (but can’t 
be ruled out due to the limitations of wide field fluorescence microscopy) for the solid-
liquid phase separation of BSA encapsulated inside GUVs. 
 
 
Figure 5.18 Phase contrast and fluorescence microscopy images of GUVs containing BSA and 
0.5% FITC-labelled BSA at total protein concentration of 40 mg/ml, in buffer at pH 3 (a-d) and 
pH 7.4 (e-h) with 50 mM NaCl after incubation at 65°C for 90 minutes (imaged at room 
temperature). Brightness and contrast were adjusted to aid visualization. Scale bar = 5 µm. 
 
 Fractal analysis 
 Describing the appearance of amorphous aggregates is generally quite difficult 
due to their irregular shape. However their morphological features can be described using 
a fractal dimension (see section 2.14), a single value representing a structural complexity 
of a given type of aggregate. 
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Prior to the analysis the images of aggregates, typically recorded in RGB format, 
images were converted to a binary format (figure 5.19). The analysis of the images was 
performed using a box counting method as described in section 2.14.2 using the 
FracLacv.2.5 plugin for ImageJ.[395] Values for the fractal dimension were obtained for 
each of the twelve grid positions selected for each image and the final value of DB was 
then reported as an average. 
 
 
Figure 5.19 Phase contrast images of BSA aggregates prepared in buffer solution (a) and 
inside GUVs (b) at pH 3, after incubation at 65°C. Insets: the corresponding binary images 
used for fractal dimension calculations. 
The fractal dimension analysis of aggregates formed at pH 3 after incubation at 
65°C are shown in table 5.1. The DB values reported in the table represent an average of 
20 high contrast images of aggregates formed under specified conditions.  
 
Table 5.1 Comparison of fractal dimension values for BSA aggregates formed at pH 3 in solution 
and inside GUVs. 
 Aggregates formed in solution Aggregates formed in vesicles 
 No NaCl 50 mM NaCl No NaCl 50 mM NaCl 
Fractal dimension 
(DB) (average) 
1.56 1.58 1.50 1.51 
Standard deviation 0.069 0.086 0.119 0.128 
Coefficient of 
variation 
4.4% 5.4% 7.9% 8.5% 
 
Fractal dimension values of 1.56 and 1.58 were calculated for BSA aggregates 
formed in buffer solution at pH 3 without NaCl and in the presence of 50 mM NaCl 
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respectively). Values of the fractal dimension calculated for aggregates grown inside 
vesicles are 1.5 and 1.51 for the formation in the absence of NaCl and in 50mM NaCl 
containing solution respectively. High contrast images of BSA aggregates inside GUVs 
were much more difficult to obtain. The interior appeared darker than in case of empty 
liposomes and therefore any structures formed inside were generally harder to focus on. 
Additionally any aggregates present inside vesicles were generally located at different 
focal depths and image quality was worse due to the presence of large halos surrounding 
the out of focus membrane. Due to these difficulties, the values of fractal dimensions 
were calculated based on the analysis of only ten images (where good data was obtained) 
for each of the buffer conditions analyzed.  
Fractal analysis of protein aggregation, mainly protein gel formation have been 
extensively studied for various types of proteins.[471–476] Values of the fractal dimension 
between 1.5 and 2.8 for amorphous aggregates[477–479] and protein gels[480] have been 
reported. They vary greatly depending on the nature of the protein used, its concentration 
and solution conditions. Fractal dimension values also differ depending on the method 
used in calculations, however the DB values obtained using rheological determination and 
the box-counting method remain in good agreement.[476] 
Fractal analysis of BSA aggregates has previously been studied. The values of DB 
published were generally higher than the ones calculated here, most probably due to the 
differences in experimental conditions used to form the aggregates between that study 
and this. One such study reported fractal dimension value of 1.68 for heat-induced 
aggregates of BSA formed at pH 7 in the presence of CaCl2 calculated using box-counting 
method.[481] The general trend illustrating the increase in the value of DB observed for 
solutions at higher NaCl concentration have previously reported by Kumagai et al. was 
also observed here.[482] Nonetheless it is important to note that the previous studies used 
significantly different solution and heating conditions.[474,483] Other approaches to 
calculating the fractal dimension have been employed, such as evaluation of DB based on 
the light scattering experiments.[473,484] 
 Conclusions 
The preparation of model cells requires encapsulation of biomolecules inside lipid 
vesicles. The choice of the encapsulation method depends on the nature and stability of 
the biomolecules, but also on the composition of the lipid bilayer. Here two methods, the 
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continuous droplet interface crossing encapsulation (cDICE) and the inverted emulsion 
method were used to successfully encapsulate BSA and EmGFP under various solution 
conditions. The methods of protein quantification presented here allow for the fast 
determination of protein concentration inside individual vesicles.  
Calibration plots for encapsulated protein at various capillary diameters were 
combined to create a surface plot, allowing the determination of protein content inside 
vesicles across a range of diameters. This method was used to measure the concentration 
of EmGFP and EmGFP/BSA protein mixture after its encapsulation in GUVs. Both 
methods used here showed encapsulation efficiencies ranging from around 25 - 110% of 
the protein content in the bulk solution. This observation remains in agreement with 
published results.[188] The variation in the encapsulation efficiency is linked to the nature 
of the vesicle preparation process. 
Aggregation of BSA was analyzed both in solution and after encapsulation into 
GUVs. The formation of BSA aggregates was induced at acidic pH and incubation at 
elevated temperature. The formation of aggregates in solution was monitored by ThT 
fluorescence and by the analysis of the solution turbidity. In vesicles, a similar analysis 
was performed using phase contrast and fluorescence microscopy. Formation of BSA 
aggregates was observed at various pHs after protein unfolding at 65°C but it was most 
prominent at pH 3 in both the bulk solution and inside GUVs. Fractal dimension analysis 
was performed in order to describe the morphological feature of aggregates formed under 
various conditions. Relatively similar values for the fractal dimensions were obtained, 
slightly lower for the aggregates formed inside vesicles compare to those formed in bulk 
solution at given solution condition. Generally higher DB values were observed for 
solutions at higher NaCl concentration. 
The results presented here illustrate how model membranes can be used as vessels 
for analysis of protein aggregation processes. Among the main advantages of this 
approach is the cell-like size of vesicles (and hence very small volumes) or the presence 
of a lipid bilayer which may be implicated in some aggregation processes. 
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Protein self-assembly following in-situ 
expression inside an artificial cell 
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 Introduction 
Advances in synthetic biology now allow artificial cells to be formed from a 
minimum number of components to perform specific functions. Several examples have 
been discussed in the introduction.[14,47,485,486] Protein synthesis inside vesicles is vital for 
minimal cell development. The requirement for increased complexity within the minimal 
cell will require the production and assembly of protein (or protein and nucleic acid) 
components in-situ. This approach can be difficult due to rapid energy depletion within 
the system once protein translation occurs and subsequent protein degradation by 
enzymes present in E.coli or wheat germ extracts.[66–68] However, development of purified 
cell-free expression systems has provided a better tools for synthetic biology and minimal 
cell research in particular.[68] 
The assembly of proteins inside cells is a feature of normal biological function[487] 
and can sometimes be associated with of the pathology of diseases such as cataract 
disease[325,488] and sickle cell anemia.[489] Protein phase diagrams have been instrumental 
in explaining many of these biological condensation events.[490] However, the connection 
between in-vitro bulk measurements and those performed under physiologically relevant 
conditions is not always clear. At the same time, observing protein assembly in live cells 
is now possible due to advances in imaging technologies and labeling techniques. 
However linking these in-cell experiments and those performed in-vitro is complex due 
to the inherent complexity of the cellular environment and the potential for fluorescent 
labels to alter the conditions under which condensation events occur.[289] Therefore, there 
is a need to observe the condensation of proteins in more physiologically relevant 
conditions, and without the use of fluorescent labels. 
Self-organization (steady-state) and self-assembly (equilibrium) driven by non-
covalent interactions are essential processes in biological systems.[491] Virtually all 
biomolecules undergo self-assembly which defines the structure and function for that 
molecule.[492] Assembly processes have been explored by synthetic biology, especially in 
the development of minimal cells.[133] The organization of proteins, mainly components 
of the cell’s cytoskeleton and spindle apparatus have been previously studied by 
encapsulating the components required for assembly within a vesicle,[97,98] for example 
embryos or egg extracts of variety of microorganisms have been used for this purpose.[100–
102,493] Noireaux and Libchaber showed the cell-free in-situ expression of α-hemolysin 
inside lipid vesicles, followed by formation of a membrane pore via assembly of the α-
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hemolysin heptamer.[51] Hence, while a number of assembly processes have been 
observed inside vesicles, either by encapsulation or after in-situ expression, there is still 
a requirement to link these observations to studies performed under more explicit control 
to explain fully the process of assembly and how it is altered by the other components 
required for normal cell function. 
Here an approach to observe the condensation of proteins in model cells in 
physiologically relevant conditions is proposed. The P23T mutant of human gamma D 
crystallin was expressed in-situ following the encapsulation of a cell-free expression 
system inside a cell sized GUV. P23T is a mutant of HGD which aggregates at 
physiological temperatures (due to an inverted temperature dependence of the solubility 
line[282]). By analysing the fractal dimension of the aggregates formed, it was possible to 
distinguish these aggregates from those formed by non-specific interactions without the 
need for labelling. 
 Results and discussion 
 Protein expression in cell-free expression system 
The P23T single mutant of human γD-crystallin was obtained by site-directed 
mutagenesis (section 2.7.3). The incorporation of the single amino acid substitution, 
proline (CCC) to tyrosine (ACC), at position 23 was confirmed by sequencing (figure 
6.1). 
 
Figure 6.1 Sequence of the P23THGD plasmid DNA aligned against the WT HGD using BLAST 
(NCBI). 
 The HGDP23T mutant (referred to as P23T throughout) and EmGFP plasmid 
DNAs were expressed in a purified E. coli based cell-free transcription and translation 
system, PURExpress using a protocol described in section 2.8. Degradation of RNA by 
traces of RNAse from the DNA purification step was prevented by adding RNAse 
Inhibitor to the reaction mixture.P23T and EmGFP plasmids were used at a concentration 
of 350 ng per 25 µl reaction volume. 
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 Monitoring the time required for completion of the expression process 
The cell-free expression mix was used to express EmGFP in a 386-well plate. The 
point at which the protein expression reaction was completed was determined by 
monitoring the change in the fluorescence intensity over time (figure 6.2). It was found 
that the expression of EmGFP proceeded for roughly 6 hours and no significant increase 
in fluorescence intensity was observed beyond that point (figure 6.3). The only exception 
was the measurement after 24 hours, where a slight increase in fluorescence intensity was 
observed. This is mostly likely due to a small increase in concentration as a result of 
reduced volume due to evaporation (condensation was observed on the cover of the plate). 
 
 
Figure 6.2 Fluorescence intensity spectra recorded over 24 hours for EmGFP expressed in a 
cell-free expression medium. 
Previous work suggests that termination of the expression reaction occurs within 
3 hours due to degradation of the ribosomes.[74] Therefore we are confident that all of the 
transcription/translation factors of the cell-free expression kit had been consumed and the 
protein concentration did not increase further after 6 hours. 
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Figure 6.3 EmGFP concentration changes during expression in a cell-free expression medium 
monitored by the increase in the fluorescent intensity over 24 hours. The expression reaction is 
finished within ~ 6 hours. 
 
 Determination of the concentration of protein expressed in the cell-free 
system  
Successful expression of P23T in the cell-free expression system was confirmed 
by SDS-PAGE analysis (figure 6.4 line 8). P23T was expressed in a manner identical to 
one described in section 2.8, in a small volume vial. BSA was used as a standard for 
quantification (figure 6.4 lines 2-6). By running the BSA at different concentrations, it 
was possible to relate the intensity of the protein band to its concentration in an unknown 
(i.e. P23T expressed in the cell-free expression system). The measurement of the band 
intensity was performed using ImageJ software.[339] The intensity of BSA bands was used 
to construct a calibration plot (figure 6.5), from which the concentration of P23T was 
obtained. The location of the P23T band was determined by comparison to the location 
of the band for HGD obtained from a purified protein solution (figure 6.4 line 9), the 
molecular weight markers (figure 6.4 lines 1 and 10) and the cell-free expression mix 
without DNA (figure 6.4 line 7). The final concentration of P23T following 24 hours 
incubation at 37°C was found to be 0.13 (+/-0.02) mg/ml. The accuracy of determining 
protein concentration by this method depends on the quality of the gel (background and 
the signal-to-noise ratio) and the quality of the image (scanner specifications).[494] 
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Figure 6.4 Expression of P23T in a cell-free expression system; (a) lines 1 and 10 show 
molecular weight marker; 2-6 BSA standards for quantification, line 7 cell free expression sys-
tem without DNA plasmid; 8, cell free expression system with P23T DNA plasmid; 9, purified 
HGD solution for comparison; (b) excised lines (7-9). 
 
 
Figure 6.5 Calibration plot for determination of protein concentration from a SDS-PAGE 
analysis obtained from five BSA concentrations 
 Protein quantification using the SDS-PAGE gel is commonly performed using 
BSA as a standard. However due to the significant difference in the size between P23T 
HGD and BSA, a second quantification using HGD as a standard was performed (figure 
6.6). The final concentration of P23T expressed under identical conditions (in a different 
experiment) and determined by comparison with HGD was also 0.13 (+/-0.02) mg/ml. 
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Figure 6.6 Expression of P23T in cell-free expression system. Lines 1 and 9 show molecular 
weight marker, 2-6, HGD standards for quantification, line 7, cell free expression system with 
HGD (P23T) DNA plasmid, line 8, cell free expression system without DNA plasmid; (b) 
excised lines 6-9). 
 
 P23T aggregate formation in solution after expression in a cell-
free expression system 
The cell-free reaction expressing P23T protein was incubated at 37°C for several 
days. Small and difficult to resolve aggregates were observed after 8 hours. After 20 
hours, the formation of defined amorphous protein aggregates was observed by phase 
contrast microscopy (figure 6.7 a). The P23T aggregates were also imaged using 
transmission electron microscopy (figure 6.7 b). The size of the aggregates increased over 
a number of days and eventually they grow to several microns in size. Since protein 
expression ceases after ~24 hours, the slow growth of the aggregates reflects the kinetics 
of the aggregation process, and not an increase in protein concentration over time. 
To ensure that the aggregates observed are those formed by the assembly of P23T, 
and not due to non-specific aggregation of other components within the PURExpress 
system, a cell-free expression mix without P23T plasmid DNA was incubated under the 
same conditions and imaged over a number of days. In this solution (in the absence of 
P23T) several clusters with sizes up to few micrometers were observed (figure 6.8). 
However, even a cursory analysis suggests that the morphology of the aggregates in the 
absence of P23T is significantly different. Furthermore, the number of aggregates formed 
was far lower. 
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Figure 6.7 HGDP23T expressed in solution in a cell-free expression system. Images recorded 
with (a) phase contrast light microscopy and (b) TEM. 
 
 
Figure 6.8 Phase contrast image of particles formed within the cell-free transcription-
translation system (without the P23T HGD plasmid DNA) after 3 days of incubation at 37°C. 
The most interesting property of the P23T mutant of HGD is the inverse 
temperature dependence of the solubility line (figure 6.9), i.e. the protein is more soluble 
at lower temperatures and aggregates “melt” upon cooling.[282] For the aggregates formed 
in the cell-free expression mixture expressing P23T, the aggregation process was 
reversible with temperature. Upon cooling to 4°C, the size and number of aggregates 
formed in the cell-free solution significantly decreased and this was not observed for the 
aggregates observed in the control sample. This strongly suggests that the aggregation 
observed in the cell-free expression system is primarily caused by the self-association of 
expressed P23T. However, the formation of P23T aggregates occurs at protein 
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concentrations that are significantly lower than in purified protein solutions (at 37°C, ~0.7 
mg/ml). 
There is a difference between the appearance of aggregates of P23T formed in the 
cell-free system and those formed from purified P23T solutions.[282] The aggregates 
formed in the purified single-component solutions used to determine the solubility line 
appear very dense, and are almost exclusively spherical aggregates of several microns in 
size. Those produced in the cell-free expression system are less dense, with an appearance 
typical of amorphous protein aggregates formed by self-association (figure 6.7). Hence, 
while it appears that there is a sufficiently high concentration of P23T within the cell free 
expression system to allow protein assembly to occur, the kinetics for the formation of 
the aggregates are quite different when compared to a purified protein solution. 
 
 
Figure 6.9 The solubility line for the P23T mutant of HGD, taken from Pande et al., 2005. 
 
  Protein aggregate formation in GUVs after expression in cell-free 
system 
 P23T mutant of human γD-crystallin 
To further explore this self-assembly, the cell-free transcription-translation 
system, together with plasmid DNA for P23T was encapsulated in phospholipid-based 
giant unilamellar vesicles. The encapsulation process was performed at 4°C to prevent 
expression taking place outside of the GUVs. The solution on the exterior of the GUVs 
contained a solution of the PURExpress mix but containing only the low molecular weight 
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components (i.e. without ribosomes or enzymes). This is necessary since previous studies 
have shown that a significant decrease in protein expression levels occurs when buffer is 
used as the external solvent.[365] This ensures that the osmotic pressure inside and outside 
of the vesicle are similar (reducing rupture) and eliminates any dilution of the components 
required for protein expression inside the vesicle due to diffusion across the membrane. 
After encapsulation, the suspension containing vesicles was incubated at 37°C to allow 
protein expression to proceed. Due to the inverted solubility of P23T, once the protein is 
expressed, self-assembly can occur within the vesicle without changing the temperature 
(figure 6.10). Phase contrast images of the vesicles were recorded every 24 hours for up 
to 10 days. After that time most of vesicles had ruptured or degraded. 
 
 
Figure 6.10 Phase contrast images of GUVs containing P23T aggregates formed after 
expression in a cell-free system, imaged immediately after formation (a) and then every 24 
hours (b-h) (i.e. 8 days are shown here). Scale bar = 5 µm. Each vesicle is indicative of those in 
the suspension (i.e. the same vesicle was not monitored over 8 days). 
Following encapsulation and during the first 24 hours of incubation at 37°C 
(during which time all of the expression occurs), no evidence of protein aggregation was 
observed. The first appearance of small aggregates (~1 μm in size) was observed 24 - 48 
hours after encapsulation (i.e. 18 - 42 hours after expression has ceased). By day 4, larger 
aggregates with a more branched structure were observed. The aggregate size continued 
to increase for a further 2-3 days. After day seven the size of aggregates remained 
unchanged and the number of vesicles in general began to decrease. 
The aggregation process within the GUVs occurs more slowly than in the un-
encapsulated cell-free expression mix. The most likely explanation for this is 
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heterogeneity in the concentration of the encapsulated solute.[188,461,462] This means that 
the concentration of the components of the cell-free expression system vary greatly 
among the vesicles, and in general is lower than in the un-encapsulated solution. These 
variations of the concentration of the individual components of the cell-free expression 
system result in the expression of various quantities of protein which we can assume is 
generally lower than measured for the un-encapsulated solution. Therefore it was 
expected that at any given time point, the sizes of aggregates varied between vesicles with 
similar diameters. Moreover some vesicles did not show any signs of aggregation, due to 
encapsulation of insufficient amounts of the components of the PURExpress system for 
protein expression to actually occur inside. Therefore, we expect that in the majority of 
vesicles, the concentration of expressed protein is lower than 0.13mg/ml, which was the 
concentration determined from the expression of P23T in un-encapsulated cell free 
expression medium. 
In general, larger aggregates formed in GUVs with larger diameters. This was 
expected, since encapsulation of larger volumes of the cell-free expression system results 
in expression of higher numbers of P23T molecules and therefore within the vesicle, more 
material is available to form aggregates. 
 For both encapsulated and un-encapsulated cell-free expression mixture, the rate 
of aggregation is significantly slower than for purified solutions of P23T. At 1 mg/ml 
large aggregates (sizes exceeding the detection range of QLS) were observed after 10-20 
min[282] for purified P23T. The main reason for this observation is simply the lower 
concentration of the protein inside the vesicles. 
 Wild type HGD 
As a control, wild type HGD was also expressed inside GUVs (figure 6.11). 
Purified WT HGD is soluble at 37°C and doesn’t form amorphous aggregates at the 
concentrations of protein expressed in the vesicle.[282] Within the interior of the GUVs no 
aggregation was observed. After three days small clusters were observed in several 
vesicles in close proximity to the lipid bilayer. For these experiments, a fluorescent dye 
(0.05 % of bodipy TR ceramide) was integrated into the phospholipid mixture during 
GUV formation (figure 6.12). 
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Figure 6.11 Phase contrast images of GUVs upon expression of WT HGD in cell-free 
expression system, imaged immediately after formation (a) and then every 24 hours (b-h) (i.e. 8 
days are shown here). Scale bar = 5 µm. Each vesicle is indicative of those in the suspension 
(i.e. the same vesicle was not monitored over 8 days). Scale bar = 5 µm. 
 
 
Figure 6.12 Self-assembled structures formed inside GUVs labelled with 0.05 % of the 
fluorescent dye, bodipy TR ceramide, upon expression of P23T (a and b) and WT HGD (c and 
d). Scale bar 5 = µm. 
The regions where aggregation is visible by phase contrast microscopy 
corresponds to areas where there is an increase of the fluorescent dye concentration within 
the lipid membrane (Figure 6.12 c and d). This was not found in similar experiments 
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performed in vesicles containing P23T aggregates (Figure 6.12 a and b), where the 
fluorescent dye is more evenly distributed in vesicles containing P23T mutant. It remains 
unclear whether the formation of these clumps in the HGD containing solutions is due 
aggregation of cell-free expression components or HGD, but in either case, it appears to 
occur only at the membrane, and not in the interior of the vesicles, which distinguishes it 
from the P23T aggregation observed previously. 
 Fractal analysis 
Due to the significant experimental differences in the morphology and kinetics of 
aggregate formation in the P23T containing vesicles, compared with purified P23T 
solutions, further analysis of the aggregates was performed. Comparisons of the aggregate 
sizes in different vesicles is not appropriate, since each vesicle contained a slightly 
different concentration of expressed P23T, which influences the overall size of the 
aggregates formed. However comparing the overall shape of aggregates (i.e. the fractal 
dimension), will provide some useful insights. We performed this comparison based on 
the fractal dimension analysis in an identical manner as described in sections 2.14 and 
5.2.6, using the box counting method available through FracLac plugin for ImageJ 
software. 
 The fractal dimension of P23T aggregates formed after expression in a cell-free 
system firstly in solution (Figure 6 a) and then inside GUVs (Figure 6 b) was calculated. 
Images of aggregates obtained by phase contrast microscopy were converted to binary 
images prior to analysis (Figure 6, inserts). 
The average of the mean values for DB obtained for P23T aggregates formed in 
solution and inside GUVs are presented in table 6.1. The differences in these values, are 
very small and may be caused by the differences in the volume and the environment in 
which the aggregation took place. 
There was more variation in the fractal dimension values calculated for each 
aggregate formed inside vesicles than for aggregates formed in solution. This can be 
caused by the variation of encapsulation efficiency, and therefore various protein 
concentrations within individual vesicles and the component of the cell-free expression 
mix.[495] The imaging of aggregates entrapped inside GUVs is also slightly more 
challenging compared to imaging aggregates free in solution. 
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Figure 6.13 Phase contrast and binary images of aggregates prepared in solution (a) and 
inside GUVs (b) for fractal dimension calculations. 
 
Table 6.1 Comparison of fractal dimension values for P23T HGD aggregates formed in 
solution and inside GUVs. 
 
Aggregates 
in solution 
Aggregates 
inside GUVs 
Fractal dimension (DB) (average) 1.38 1.34 
Standard deviation 0.095 0.159 
Coefficient of variation 6.9 % 11.9 % 
 
The values for the fractal dimension of P23T aggregates are significantly different 
from those obtained for BSA aggregates formed at pH 3 after thermal denaturation (1.51 
and 1.5 for aggregates formed in the presence of 50 mM NaCl and in its absence, 
respectively).  
Fractal analysis of protein aggregates has been extensively studied for various 
types of proteins.[471–476] Values of the fractal dimension between 1.5 and 2.8 have been 
observed for various types of aggregates (including amorphous aggregates and protein 
gels.[477–480] These values vary greatly depending on the nature of the protein used, its 
concentration and the solution conditions. The fractal dimension values also differ 
depending on the method used in calculations, however the DB values obtained using 
rheological determination and the box-counting method remain in good agreement.[476] 
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Previously published fractal dimension values, ranging from 1.5 to 2.8 have been 
measured for aggregates formed in purified protein solutions. These aggregates formed 
via processes driven by non-specific interactions between unfolded or partially unfolded 
species (induced by heat denaturation or extreme pHs) and are compact structures. The 
P23T aggregates with fractal dimensions of ~1.3 were formed in the cell-free expression 
system, suggesting the formation of loose amorphous material, quite different to those 
observed in purified solutions. The formation of aggregates at such low P23T 
concentration is already somewhat surprising, since it is below the solubility boundary 
for the purified protein. Hence, the formation of aggregates with a significantly different 
fractal dimension is not unexpected. If it was possible to produce higher concentration of 
P23T from the cell-free expression system, we would expect the fractal dimension to 
increase. At the very least, this very specific fractal dimension for the P23T aggregates 
distinguishes them from other non-specific aggregates and provides further confirmation 
of P23T specific aggregates after expression of the protein. Interestingly these 
measurements are consistent with the values for of fractal dimension reported for sparse, 
less compact protein self-assemblies found in nature.[496] 
 Protein expression in mammalian cells 
Here an EmGFP fusion protein of both human γD-crystallin and the P23T mutant 
were expressed in HEK 293T/17 mammalian cells to monitor expression and aggregation 
of these proteins inside cells. 
 Mammalian expression vectors 
 Plasmid DNA with the HGD gene fused to EmGFP was designed for propagation 
in E.coli and optimal expression in mammalian cells. It was synthesized by GeneArt 
(ThermoFisher, Germany). The HGD gene was inserted into the pcDNA6.2_C-
EmGFPDEST mammalian vector at the attL2/attL1 site (figure 6.14). The EmGFP-HGD 
vector contained a blasticidin resistance gene for selection of stable transfected cell lines. 
The EmGFP-P23T vector was obtained by site directed mutagenesis of the 
EmGFP-HGD mammalian expression vector using protocol described in section 2.9.3. 
The Vivid Colors™ pcDNA™ 6.2/EmGFP GW/TOPO mammalian expression vector 
was used to express free-EmGFP (not fused to any other protein). 
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Figure 6.14 Map of the mammalian vector pcDNA6.2_C-EmGFP-DEST_A321 with a HGD 
gene obtained using SnapGene software. 
 Transfection of HEK 293T/17 mammalian cells with the three vectors was 
performed using lipofectamine 2000 (section 2.13). After transfection, cells were imaged 
using fluorescence microscopy to confirm the presence of EmGFP expressing cells. 
Relatively high transfection efficiencies (ca. 70-90%) were obtained depending on the 
type of the vector or the type of culture flask used (figure 6.15).  
Images of both transient and stable transfected HEK cell lines were obtained using 
an upright microscope at either 60x or 100x. In order to do that, cells were grown on glass 
surface chambers or coverslips. These surfaces were coated with poly-D-lysine since 
HEK cells do not easily grow on glass directly. Transfected cells attached more efficiently 
to the pretreated surface in the presence of fetal bovine serum as opposed to bovine calf 
serum, which was routinely used to maintain the cell growth. 
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Figure 6.15 HEK 293T/17cells after transfection with the EmGFP-HGD (left) and the EmGFP-
P23T (right) plasmid DNA, grown in a 6-well plate. Scale bar = 100 µm. 
 
 EmGFP expression in HEK 293T/17 mammalian cells 
HEK cells expressing EmGFP are shown in figure 6.16. The transfection 
efficiency was higher for this plasmid than for either of the fusion protein plasmids. These 
cells easily attached to the pretreated glass surfaces (poly-D-lysine). The EmGFP was 
evenly distributed within the cells and no signs of aggregation were observed. The areas 
where the fluorescence intensity is lower corresponds to the location of cellular 
organelles, such as the nucleus. 
 
 
Figure 6.16 Phase contrast and fluorescence microscopy images of HEK 293T/17cells 
expressing the EmGFP. Scale bar = 10 µm. 
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It was important to ensure that the EmGFP didn’t aggregate by itself inside cells, 
since as part of a fusion protein, it will be used to detect regions of protein aggregation in 
cells expressing HGD and P23T. For in-cell measurements (unlike in the GUVs described 
earlier), fluorescent tags are essential to distinguish the protein of interest from the rest of 
the cellular milieu.  
 HGD expression in HEK 293T/17 mammalian cells 
HEK cells expressing the EmGFP-HGD fusion protein are shown in figure 6.17. 
These cells required a much longer time period to attach to the pretreated glass surfaces. 
The attachment was however significantly improved in the presence of 10% fetal calf 
serum. The growth rate of the EmGFP-HGD expressing cells was slightly slower 
compared to those expressing EmGFP or the P23T fusion protein. 
The expressed EmGFP-HGD was evenly distributed within the cells suggesting 
that the presence of the EmGFP tag does not affect the HGD solubility (at the relatively 
low concentrations that are likely to be achieved in the cell in any case). Again areas with 
lower fluorescence intensity corresponds to cellular organelles (figure 6.17a). 
 
 
Figure 6.17 Phase contrast and fluorescence microscopy images of HEK 293T/17cells 
expressing the EmGFP-HGD fusion protein. Scale bar = 10 µm. 
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 HGDP23T expression in HEK 293T/17 mammalian cells 
HEK cells expressing the EmGFP-P23T fusion protein are shown in figure 6.18. 
These cells exhibited a similar growth rate and the ability to adhere to the poly-D-lysine 
pretreated glass surface as the EmGFP expressing cells. 
 
 
Figure 6.18 Phase contrast and fluorescence microscopy images of HEK 293T/17cells 
expressing the EmGFP-P23THGD fusion protein. Scale bar = 10 µm. 
Within the interior of the cells (of both transient and stable cell lines) areas of 
increased fluorescence intensity were observed. These regions of increased intensity are 
located throughout the cells in which they are observed (figure 6.18 a, e and i) and 
correspond to sizes up to 1 µm. These areas are expected to represent the self-assembly 
structures composed of the EmGFP-P23T fusion proteins. Additionally, formation of 2 
to 3 larger areas, with sizes up to 5 µm, within a single cell was also observed (figure 6.18 
c, g and k). No difference in the average size of the aggregates was observed between 
transient and stable transfectants. The larger structures observed possibly consist of 
intracellular vesicles entrapping the overexpressed and self-assembled proteins as these 
structures appear in close vicinity to the cell membrane. Fluorescent labeling of other 
cellular structures would be required to more precisely asses the location of the aggregates 
within the cell interior. 
The increase of the intensity observed by fluorescence microscopy does not 
always corresponds to the increased in density in the phase contrast image, which was 
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expected since there is little difference in refractive index between the cell organelles and 
protein aggregates. 
The P23T aggregate formation was observed in HEK cells within three days after 
transfection (two days from the seeding on the glass slide), which is consistent with our 
observation in cell-free expression system. However, more investigation is required to 
assess what effect cell division has on the aggregate formation and growth. The 
aggregates formed in HEK cells had sizes ranging from 1 µm to 5 µm. These sizes are 
slightly larger than the average aggregate sizes observed in vesicles (up to ~3.5 µm, which 
is not at all surprising considering the larger size of the cells (~15 μm). 
Various mammalian cell lines have been used to study cellular processes such as 
protein-protein interactions, protein behavior, localization within cellular environment[497 
–499] or protein aggregation.[500,501] Those studies usually involve expression of fusion 
proteins or other methods of fluorescent labelling in order to avail of various 
supperresolution microscopy techniques.[502] Careful interpretation of such studies is 
necessary not only due to the complexity of the cellular environment but also due to the 
possible effect which various strategies of protein labelling may have on its 
behavior.[289,503–505] Comparison to the experiments in model cells mimicking studied 
process may make the interpretation less problematic.  
 Conclusions 
An approach to investigate protein condensation in physiologically relevant 
conditions has been discussed. This can be achieved with in-situ expression of a protein 
(the P23T mutant of human gamma D crystallin) from a cell-free expression medium 
encapsulated in a giant unilamellar vesicle of cell-size. The formation of self-assembled 
P23T structures was observed following in-situ expression using a cell-free expression 
system encapsulated in a GUV. Due to the low protein concentration, these structures 
were formed after incubation for several hours at 37°C. Measuring the fractal dimension 
of the aggregates formed allowed P23T specific aggregates to be distinguished from those 
formed via non-specific interactions without the need for labeling. 
The formation of self-assembled protein structures in a GUV encapsulating the 
cell-free expression system, occurs at much lower concentrations than for purified protein 
in an in-vitro system. We have chosen to express the P23T mutant of human gamma-D 
crystallin, since it forms amorphous protein assemblies with an inverse temperature 
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dependence of the solubility line (i.e. it forms reversible aggregates at higher temperatures 
that return to a monomeric state when the temperature is lowered). This inversion of the 
temperature dependence of the solubility line in the mutant occurs without a change in 
protein structure, which makes it possible to both express protein and monitor assembly 
at 37°C over a number of days. 
The HGD and the P23T mutant was also expressed in mammalian cells. The 
crowded cellular environment and the presence of the tag protein was shown not to affect 
the solubility of the wt HGD protein. In case of the P23T single mutant fusion protein, 
the formation of the protein aggregates observed by fluorescence microscopy suggest a 
formation of self-assembled protein structures, similar to those observed in label-free 
conditions in giant unilamellar vesicles. 
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Summary and Concluding Remarks 
Building even a simple artificial or minimal cell can be a complex process, 
requiring suitable preparation techniques and functionalisation of both the membrane 
surface and the interior of the cell. In this thesis a critical comparison of the methods to 
prepare giant unilamellar vesicles as basic building block for an artificial cell has been 
discussed. The relative merits of these preparation methods when applied to the 
encapsulation of biomolecules was also presented. This comparison of experimental 
techniques provides reliable information for tailoring the selection of experimental 
approach when building an artificial cell. 
Bottom-up approaches to synthetic biology allow formation of minimal cells 
composed of the basic components required to perform specific functions. To-date many 
processes and chemical reactions have been studied in minimal cells; many more remain 
to be explored. In order to broaden the range of the applications, both the surface and the 
interior of the model cell needs to be functionalized with versatile molecules. 
The growing interest in incorporating glycolipids into lipid bilayers is driven by 
the increasing number of their biomedical applications, primarily targeted drug delivery. 
Glycolipids are ideal candidates since the complementarity of sugar residues is vital to 
the molecular recognition in biological cells. The specificity and mode of interaction can 
be modified by altering the functionality of the sugar-based head group. Furthermore, the 
structure, glycolipid concentration and the nature of solvent, can significantly alter the 
phase behaviour of the glycolipid within a membrane. We have shown how a change in 
the concentration of an acetylated, galactose-based glycolipid can change the lipid phase 
behaviour, leading to the formation of either lamellar or columnar lipid phases. This 
behaviour needs to be carefully considered when designing a minimal cell, since phase 
separation and consecutive formation of non-lamellar phases may alter the distribution 
within the bilayer or diminish the number of glycolipid molecules remaining available 
for interactions with other particles or cells.  
 The self-assembly of proteins is required to maintain the structure and biological 
function of a cell. Proteins may also self-assemble in response to a change in 
environmental conditions, in some cases leading to disease. Studies of the aggregation 
process, have traditionally been performed in-vitro, mainly in solutions of purified 
proteins. This approach provides vital information regarding the mechanism or the nature 
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of the forming structures, however it also has a significant drawbacks as it lack the 
complexity of the cellular environment. On the other hand studies in cells are limited due 
to the sensitivity of cell culture and the identification of the key factors that play a role in 
the aggregation process may be difficult to elucidate. A minimal l cell provides an idea 
platform to carry out such analysis, as it provides a controlled, cell-like conditions. 
Aggregation of BSA in GUVs was induced under harsh environmental conditions 
(beyond the sensitivity of cell) and analysed using a fluorescent dye (Thioflavin T) and 
various modes of microscopy. To examine protein assembly under more physiologically 
relevant conditions, the P23T mutant of human gamma D crystallin was examined after 
in-situ expression from a cell free expression system inside a GUV. We have shown that 
the aggregation observed is specifically related to P23T and not non-specific aggregation 
of other components and occurs at a rate that is determined by the concentration of protein 
in the vesicles. Furthermore, the self-assembly of P23T was also be induced following 
transfection in mammalian cells. The analysis of the P23T self-assembly in minimal and 
biological cells furthers our understanding of the mechanism by which this mutation 
which causes genetic cataract leads to condensation in lens fiber cells. 
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